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ABSTRACT 
Multiple myeloma (MM) is characterised by the proliferation of clonal plasma cells 
and a number of novel, highly effective anti-MM agents have improved long-term 
survival. However, eventually all patients become resistant and the disease remains 
incurable. The occurrence of disease relapse after the apparent eradication of the 
clonal population indicates the persistent survival of a drug resistant, ‘progenitor’ 
subpopulation. Understanding the mechanisms that underlie these patterns of 
resistance, including the characterisation of MM progenitors, is therefore critical to 
improving clinical outcomes. A cancer stem cell model has been proposed in the 
context of MM, based on the lack of syndecan-1 (CD138) in clonal, light chain-
restricted cells. This work did not substantiate this claim, and data from a series of 
primary samples suggest that lack of CD138 is not a robust marker for a progenitor 
population of MM cells. The bone marrow (BM) microenvironment is known to play 
a critical part in MM cell survival and resistance, mediated by cytokines present 
within MM cell niches, and by cell-contact dependent pathways activated in MM 
cells and within adjacent supportive BM cells. This work examines the role of A 
Proliferation-Inducing Ligand (APRIL), and of the Notch signalling pathway. The 
data suggest that soluble APRIL confers protection against Dexamethasone-induced 
apoptosis, whilst the Notch ligand Delta-like ligand-1, expressed on the stromal cell 
line, HS-5, enhances stroma-mediated protection against bortezomib. 
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CHAPTER 1. INTRODUCTION 
1.1 Multiple myeloma - the clinical problem 
Multiple myeloma (MM) is a haematological malignancy characterised by the 
proliferation of clonal, terminally differentiated plasma cells. It is typified by 
infiltration of the bone marrow (BM) compartment by malignant plasma cells, 
associated with the presence of a detectable paraprotein, and causes symptoms due to 
a variety of end-organ injuries: anaemia, bone pain and pathological fractures, renal 
failure, hypercalcaemia and recurrent infection.  
1.1.1 Epidemiology 
MM accounts for 1-2% of all newly diagnosed cancers and around 10-15% of newly 
diagnosed haematological malignancies. In the UK there are around 4,000 new cases 
per year and this incidence has been stable over the last two decades. It is 
predominantly a disease of older people, with a median age at presentation of 73 
years. It is 40-50% more common in men than women, and shows varying ethnic 
distribution, with twice as many patients of Afro-Caribbean origin, compared to 
European, and a lower incidence in those of Asian descent.  
The prevalence of the condition in affluent countries is increasing steadily as survival 
rates improve following the introduction of a number of novel therapies 1,2. Most 
recently, five-year survival estimates of 41% in all ages have been reported 1,3. 
However, importantly, despite the notable advances over the last few decades, MM 
remains incurable. 
The aetiology of the disease is unclear, with increasing age, male sex, preceding 
monoclonal gammopathy of undetermined significance and African ethnicity, as 
noted above, being the clearest epidemiological risk factors. It is almost certainly not 
a single disease entity 4 and a variety of genetic and environmental factors have been 
implicated in its pathogenesis. 
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1.1.2 Presentation and diagnosis 
Most cases of MM present de novo with a combination of the symptoms outlined 
above but a proportion are preceded by the pre-malignant condition, monoclonal 
gammopathy of undetermined significance (MGUS). It is now felt that all MM cases 
are preceded by MGUS 5-7, which in the majority goes undetected. 
1.1.2.1 MGUS 
This is usually picked up with the incidental finding of a blood serum or urinary 
paraprotein. By definition it is asymptomatic, with evidence of a small population of 
clonal plasma cells (<10% on BM trephine immunohistochemistry) but with no 
evidence of end-organ damage attributable to this clone. This may be harder to 
determine in individuals with other comorbidities which cause similar clinical 
problems to myeloma, e.g. anaemia and renal impairment. It has the same 
epidemiological risk factors as myeloma, increasing in incidence with age 
particularly - 5% of those over 70 years 8. There is an overall annual progression rate 
of 1%, but a number of factors are linked to higher progression rates, including a 
paraprotein concentration >15g/l, IgA or IgM paraproteins and/or an abnormal free 
light chain ratio 9. 
1.1.2.2 Smouldering or asymptomatic myeloma 
This term describes a condition in which there is evidence of a larger plasma cell 
clone than can be attributed to MGUS alone (clonal BM plasma cells >10%, 
paraprotein >30g/l) but with no evidence of end-organ impairment. The annual 
progression rate falls with time from diagnosis, with 10% progressing annually in the 
first five years, 3% per year in the subsequent five years and then 1% per year for the 
final ten years 10. The current consensus is that treatment of these patients prior to the 
development of symptomatic myeloma is not beneficial, but this may change with 
studies of pre-emptive chemotherapy in high risk smouldering MM 11.  
1.1.2.3 Symptomatic myeloma 
Symptomatic myeloma is defined by the presence of a substantial clone of BM 
plasma cells (>10%, i.e. equivalent to that present in smouldering MM), a detectable 
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monoclonal protein in blood serum or urine and symptoms indicative of myeloma-
related organ or tissue injury (so-called ‘CRAB criteria’): hypercalcaemia, renal 
dysfunction, anaemia and bone disease (osteopaenia, lytic lesions, pathological 
fractures) 12. Other features may be present including fatigue, weight loss, recurrent, 
severe or atypical bacterial infections, symptomatic hyperviscosity or amyloidosis. 
The diagnosis is made by demonstrating these features on blood and urine tests, bone 
marrow biopsy (aspirate and trephine) and imaging (plain radiographs, computed 
tomography scans, magnetic resonance imaging). The International Staging System 
13 uses albumin and beta-2-microglobulin levels to stratify disease severity at 
diagnosis and has prognostic value (Table 1-1). 
Table 1-1 International Staging System for Multiple Myeloma. 
Stage Criteria Median survival (months) 
I 
Serum β2-microglobulin <3.5mg/L 
Serum albumin ≥3.5g/dL 
62 
II Not stage I or III* 44 
III Serum β2-microglobulin ≥5.5mg/L 29 
*There are two categories for stage II: serum β2-microglobulin <3.5mg/L and serum 
albumin <3.5g/dL; or serum β2-microglobulin 3.5 to <5.5mg/L, irrespective of the serum 
albumin level 13. 
Additionally, characterising any genetic abnormalities present in the clonal plasma 
cell, by G-banding or fluorescence-in-situ-hybridisation (FISH), can also aid 
prognostication (see section 1.1.3). 
At this stage the malignant plasma cells are confined to the BM, and the disease is 
therefore termed ‘medullary’.  
1.1.2.4 Extramedullary myeloma and plasma cell leukaemia 
A small proportion of patients present with highly aggressive disease characterised 
by extensive extramedullary involvement. This may be in the form of soft tissue 
masses, i.e. extramedullary plasmacytomas, or of circulating malignant plasma cells, 
so-called plasma cell leukaemia. These two disease manifestations may also arise in 
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later stage disease. Plasma cell leukaemia is associated with a number of distinctive 
features that distinguish it from MM, but it is highly likely that it reflects evolution 
of the BM disease rather than being a truly separate disease entity. The clonal plasma 
cells are usually CD138+ but typically CD56−.  
1.1.3 Multiple myeloma - the genetic context of pathogenesis 
The clonal population in MGUS is believed to originate from post-germinal-centre B 
cells. A number of sequential genetic, epigenetic and BM microenvironmental 
changes then govern the evolution of MGUS to symptomatic MM, with additional 
step-wise changes underpinning the progression of MM to terminal end-stage disease, 
with extramedullary involvement. These changes are summarised in Figure 1-1.  
 
Figure 1-1 Multistep pathogenesis of multiple myeloma. 
Primary genetic events, namely hyperdiploidy or IgH translocations, constitute the initiation 
events that trigger evolution from MGUS to MM. These various events result in aberrant 
expression of D-type cyclins (D1, D2 and D3). Secondary genetic events occur during the 
progression of MM and include chromosomal regional deletions or gains, additional 
translocations and discrete mutations affecting known oncogenes or cell survival pathways. 
Adapted from Kaiser et al, Chapter 5: The genetic and epigenetic mechanisms underlying 
the behaviour of myeloma. Myeloma. Cambridge University Press, 2014. 
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Primary genetic events (so-called ‘initiation events’) are present at the MGUS stage 
and fall into two broad categories. Around half of patients develop hyperdiploidy, in 
the form of trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21, either singly or in 
combination. The other 50% (‘non-hyperdiploid’) have immunoglobulin heavy chain 
(IgH) translocations, in which the strong IgH transcriptional promoters are 
juxtaposed with known oncogenes, such as critical cell cycle proteins. These lesions 
appear more common in female patients (50% versus 38% of male patients). There 
are five commonly observed translocations.  
1. t(4;14) is present in 10% of MM patients, has a positive association with IgA 
MM and independently predicts for poorer outcome. It results in increased 
expression of two genes, fibroblast growth factor receptor 3 (FGFR3) and 
multiple myeloma SET-domain containing protein (MMSET) on chromosome 
4p16 14. FGFR3 overexpression seems to drive MM cell proliferation but 
MMSET may be more critical to disease pathogenesis and has global epigenetic 
effects. 
2. t(6;14) is rare and only present in 0.8% of MM patients. It results in 
overexpression of cyclin D3 (CCND3) on chromosome 6p21, a cell cycle 
regulator that promotes proliferation. 
3. t(11;14) affects 15% of MM patients, approximating the IgH promoter with 
another cell cycle regulator, cyclin D1 (CCND1) on chromosome 11q13. It is 
associated with lambda light chain expression and slowly progressive disease. 
4. t(14;16) is present in 3% of MM patients and results in overexpression of the 
transcription factor c-MAF on chromosome 16q23, with upregulation of its 
downstream target, cyclin D2 (CCND2). 
5. t(14;20) is another rare event (in 1%), which results in overexpression of the 
transcription factor MAFB on chromosome 20q21, which has overlapping 
downstream targets to c-MAF and therefore also upregulates CCND2. 
 
Angiogenesis 
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Table 1-2 Translocation and Cyclin D groups. 
Group 
Primary 
translocation 
Gene at 
Breakpoint 
D-Cyclin Ploidy 
Proliferation 
Index 
Bone disease 
(% MRI Pos) 
Frequency 
(%) 
Prognosis 
6p21 6p21 CCND3 D3 NH Average 100 3 ? Good 
11q13 11q13 CCND1 D1 D, NH Average 94 16 Good 
D1 None None D1 H Low 86 34 Good 
D1 + D2 None None D1 and D2 H High 100 6 ? Poor 
D2 None None D2 H, NH Average 67 17 ? 
None None None None NH Average 100 2 ? Good 
4p16 4p16 FGFR3/MMSET D2 NH > H Average 57 15 Poor 
maf 
16q23 
20q11 
c-maf 
mafB 
D2 NH High 55 
5 
2 
Poor 
Abbreviations: D1, cyclin-D1; D2, cyclin-D2; D3, cyclin-D3; MRI, magnetic resonance imaging; pos, positive; D, diploid; H, hyperdiploid; NH, non-
hyperdiploid; adapted from 15. 
 
 23 
One consistent finding in the majority of MM patients is increased aberrant 
expression of one of the D-type cyclins 16. This was initially shown by gene 
expression profiling, but has since been confirmed on western blotting and 
immunohistochemistry 17,18. This group of proteins is involved in the tight regulation 
of mammalian cell proliferation, acting to control entry to the cell cycle at the G1/S 
border. Primary genetic events in MM lead directly and indirectly to upregulation of 
CCND-1, -2 or -3, which therefore constitutes a major oncogenic phenomenon in 
MM. MM patients may be classified by their translocation and cyclin D-type status 15 
(see Table 1-2) and this has been shown to have biological correlates and prognostic 
relevance 19. 
Secondary genetic events occur during the progression to symptomatic MM. These 
include copy number changes, mutations, e.g. in the RAS oncogenes, and epigenetic 
changes, that are likely to influence prognosis. At disease relapse, progression events 
(e.g. translocations involving the c-MYC gene - t(8;14) - and mutations or deletions 
causing loss of TP53 function) and the emergence of dominant and/or drug resistant 
clones 20 makes the disease more difficult to treat. The acquisition of TP53 loss often 
heralds end-stage disease. 
1.1.4 Current treatment approaches and disease course. 
Management of MM should be directed towards both disease modification and 
symptom control. Despite significant improvements in clinical outcomes and overall 
survival associated with a broader array of more effective novel therapies, the 
condition remains incurable. Consequently all treatment decisions need to weigh up 
the short and medium term disease reduction benefits with the not-insignificant 
treatment-associated toxicities that may persist and accumulate over the course of the 
disease.  
Management strategies will be principally determined by the age and comorbidities 
of a patient (Figure 1-2); those patients that are medically ‘fit’ (usually <65 years old, 
without major renal, cardiac, liver or lung dysfunction) are candidates for intensive 
chemotherapy (‘induction therapy’), consolidated with high-dose melphalan and 
autologous stem cell transplant (ASCT) 21. The aim of this is to achieve as deep a 
 24 
remission as possible, as this is believed to correlate with longer-term disease control. 
Of note, agents used at induction need to have minimal stem cell toxicity in order to 
allow sufficient numbers of patient stem cells to be harvested prior to treatment with 
high dose melphalan.  
 
Figure 1-2 Natural history and treatment overview in multiple myeloma. 
Abbreviations: PAD, bortezomib, adriamycin, dexamethasone; CTD(a), cyclophosphamide, 
thalidomide, dexamethasone (attenuated); VTD, bortezomib, thalidomide, dexamethasone; 
VMP, bortezomib, melphalan, prednisolone; MPT, melphalan, prednisolone, thalidomide; 
M200, melphalan 200mg/m2; CVD, cyclophosphamide, bortezomib, dexamethasone; Rd, 
lenalidomide, dexamethasone; BTD, bendamustine, thalidomide, dexamethasone; Pom, 
pomalidomide (adapted from Myeloma and MGUS, M J Streetly, Medicine 41:5). 
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The standard of care for ASCT-eligible patients is generally a triple regimen 
incorporating bortezomib (e.g. PAD, VTD; Figure 1-2), as this has been shown to 
achieve deeper responses more quickly 22, before consolidation with high-dose 
melphalan. Patients who are not fit for intensive chemotherapy are treated on 
chemotherapy regimens that are often dose- and schedule-adjusted to reduce 
toxicities and improve tolerability. 
Anti-myeloma agents are combined in a number of different regimens and at 
different doses depending on disease stage and treatment goal. Melphalan, for 
example is used at 200mg/m2 in the context of high dose therapy with ASCT (also 
known as M200 autograft). It is also prescribed in elderly patients unfit for intensive 
treatment, at 0.25mg/kg orally, in combination with prednisolone and thalidomide. 
The characteristics of the commonly used and more novel anti-myeloma agents are 
summarised in Table 1-3. 
Response to treatment is assessed by a number of parameters in combination: serum 
or urine paraprotein quantification by protein electrophoresis, serum free light chain 
quantification and BM plasma cell infiltration on trephine biopsy. Clinical 
parameters, such as reduction in bone pain, and radiological assessments are also 
valuable.  
In addition to disease-modifying approaches, supportive care is critical in MM. Bone 
disease is tackled specifically using bisphosphonates, and pain is managed pro-
actively with analgesia (non-opiate and opiate), titrated carefully to minimise toxicity. 
Blood product support, in the form of red cell or platelet transfusions, are useful at 
all stages of disease for symptom-relief and to allow effective delivery of 
chemotherapy. Surgical interventions, such as vertebroplasty or kyphoplasty, and 
radiotherapy may also be useful in the context of troublesome or isolated bone or soft 
tissue disease. 
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Table 1-3 Key anti-myeloma agents. 
Compound Context of use Mechanism of action 
Steroids, e.g. 
dexamethasone, 
prednisolone 
Component of majority of 
chemotherapy combinations. 
Presentation & relapse. 
Immunomodulatory and directly 
toxic to lymphocytes. 
Cyclophosphamide 
CVD, CTD(a). 
Presentation & relapse. 
Alkylating agent. 
Adriamycin 
PAD. 
Presentation. 
Cytotoxic anthracycline. 
Melphalan 
M200 autograft, MPT, MPR, 
VMP. 
Presentation & relapse. 
Alkylating agent. 
Bortezomib 
PAD, CVD, VTD. 
Presentation & relapse. 
Reversible proteasome inhibitor. 
Thalidomide 
CTD, MPT, VTD, BTD. 
Presentation & relapse. 
Anti-angiogenic. 
Lenalidomide 
Rd. 
Relapse. 
Immunomodulatory, anti-
angiogenic, apoptotic. 
Pomalidomide 
Pom/D. 
Relapse. 
Immunomodulatory, anti-
angiogenic. 
Bendamustine 
BD, BTD. 
Relapse. 
Alkylating agent. 
Abbreviations: CVD, cyclophosphamide, bortezomib, dexamethasone; CTD(a), 
cyclophosphamide, thalidomide, dexamethasone (attenuated); PAD, bortezomib, adriamycin, 
dexamethasone; M200, melphalan 200mg/m2; MPT, melphalan, prednisolone, thalidomide; 
MPR, melphalan, prednisolone, lenalidomide; VMP, bortezomib, melphalan, prednisolone; 
VTD, bortezomib, thalidomide, dexamethasone; BTD, bendamustine, thalidomide, 
dexamethasone; Rd, lenalidomide, dexamethasone; Pom/D, pomalidomide, dexamethasone; 
BD, bendamustine, dexamethasone. 
1.1.5 Clinical drug resistance 
Eventually patients will become resistant to currently available anti-myeloma agents 
and/or are unable to receive chemotherapy because of co-morbidities including 
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treatment-related toxicities. The occurrence of disease relapse after the apparent 
eradication of all evidence of the clonal population (i.e. after so-called stringent 
complete response, defined by no evidence of clonal BM plasma cells, no detectable 
serum or urine monoclonal proteins, and normal serum free light chain quantification 
and ratio) indicates the persistent survival of a small population of clonal cells 
resistant to the original treatment. More frank drug resistance is seen when, clinically, 
there is the loss of disease response to an agent being currently used, and/or failure to 
respond to an agent that was previously effective.   
1.2 Multiple myeloma - current biological models of drug 
resistance 
1.2.1 The progenitor compartment 
The cancer stem cell (CSC) is hypothesised to be responsible for tumorigenesis, 
disease relapse and metastases in malignant disease and putative CSCs have been 
identified in diverse malignancies including acute myeloid leukaemia 23, breast 
cancer 24, and brain tumours 25. In these examples, fractions with distinctive 
phenotypes (e.g. CD34++CD48− in AML) have been identified which show 
consistently greater capacity to engraft in xenograft models, compared to the bulk 
tumour. These sub-populations have also been found to possess various ‘stem cell’ 
attributes: formation of spheroids in vitro 25; expression of stem cell markers such as 
Oct-4 24 and dysregulation of important self-renewal pathways such as Wnt, 
Hedgehog 26 and Notch. 
The existence of a CSC in multiple myeloma was first proposed in 1977 when 
Hamburger and Salmon 27 established a soft agar-based assay to grow colonies of 
malignant plasma cells from the bone marrow aspirates of patients with MM. The 
authors demonstrated a plating efficiency of 0.001-0.1% with a linear relationship 
between the concentration of cells plated and the number of colonies generated; this 
supported the theory that each colony was derived from a single (stem) cell. The 
cells comprising each colony had plasmablast or plasma cell morphology, intra-
cytoplasmic immunoglobulin and a high proportion of actively cycling cells. 
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It was not until 2004 that a specific phenotype was proposed for the putative MM-
CSC. Syndecan-1 (CD138) is a transmembrane heparan sulfate proteoglycan and is a 
highly specific marker for terminally differentiated plasma cells, being absent from 
all other B-lineage and haematopoietic cells. Matsui et al. 28 postulated that the 
precursor population in MM might be clonally related to the bulk malignant cell 
population but lack the maturity marker and therefore be CD138-negative (CD138−). 
The heparan sulfate proteoglycans (HSPGs) are an important group of 
transmembrane macromolecules, comprising a core protein to which un-branched, 
polysaccharide heparan sulfate (HS) chains are covalently attached. Their pattern of 
expression is tightly regulated and cell type- and lineage-specific. They are thought 
to be involved in cell-cell and cell-matrix adhesion and also in cell proliferation 
(review 29). HSPGs function both through their core protein and their attached HS 
chains. The core protein of syndecan-1 is known to bind integrin molecules 30 and 
signaling is believed to occur via the cytoplasmic domain, which contains peptide 
sequences that may interact with cytoskeletal proteins and serve as substrates for 
cellular kinases. Additionally the HS chains of HSPGs may bind and present a 
variety of proteins including cytokines. CXCL12 is an important chemokine within 
the BM plasma cell niche and the splice variant CXCL12γ has been demonstrated to 
bind HS chains with particular avidity 31.  
Syndecan-1 is the principal HSPG expressed on malignant plasma cells and 
suppressing its expression results in the absence of HS chains on MM cells, coupled 
with reduced cell proliferation and survival 32,33. It has been shown to bind a number 
of chemokines, cytokines, growth factors and ECM proteins in MM: it acts as a co-
receptor for hepatocyte growth factor (HGF) and other members of the epidermal 
growth factor (EGF) family 34, promoting signaling via the phosphatidylinositol 3-
kinase (PI3K)/AKT and RAS/mitogen-activated protein kinase (MAPK) pro-survival 
pathways. Two other important growth factors for MM cells within the BM niche are 
A PRoliferation-Inducing Ligand (APRIL) and B-cell activating factor (BAFF) 
which both act through the nuclear factor-κB (NF-κB) as well as the PI3/AKT and 
MAPK pathways. Both factors bind to B-cell maturation antigen (BCMA) and 
transmembrane-activator and calcium-modulator and cyclophilin ligand-interactor 
(TACI) receptors, which are widely expressed on MM cells, but it is known that the 
activation of TACI by APRIL usually requires interaction with syndecan-1 35,36.  
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Matsui's hypothesis that the CD138− sub-population of the MM clone was 
clonogenic was supported by the finding of clonotypic (clonally-related) circulating 
B-cells in the peripheral blood of some MM patients 37-39. Matsui's group evaluated 
CD138+ and CD138− sub-populations within two human myeloma cell lines 
(HMCL), RPMI-8226 and NCI-H929. It was shown that the CD138− cells had 
greater colony-forming (‘clonogenic’) potential than the CD138+ cells within an in 
vitro colony-forming assay; they expressed typical B-cell antigens such as CD19 and 
CD20 and they appeared more proliferative (higher Ki67 expression). This pattern 
was also seen in primary tumour cells isolated from MM patient BM aspirates (21 
out of 24 aspirates) and a smaller number of patient PB samples (two out of four); 
CD138+CD34− MNCs were compared to CD138−CD34− MNCs, both presumed to 
be clonal. Primary CD138−CD34− BM MNCs successfully engrafted into 
NOD/SCID mice, with subsequent infiltration of the murine BM by human CD138+ 
cells and detectable human immunoglobulin (matching the original patient isotype) 
in the peripheral blood of the mice. In contrast, primary CD138+CD34− BM MNCs 
did not engraft or recapitulate disease in the NOD/SCID system. Colony formation 
(assessed by the in vitro colony-forming assay) was reduced by depleting the 
CD138−CD34− BM MNCs of CD45+CD19+CD22+ cells or by treating with a 
monoclonal anti-CD20 antibody (Rituximab). 
Following this landmark work, Matsui et al. 40 extended their characterisation of the 
MM CSC by demonstrating persisting clonogenicity of HMCL-derived CD138− 
cells after treatment with commonly used anti-MM agents, specifically 
dexamethasone, lenalidomide, bortezomib and cyclophosphamide. This was also 
seen in primary MM cells and supported the concept of a drug resistant stem cell 
compartment. Additional stem cell characteristics were reported in the HMCL 
CD138− sub-population: enhanced ABCG2/BCRP transporter activity (Hoescht side 
population assay), high aldehyde dehydrogenase activity (Aldefluor assay) and 
quiescence. Further evidence for the CD20+CD27+ phenotype was provided by 
demonstrating reduced colony formation following (i) depletion of CD138− cells 
bearing these antigens using Microbeads; (ii) treatment of CD138− cells with 
Rituximab (anti-CD20) or (iii) treatment of CD138− cells with Alemtuzumab (anti-
CD52). Finally CD138−CD19+CD27+ B cells were isolated from the peripheral 
blood of four patients with MM and all were successfully engrafted into NOD/SCID 
 30 
mice, with resultant human CD138+ marrow infiltration. The clonality of the cells 
was demonstrated by PCR of patient-specific sequences in the immunoglobulin 
heavy chain gene. 
In a parallel study by the same group, Peacock et al. 41 reported on the role of 
Hedgehog (Hh) signaling in MM cancer stem cells. The greatest Hh activity was 
concentrated in the CD138−CD19+ subset of HMCL and primary MM cells. 
Administration of an Hh ligand promoted expansion of this compartment, without 
differentiation, and blockade of the Hh pathway inhibited colony formation by 
CD138− cells and led to terminal differentiation into CD138+ cells. More recently 
this group 42 examined baseline telomerase activity (TA) in HMCL and primary MM 
cells and used imetelstat to block TA. Prolonged TA blockade in CD138− cells 
resulted in reduced telomere length and reduced clonogenicity. Seventy-two hour 
treatment of CD138− cells also reduced clonogenicity and led to downregulation of 
key stem cell genes such as OCT3/4, NANOG, SOX2, GAS1 and HES1. Treatment of 
NOD/SCID mice with imetelstat after infusing HMCL reduced MM cell engraftment 
and prolonged survival, as did infusing HMCL pre-treated with imetelstat. Most 
recently the Matsui group used the 5T33 MM mouse model 43 to evaluate the 
CD138+ and CD138− fractions. Interestingly, in this setting the CD138+ fraction 
had greater clonogenic and tumour-initiating capacity, coupled with an increased 
proportion of side population cells and enhanced aldehyde dehydrogenase activity, 
when compared to the CD138− fraction.  
MM CSCs were studied indirectly by Kirshner et al. 44; they reported a novel system 
in which whole BM MNCs were cultured in a three-dimensional, semisolid media - 
Matrigel. When BM MNCs from normal donors were set up, the system 
recapitulated normal BM micro-architecture. This was lost when MM BM MNCs 
were cultured; they developed a more disordered three-dimensional structure. 
However, non-proliferating, clonogenic, CD20+ cells localised to the ‘endosteum’ 
(fibronectin/collagen coating wells), mimicking normal haematopoietic stem cells, 
and were resistant to melphalan. 
Reports from other groups have challenged the postulated CD138− MM stem cell 
phenotype. In 1998 Yaccoby et al. devised a novel xenograft model for MM 45.  
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Primary MM cells were injected into fragments of human foetal bone implanted into 
SCID mice (so-called SCID-Hu model). Engraftment was confirmed by the finding 
of detectable human immunoglobulin in murine peripheral blood and the disease was 
recapitulated with high blood calcium levels and enhanced osteoclast activity in the 
human bone fragments, coupled with abnormally high bone resorption. This was the 
first model in which primary MM cells (as opposed to HMCL) were successfully 
engrafted into a xenograft host and the presence of the human BM microenvironment 
provided by a foetal bone fragment was clearly critical. Using this system, the group 
then went on to explore requirements for successful primary MM cell engraftment 46. 
Purified CD38++CD45− primary BM plasma cells from MM patients consistently 
engrafted and proliferated in SCID-hu mouse models and sequential transfer of 
tumour cells into fresh murine hosts was possible. Unselected BM and peripheral 
blood MNCs from MM patients also engrafted. However, plasma cell-depleted (i.e. 
CD138−) BM and peripheral blood cells were not capable of engraftment.   
A number of groups have demonstrated that CD138 (syndecan-1) plays a critical role 
in the growth, dissemination and survival of both HMCL and primary MM cells. In 
2002 the Sanderson group 47 reported that overexpression of soluble syndecan-1 by 
the B cell line ARH-77 made it hyperinvasive in a collagen-gel model relative to 
controls. Reducing syndecan-1 expression 48 by three different methods inhibited the 
growth of both primary MM tumours in a SCID-Hu model and CAG myeloma cell 
line tumours in SCID mice. Impaired growth of MM cells was also seen when 
syndecan-1 was knocked down using small hairpin RNA (shRNA) in a different 
xenograft model 33. More recently Reijmers et al. 32 evaluated the importance of 
syndecan-1 HS core proteins and HS side chains in HMCL. They demonstrated that 
knockdown of HS on HMCL reduced growth rates and increased baseline apoptosis 
in vitro. A similar effect was seen after knockdown of EXT1, a co-polymerase 
essential for HS side chain synthesis. In vivo, the same pattern was seen, with a 
striking suppression of tumour growth in the xenograft model when EXT1 was 
knocked down. They postulated that syndecan-1 and its side chains are crucial for 
growth and survival of MM cells due to their interactions with ligands in the BM 
microenvironment such as integrins and cytokines.  
 32 
Following on from the observations of Matsui, a number of other groups sought to 
examine the CD138+ and CD138− subpopulations from the specific perspective of 
clonogenicity and so-called stem cell characteristics. Like Matsui's group, the 
Anderson group 49 utilised Hoescht 33342 staining to identify and characterise the 
so-called ‘side population’ (SP) in a number of HMCL and in primary MM BM 
samples. This technique has been used in a number of malignancies to identify cells 
that may have stem cell-like properties, with distinctive flow cytometric 
characteristics owing to enhanced efflux of the DNA-binding dye Hoescht 33342. 
The group observed that the SP cells expressed CD138 (in contrast to Matsui's 
findings) had enhanced ABCG2 transporter expression and activity and higher 
proliferation compared to non-SP cells. SP cells possessed both clonogenic potential 
and the capacity to regenerate the original population containing both SP and non-SP 
fractions. In vivo, the SP population had higher tumorigenicity compared to non-SP 
cells. Interestingly, adherence to BM stroma increased the size and activity of the SP 
fraction. Thus this work seemed to suggest that clonogenic function was independent 
of CD138 expression levels. The side population was also evaluated by Nara et al. 50. 
SP and non-SP cells were isolated from a number of HMCL (including RPMI-8226) 
and CD138− populations were found in both. Serial transplantation of both SP and 
non-SP cells into NOD/Shi-SCID IL-2γnul mice revealed that SP cells had a much 
greater capacity for self-renewal. In keeping with this, HMCL SP cells upregulated a 
number of oncogenes involved in cell cycle and mitosis, such as CCNB1, when 
compared to non-SP cells, and some of the same genes were upregulated in primary 
MM SPs.  
These findings were supported by those of Chiron et al., who examined the 
clonogenicity of the CD138+ and CD138− fractions of two primary plasma cell 
leukaemia samples 51. In both patients, the number of colonies generated correlated 
directly to the percentage of CD138+ cells in the starting cell fraction, with no 
colonies generated by the CD138− fractions. A novel cell line was generated from 
the CD138+ fraction of one primary sample. 
The impact of CD138 expression on clinical outcome has only been reported by one 
group: Kawano et al. 52 analysed a large series of primary MM BM samples (90 new 
diagnosis, 15 relapse), specifically evaluating the phenotype of CD38++ clonal 
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tumour cells, and dividing them into patients with ‘high’ CD138 (>20% 
CD38++CD138−) and ‘low’ CD138 (<20% CD38++CD138−). A correlation 
between relapsed/progressive disease and low CD138 expression was found, and in 
patients with newly diagnosed MM or in those receiving high-dose melphalan with 
autologous stem cell rescue, a poorer outcome and reduced overall survival was seen 
in those with low CD138.  Two cell lines were established from a single MM patient 
with low CD138 expression, derived from the CD138− (KYMM-1) and CD138+ 
(KYMM-2) MM cells. When expression of key B lineage genes was examined, 
KYMM-1 had a more immature phenotype with upregulation of BCL6 and PAX5, 
and downregulation of IRF4, PRDM1 and XPB1, when compared to KYMM-2. In 
killing assays, KYMM-1 cells were less sensitive to lenalidomide. It was 
hypothesised that these features were associated with lower CD138 expression. 
Hosen et al. 53 sought to clarify whether Matsui's subpopulation of CD138−CD19+ 
clonogenic cells was the same as the clonotypic CD19+ B cells previously identified 
by groups such as Pilarski et al. Their in vitro MM colony-forming cells were 
enriched for CD138−CD19−CD38++ plasma cells, while in contrast CD19+ B cells 
failed to generate MM colonies. In vivo, in a SCID-rab model, 
CD138−CD19−CD38++ plasma cells and CD138+ plasma cells engrafted (three out 
of nine and four out of nine respectively) while CD19+ B cells did not. This 
suggested that CD19+ clonal MM cells lacked the capacity to engraft, in contrast to 
Matsui's reports.  
The ability of different primary MM BM cell fractions to engraft different xenograft 
models (NOD/SCID, NSG or RAG2−/γc− mice) was evaluated by Kim et al 54. A 
clonogenic CD38++CD138+ fraction was identified prospectively, which was 
capable of repopulating a human foetal bone graft with clonotypic CD19+CD38low 
and CD38+CD138+. Sub-fractionating CD38++CD138+ cells showed that 
specifically CD45low/− or CD19− cells were capable of engraftment, while those 
that were CD45+ or CD19+ were not. Some of the inconsistencies between their 
findings and those of Matsui et al. were attributed to differences in the xenograft 
model, emphasising the critical role of the BM microenvironment in allowing 
engraftment of tumour-initiating MM stem cells. 
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Christensen et al. 55 examined 31 primary MM patient BM MNCs and two HMCL 
using the same flow cytometry-based strategies and antibodies as Matsui and found a 
number of important discrepancies. When MM BM MNCs were analysed 
immediately after sampling, a single CD138+ population was seen with no evidence 
of a second CD138− clonal population. However, if there was a time lag between 
sampling and analysis, a CD138− population was apparent. In all cases the CD138− 
cells were AnnexinV-positive (AV+), indicative of apoptosis. In optimally growing 
HMCL, the CD138− population was very small and also AV+. Dexamethasone (Dex) 
treatment and starvation were both able to generate increased percentages of 
CD138−AV+ cells. Finally, qPCR was employed to look for evidence of differential 
translation of CD138 in the two cell sub-populations but none was found. The group 
concluded that the CD138− subpopulation was an apoptotic artefact resulting from 
sampling and handling differences. This supports the observation that apoptotic MM 
cells shed syndecan-1, made in 1998 56.  
1.2.2 The bone marrow microenvironment 
It is now well-accepted that the BM microenvironment is critical for maintaining the 
malignant clone in vivo, through the interactions of multiple pathways (for example, 
the PI3K/AKT-pathway, the JAK/Stat3-pathway and the NF-κB-pathway) in ways 
which are not fully understood. The critical players in the BM microenvironment are 
manifold and varied - the current list is tabulated in Table 1-4 - and these influence 
homing, migration and adhesion, and with that survival and potentially drug 
resistance.  
These interactions also mediate the secondary effects of the malignant MM cells, for 
example bone disease. The hallmark uncoupling of the balanced functioning of bone-
producing osteoblasts and bone-resorbing osteoclasts in MM is mediated through 
soluble factors. Receptor activator of NF-κB (RANK)/ RANK-ligand (RANKL) 
interactions, reduced osteoprotegrin (OPG) and increased MIP-1α all increase 
osteoclast activity, while MM cell-derived DKK1 and T cell-derived IL-3 inhibit 
osteoblast function. Osteoclasts are in turn potent producers of IL-6, APRIL and 
BAFF, further stimulating MM cell growth and survival. 
 35 
Table 1-4 Factors mediating interactions between MM cells and the BM 
microenvironment. 
Soluble factors Cell types 
Cell surface 
receptors 
Extracellular 
matrix 
IL-6 
IGF-1 
IL-3 
VEGF 
HGF 
MIP-1α 
DKK1 
TNF-α 
SDF-1 
APRIL 
BAFF 
MMP2, 7, 9 
Osteoblasts 
Osteoclasts 
Endothelial cells 
Bone marrow stromal 
cells 
Mesenchymal stromal 
cells 
T cells 
Dendritic cells 
Monocytes/ macrophages 
Integrins 
• VLA-4 
• LFA-1 
• Integrin β7 
CD44 
CXCR4 
CCR2, 7 
N- and E-Cadherin 
Collagen 
Laminin 
Fibronectin 
Abbreviations: IL-3/6, interleukin-3/6; IGF-1, insulin-like growth factor I; VEGF, vascular 
endothelial growth factor; HGF, hepatocyte growth factor; MIP-1α, macrophage 
inflammatory protein-1α; DKK1, Dickkopf-related protein 1; TNF-α, tumour necrosis 
factor-α; SDF-1, stromal-derived factor-1; APRIL, a proliferation inducing ligand; BAFF, B 
cell activating factor; MMP, matrix metalloproteinases; LFA-1, lymphocyte function-
associated antigen-1; VLA-4, very late antigen-4. Adapted from Khwaja et al, Chapter 6: 
The myeloma bone marrow microenvironment and survival signaling. Myeloma. Cambridge 
University Press, 2014. 
Initially it was believed that soluble factors within the BM liquid milieu were most 
important for the maintenance and expansion of MM cells in vivo. IL-6, VEGF, IGF-
I, TNF-α, SDF-1α and CD40 are just some of the cytokines and growth factors which 
have been implicated in promoting MM cell survival (see reviews 57,58, Figure 1-3).  
In 1994, Kim et al. 59 demonstrated that the adhesion of HMCL to vascular cellular 
adhesion molecule 1 (VCAM-1) on BMSCs upregulated IL-6 secretion by BMSC, 
which in turn induced proliferation and blocked apoptosis in HMCL. 
Paraformaldehyde fixation of BMSCs prior to co-culture with HMCL abrogated IL-6 
secretion without impairing adherence 60, confirming the BMSCs as the source of the 
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soluble factor. IL-6 upregulation is triggered at least in part through the NF-κB-
binding motif in the IL-6 gene promoter. IL-6 may act both as a proliferative factor 
and also to directly inhibit Dex-induced apoptosis 61. 
 
Figure 1-3 Interactions between myeloma cells and the bone marrow 
microenvironment. 
This depicts five key cellular players within the BM microenvironment which interact with 
MM cells via soluble factors or direct cell-cell contact. Adapted from 58. 
It has subsequently become apparent that cell-cell interactions are also critical, 
between myeloma cells and their multiple cell neighbours, including other 
haematopoietic cell types (B- and T-lymphocytes, NK cells, dendritic cells and 
macrophages, megakaryocytes and platelets) and non-haematopoietic BM stromal 
cells (fibroblasts, chondrocytes, osteoblasts and osteoclasts). The contributions of 
these two broad categories were examined by Dalton's group 62, in the context of 
drug resistance. They had previously demonstrated that HMCL and leukaemia cells 
adhering to the extracellular matrix (ECM) component fibronectin had increased 
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resistance to a number of cytotoxic drugs 63. They went on to examine the influence 
of intact live BMSCs on HMCL sensitivity to the topoisomerase II inhibitor 
mitoxantrone. This was chosen as a surrogate for doxorubicin, the topoisomerase 
inhibitor used most commonly clinically against myeloma, because doxorubicin 
fluoresces and can therefore interfere with flow cytometry-based assays. They 
compared four culture conditions: (1) HMCL co-cultured (both adherent and non-
adherent) with BMSCs; (2) HMCL adhered to BMSCs; (3) HMCL in Transwell-
culture with BMSCs (i.e. without direct cell-cell contact); and (4) HMCL cultured in 
media conditioned by the prior presence of BMSCs. BMSCs were derived from 
normal healthy donors after long term culture of BM MNCs, and comprised 
predominantly fibroblasts. When NCI-H929 or RPMI-8226 cells were treated with 
mitoxantrone, those cultured alone in suspension had almost twice as much apoptosis 
compared to those co-cultured with BMSCs. When HMCL were co-cultured with 
BMSC for varying durations, then separated into stably adherent and suspension 
fractions, and then treated with mitoxantrone, the same trend was seen with 
significantly reduced killing in the BMSC-adherent HMCL. When HMCL cultured 
in Transwell inserts above BMSC were treated alongside HMCL cultured in BMSC-
conditioned media, there was much greater killing seen in conditioned media. This 
implied that while soluble factors secreted by BMSC were important, a dynamic 
interplay was required between HMCL and BMSCs to stimulate production of the 
most protective factors by BMSCs. Interestingly the addition of anti-VEGF, anti-IL-
6 or anti-bFGF blocking antibodies individually to the co-cultures did not ablate the 
protection, implying that a combination of factors was involved rather than a single 
dominant one. It was striking that when HMCL were co-cultured with BMSCs there 
was time-dependent inhibition of DNA synthesis (as assessed by [3H]thymidine 
incorporation) in MM cells, indicative of cell cycle arrest. A BrdU uptake-based 
assay confirmed that this occurred in G1 phase. If a Transwell insert was used, such 
that MM cells were only exposed to soluble factors, the opposite finding was seen, 
with proliferation of HMCL. This highlights the importance of the cellular context - 
the additional cell-cell interactions present with direct co-culture clearly had a 
dramatic effect on the influence of secreted soluble factors on HMCL. 
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1.2.2.1 APRIL 
A PRoliferation-Inducing Ligand (APRIL) is a member of the tumour necrosis factor 
(TNF) superfamily, with both structural and functional homology to other family 
members. It was first implicated in cancer in 1998, when it was found to be 
abundantly expressed in a number of different transformed cells lines and several 
cancer types 64; recombinant APRIL was able to stimulate cell growth in various 
malignant cell lines.  
 
Figure 1-4 APRIL-driven signaling pathways. 
APRIL (red hexagon) interacts with HSPGs, TACI and BCMA on the cell surface (1). This 
interaction with the latter two receptors triggers the recruitment of TRAF molecules, with 
resultant activation of a number of transcription factors (2). This leads to upregulation and 
downregulation of various proteins involved in apoptosis and cell survival (3). Abbreviations: 
HSPGs, heparin sulphate proteoglycans; TRAF, TNF-receptor associated factor. Adapted 
from 65. 
APRIL acts via two receptors: B-cell maturation antigen (BCMA) and 
transmembrane-activator and calcium-modulator and cyclophilin ligand-interactor 
(TACI). These are both shared with another member of the TNF superfamily, B-cell 
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activation factor (BAFF, also known as BLyS), and binding of these receptors by 
APRIL or BAFF activates classical survival pathways including NF-κB 66 (see 
Figure 1-4). 
There is now much greater understanding of APRIL's physiological importance. 
Initially Varfolomeev et al. 67 observed that an APRIL knockout mouse appeared to 
be entirely normal, in viability, fertility and in immune cell compartment number and 
function. It was therefore assumed that APRIL was dispensable and that BLyS/ 
BAFF was the dominant plasma cell survival factor in mice. Subsequently it was 
noted that these mice had decreased secreted IgA, secondary to defects in class-
switch recombination 68. This effect appeared to be mediated through the TACI 
receptor, with co-ligation of HSPGs playing an essential role within this pathway 69. 
APRIL has also been shown to be a critical survival factor for activated B cells and 
plasmablasts in adult bone marrow, and once again co-binding to HSPGs appeared 
important 70. This population of transitory plasmablasts required APRIL in order to 
differentiate into long-lived plasma cells, enhancing immunoglobulin responses. 
Plasma cells outside the BM have also been shown to require APRIL for their 
survival. Huard's group demonstrated that in human mucosal tissue, APRIL was 
secreted by neutrophils and retained by HSPGs in APRIL-rich ‘plasma cell niches’ 
containing increased numbers of IgG-producing plasma cells 71. The same group 
went on to explore the source of APRIL within the BM 72, and demonstrated that 
APRIL production was triggered during haematopoiesis by stem cell factor, 
thrombopoietin, IL-3 and FMS-like tyrosine kinase 3 ligand. Thus secretion peaked 
in myeloid precursors, ensuring that haematopoiesis and long-term plasma cell 
survival were linked within the BM. The role of HSPGs in APRIL-plasma cell 
interactions was evaluated by Reijmers et al 73. They knocked-down a key enzyme 
controlling HSPG chain flexibility, and thereby ligand binding, and demonstrated 
that this resulted in decreased plasma cells numbers and immunoglobulin levels. 
There appeared to be a particular failure to respond to APRIL-mediated survival 
signals, implying that normally conformed and functioning HSPGs are essential for 
the recruitment and retention of factors needed to support plasma cell survival. 
Syndecan-1 has been specifically shown to act as a co-receptor for APRIL and TACI 
on the MM cell surface 74. 
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It has been shown that the majority of HMCL and primary MM cells express either 
BCMA, TACI or BAFF-R 75, while APRIL and BLyS/BAFF are also consistently 
present in the BM of MM patients. Moreaux et al. were the first group to propose 
that APRIL and BAFF were directly implicated in drug resistance in MM cells 76. 
They first confirmed the over-expression of BCMA, TACI and BAFF-R by HMCL 
and primary MM cells. APRIL and BAFF were also expressed by the majority of 
HMCL and primary MM cells, detectable as RNA and, in the case of APRIL, in the 
culture supernatant. IL-6-dependent HMCL (XG-13, -14 and -20) were able to 
proliferate in the absence of IL-6 if APRIL or BAFF were present, and were also 
protected from IL-6 deprivation-induced apoptosis. Cytokine-independent HMCLs 
proliferate autonomously, but growth of RPMI-8226 and L363 was blocked by the 
addition of the receptor antagonist TACI-Fc, and this effect could be reversed by the 
addition of excess recombinant APRIL and BAFF. These two lines were sensitive to 
Dex-induced apoptosis, but significant protection was seen in the presence of both 
APRIL and BAFF. Enhanced survival after Dex treatment was also seen in primary 
MM cells in the presence of APRIL or BAFF. These effects were mediated by NF-
κB and PI3K/AKT pathway activation, and could be inhibited by small molecule 
inhibitors of these pathways.  
Subsequently the same group demonstrated that differences in TACI gene expression 
and that of 658 other genes in primary MM tumours at diagnosis allowed two groups 
to be distinguished 77, with a BM microenvironment-dependent (TACIhigh) and a 
plasmablastic signature (TACIlow). Importantly, TACIlow patients had clinical 
parameters associated with a poorer clinical prognosis. Moreaux et al. also confirmed 
that monocytes, neutrophils and osteoclasts are the main source of BAFF and APRIL. 
The implication of this segregation was that TACIhigh patients might specifically 
benefit from treatment by BAFF/APRIL inhibitors. This was evaluated by Yaccoby 
et al. 78 when they tested two compounds: Atacicept (TACI-Ig) which blocks both 
APRIL and BAFF binding, and BAFFR-Ig, which only blocks BAFF. Using their 
SCID-hu model, they confirmed Moreaux's proposal, showing that the growth of 
MM cells derived from TACIhigh patients were inhibited by Atacicept to a much 
greater degree than those derived from TACIlow patients. BAFFR-Ig treatment 
produced similar but weaker inhibition.  
 41 
Our own group has recently demonstrated abundant expression of APRIL in MM 
patient BM trephines, synthesized by myeloid cells and taken up by MM cells 18. It 
was also seen that APRIL stimulated cell cycle progression in primary CD138+ MM 
cells, but only in genetic sub-types of MM carrying two recurrent translocations into 
the IgH gene locus and expressing cyclin D2.  
1.2.3 Survival pathways underlying drug resistance 
A wide array of interacting factors have been implicated in MM cell survival and 
drug resistance, and these feed into a number of key cellular pathways known to be 
relevant in cell survival more broadly.  
1.2.3.1 NF-κB  
Dysregulated NF-κB signaling has been implicated in a number of cancer types, 
which reflects its central physiological role in immunity and inflammation. NF-κB 
itself is a key regulator of cell survival and proliferation, and may be activated by 
one of two routes: the canonical classical pathway, activated by ligands such as TNF, 
or the non-canonical alternative pathway, activated by APRIL/ BAFF. Within MM, a 
number of genetic abnormalities in NF-κB pathway components have been identified, 
for example TRAF3 deletion or inactivation of the negative regulator CYLD 79. 
There are also a number of BM microenvironmental stimuli that seem to act through 
this pathway, including BAFF and APRIL 80 and adhesion to extracellular matrix 
components such as fibronectin 81. Importantly, it is thought that the proteosome 
inhibitors, of which bortezomib (BZM) is the most widely used example, are 
potential antagonists to this pathway, although some groups have demonstrated 
resistant NF-κB activation in the presence of BZM 82. 
1.2.3.2 PI3K/AKT/mTOR 
PI3K proteins are a group of enzymes that activate downstream targets through a 
series of phosphorylation steps, leading to the activation of AKT and the formation 
of mTOR signaling complexes. Ultimately this pathway has a profound influence on 
cellular proliferation and survival through a host of complex positive and negative 
downstream regulators, and is commonly dysregulated in malignancy. This may 
occur through mutational events that either increase activation of the component 
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parts or through loss of function mutations that impair the natural inhibitors of the 
pathway, such as PTEN. In MM a number of the BM microenvironment factors, both 
soluble and contact-based, activate the PI3K pathway, including IL-6, IGF-I, BAFF 
and APRIL 18,76,83,84. A number of preclinical studies have suggested that inhibitors 
of this pathway may be toxic to MM cells, particularly those with t(4;14) or t(14;16) 
85, and the alkylphospholipid perifosine which impairs AKT activation has entered 
early phase clinical trials. It appears that combination treatments are most likely to be 
effective 86.  
1.2.3.3 RAS/RAF/MEK 
A large proportion of MM patients are found to have activating mutations in NRAS 
or KRAS genes 87. RAS activation has numerous complex downstream targets, but a 
key effector is the RAF/MEK/MAPK protein complex. As with PI3K/AKT, a 
number of the known MM survival factors act through this pathway, including IL-6, 
IGF-I, MIP-1α and SDF-1. 
1.2.3.4 JAK/STAT 
IL-6 and SDF-1 are both considered to act via activation of JAK signaling in MM. 
Activated Janus tyrosine kinases then activate a number of downstream signaling 
pathways, including STAT, PI3K/AKT and RAS/RAF/MEK. Mutations in these 
factors are rare in MM but they are likely to be involved intermediates for a number 
of survival factors within the BM. 
1.2.3.5 Notch signaling 
In addition to soluble factors, the resistance offered by BMS in MM also results from 
interactions requiring direct cell-cell contact 62. The Notch pathway is a highly 
conserved pathway with critical embryological roles in cell proliferation, survival, 
apoptosis and differentiation in a number of tissues. Increasingly it is a pathway of 
interest in the context of malignancy as it appears to be dysregulated or abnormally 
activated in a number of malignancies (reviewed in 88), both solid, e.g. breast, lung, 
colon, and haematological, e.g. T-ALL 89. There is growing evidence that the Notch 
pathway may be involved in both inherent and acquired drug resistance and has been 
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associated with cancer stem cells in a number of solid organ malignancies (breast 
cancer, glioma).  
Mammalian cells may express any one or all of four cell-associated Notch receptors 
(Notch1, Notch2, Notch3 and Notch4), which may be activated by any one of five 
Notch ligands from either the Jagged- (Jagged1 (Jag1), Jag2) or Delta-like families 
(Delta-like Ligand1 (DL1), DL3, DL4) (see Figure 1-5).  
 
 
Figure 1-5 Mammalian Notch receptors and ligands 
Signal-initiating cells express Notch ligands of the Jagged families (JAG1, JAG2) or Delta-
like (DL1, DL3, DL4). There are four mammalian heterodimeric Notch receptors (Notch1, 
Notch2, Notch3 and Notch4) are expressed by signal-receiving cells. Abbreviations: NECD, 
Notch extracellular domain; NTMIC, Notch transmembrane and intracellular domain; CR, 
cysteine rich; EGF, epithelial-like growth factor; DSL, Delta, Serrate and Lag-2; Lin, LIN-
12 repeats; HD, heterodimerisation domain; RAM, RBP-J-associated molecule; ANK, 
ankyrin repeats; TAD, transactivation domain; PEST, proline, glutamic acid, serine, 
threonine sequence; (adapted from 90). 
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There is significant structural homology between both the ligands and the receptors. 
Epithelial growth factor-like (EGF) repeats and the distal amino-terminal domain 
called DSL (Delta, Serrate, and Lag-2) are present in all the ligands. DSL is involved 
in receptor binding. Jag1 and Jag2 contain an additional proximal cysteine-rich (CR) 
domain between the EGF-like repeats and the plasma membrane. The Notch 
receptors are heterodimeric - following translation, the Notch receptor polypeptide is 
glycosylated and then cleaved to form two subunits (see review 91). These are the 
Notch extracellular domain (NECD) and the Notch transmembrane and intracellular 
domain (NTMIC) and they are transported to the cell membrane as a complex held 
together by non-covalent bonds between the N- and C- terminal halves of the 
heterodimerization domain. The NECD contains EGF-like repeats, a cysteine-rich 
LIN-12 repeats (LIN domain), which prevents ligand-independent activation, and the 
proximal HD domain. The NTMIC contains an RBP-J-associated molecule (RAM) 
domain (closest to the cell membrane), followed by ankyrin repeats (ANK) that bind 
to the CSL (CBF1/RBP-J/Suppressor of Hairless/LAG-1) transcription factor, a 
transactivation domain (TAD; only Notch1 and Notch2), and a PEST (proline, 
glutamic acid, serine, threonine) sequence that regulates the stability of NICD. 
The mechanism of signal transduction is a hallmark of the Notch pathway - 
activation relies on the ligand causing proteolysis of the receptor, with the release of 
an active fragment capable of forming a transcription complex. Signaling is initiated 
when DSL and areas of the EGF-repeat domain of the ligand bind to particular EGF-
repeats within NECD (Figure 1-6 (1)). This causes a conformational change in the 
Notch receptor, exposing a cleavage site in the NTMIC. Cleavage at this point by 
ADAM (A Disintergrin And Metalloprotease) proteases creates a membrane-tethered 
intermediate (Figure 1-6 (2)) called Notch extracellular truncation (NEXT), which is 
a substrate for gamma secretase. 
The action of gamma secretase on NEXT releases the intracellular portion of the 
receptor (NICD; Figure 1-6 (3)) into the cytoplasm, from where it can translocate 
into the nucleus (Figure 1-6 (4)). Here NICD heterodimerizes with DNA-binding 
transcription factor CSL (Figure 1-6 (5)). CSL (CBF1/ RBP-J) is a transcriptional 
repressor but interaction with NICD converts it into a transcriptional activator. A 
complex is formed with additional transcriptional regulators such as MAML1. Thus 
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activation of Notch receptors leads directly to transcriptional de-repression of genes, 
including the HES and HEY families of transcription factors 92. Recent work in T-
ALL suggests that Notch signaling also activates the NF-κB pathway, mediated by 
Hes-1-induced suppression of CYLD 93, a negative regulator of NF-κB. 
 
Figure 1-6 Activating the Notch signaling pathway. 
Signaling is initiated by ligand binding to Notch receptor (1). This initiates two subsequent 
proteolytic cleavages of the Notch receptor by the ADAM-family protease (2) and then γ-
secretase (3). The NICD is thus released into the cytoplasm (4) and translocates to the 
nucleus where NICD heterodimerises with the DNA-binding transcription factor CSL (5). 
Additional co-activators are also recruited, including mastermind-like proteins (MAML1-3) 
ultimately leading to transcription of downstream target genes, such as those belonging to 
the HES and HEY families. Abbreviations: ADAM, a disintergrin and metalloprotease; 
NEXT, Notch extracellular truncation; NICD, Notch intracellular domain; CSL, CBF1/RBP-
J/Suppressor of Hairless/LAG-1; adapted from 90 and 91. 
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Activation of Notch signaling therefore requires interaction between cell surface 
receptors and membrane-associated ligands on adjacent cells. There is cross-talk 
with bi-directional signaling (both heterotropic and homotropic) activated by 
receptor-ligand interactions, allowing downstream modulations in both cell 
populations. The second cleavage step in Notch activation (Figure 1-6 (3)), in which 
gamma secretase acts on NEXT to release NICD into the cytoplasm, has become an 
attractive target for pharmacological intervention. Gamma secretase inhibitors (GSI) 
94 are under investigation in a number of haematological malignancies but Notch 
proteins are not their only substrate - they may also cleave β-amyloid precursor 
protein (hence their use in Alzheimer’s disease), syndecan and CD44. There are 
therefore potential off-target effects, which may be erroneously attributed to Notch 
pathway inhibition. 
Notch ligands (Jag1/2, DL1/3/4) are expressed by BM stromal cells 95,96 and several 
genes involved in Notch signaling are aberrantly expressed in mouse plasmacytoma 
97.  Notch receptors and ligands have been described in HMCL 96,98,99 and in primary 
tumours by immunohistochemistry (IHC) on BM sections. Skrtic et al. 100 evaluated 
Notch1 and Jag1 expression by IHC on 80 newly diagnosed MM BM trephines and 
20 MGUS patients. Notch1 and Jag1 were both positive in 92% of MM but 0% of 
MGUS cases. Notch1 was strongly expressed in the majority whereas Jag1 
expression was relatively weak. Progression from MGUS to MM was associated 
with upregulation of both proteins. There was no association between expression of 
either Notch1 or Jag1 and IgH translocation status or clinical outcome. However, 
strong Notch1 signaling was associated with a diffuse infiltrative pattern of BM 
involvement. 
There do not appear to be fixed relationships between specific Notch receptors and 
their various ligands, with different ligands implicated in different disease settings or 
by different research groups. Cheng et al. 101 looked at the regulation of dendritic cell 
(DC) differentiation and demonstrated that while DL1 promoted DC maturation, 
Jag1 stimulated the accumulation of DC precursors and prevented their subsequent 
transition to a more mature phenotype. Expression of the two ligands by stromal cells 
differed by location, such that BM stroma was strongly Jag2+ whereas splenic 
stroma expressed more DL1, and Notch activation by the two ligands produced 
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different patterns of downstream HES1 expression. This suggests the presence of 
ligand-specific effects in which Notch signaling results in differing outcomes. Choi 
et al. 102 lent further support to this concept in their work looking at expression of 
Notch ligands by non-small cell lung cancer cell lines. Jag1, Jag2, DL1, and DL3 
were all present, but Jag1 and Jag2 were differently regulated - in certain EGFR-
dependent lines Jag1 expression was also dependent upon EGFR activation whereas 
Jag2 expression was not. Jag1 appeared critical for cell survival, whereas Jag2 
functioned as a chemoattractant for human monocytes. Jag2 depletion led to 
enhanced expression of IL-1 and other related pro-inflammatory cytokines. In these 
lines at least distinct biological roles for Jag1 and Jag2 were present. 
In 2004, Nefedova et al. 96 demonstrated Notch1 activation in HMCL (NCI-H929, 
RPMI-8226 & U266) after co-culture with primary BM stromal cells, fibroblast cell 
lines (3T3) expressing Jag1 and in the presence of soluble recombinant Jag1. This 
activation was evidenced by upregulation of the downstream target HES1 in HMCL 
expressing Notch1 and Notch2. Jag1-mediated Notch activation was associated with 
HMCL cell cycle arrest. When treating HMCL with melphalan and mitoxantrone, 
apoptosis could be attenuated by prior Notch1 activation, and it was therefore 
proposed that Notch-1 signaling might be a mechanism mediating BM stromal 
influence over MM cells, including drug resistance. Of note, they demonstrated that 
U266 cells lacked Notch1 and that they did not have any reduction in chemotherapy-
associated killing in the presence of Jag1+ fibroblasts. After overexpressing either 
intact Notch1 or intracellular Notch1 in U266 cells, there was a significant increase 
in resistance to drug-induced apoptosis, suggesting that Notch1 was a critical 
requirement for drug resistance in this system. 
In the same edition of Blood, Jundt et al. 98 described high Notch1, Notch2 and Jag1 
expression on primary MM cells (detected by IHC) and HMCL (by Western blotting), 
in contrast to low or absent expression by non-maligant plasma cells. They also 
demonstrated baseline constitutive Notch activation in RPMI-8226, OPM-2, NCI-
H929, LP-1 and U266 cells by RT-PCR of HES1. Upregulation of HES1 was seen in 
all but NCI-H929 and U266 cells after co-culture with Jag1+ HtTA-jag10 cells (a 
modified HeLa-derived cell line). Interestingly and in direct contrast to the findings 
of Nefedova et al., Jag1 exposure was associated with increased proliferation in all 
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HMCL with the exception of NCI-H929 and U266 cells (measured by thymidine 
incorporation). This effect could be inhibited by the addition of a gamma secretase 
inhibitor (GSI) - DAPT. 
More recently the ability of GSI (unspecified, Enzo Life Sciences) to inhibit MM cell 
growth has also been demonstrated by Hu et al 103. They treated RPMI-8226 cells 
with escalating doses of GSI and showed that proliferation (quantified by MTT assay) 
was inhibited in a dose- and time-dependent manner, with higher proportions of cells 
in G0/G1 after treatment. Notch1, Jag1 and Jag2 were downregulated in GSI-treated 
cells, in a similar dose- and time-dependent fashion. This appeared to confirm that 
Notch activation in MM cells causes proliferation. 
Houde et al. 99 postulated a link between IL-6 and Notch activation; they proposed 
that when NICD binds CBF1/RBP-Jk, it is transformed into a transcription factor for, 
amongst other things, NF-κB2 and IL-6. Thus when the Notch pathway is activated 
in BM stromal cells (as opposed to in MM cells), IL-6 production and secretion 
might be induced, acting as a growth factor to adjacent MM cells. They 
demonstrated overexpression of Jag2 in a panel of HMCL (by RT-PCR, IHC, flow 
cytometry and Western blotting), when compared to non-MM cell lines and normal 
peripheral blood plasmablasts. The relevance of this finding was confirmed by 
demonstrating similar Jag2 overexpression in a series of MM and MGUS patient 
samples. Notch1/2/3/4 and Jag1 were variably present in the HMCL. Interestingly, in 
the U266 cells evaluated Notch1 was present (albeit at much lower levels than those 
seen in other lines) and Notch2 was absent; this contradicts the findings of Nefedova 
and Jundt et al. and does suggest that expression of Notch receptor subtypes is not 
fixed. Jag2 overexpression was attributed to hypomethylation of the Jag2 promoter 
sequence. Co-culture of MRC5 immortalised fibroblasts with RPMI-8226 cells was 
associated with induction of HES1 expression by the fibroblasts, at a level 
proportional to the number of MM cells in the co-culture. This was accompanied by 
an increase in IL-6 detected in the culture supernatant, which was not seen when a 
Transwell insert was used to separate the two cell types. VEGF, IGF-I and IGF-II 
were also increased in the co-culture. Incubation of the MRC5 cells with a Jag2-
binding peptide (which activates Notch signaling) had a similar effect on IL-6, 
VEGF and IGF-I secretion, while use of an anti-Notch1 monoclonal antibody (shown 
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to block Notch signaling) reversed the effect of co-culture with MM cells. Thus it 
appeared in this system that Jag2++ MM cells were inducing IL-6 production by 
stromal cells via activation of the Notch pathway, and this may be an important 
mechanism by which Notch signaling promotes MM cell survival and proliferation. 
Chiron et al. 104 also argued for a critical role of Jag2 in MM self-renewal. In 2012 
they demonstrated that only HMCL expressing high levels of Jag2 were capable of 
spontaneous colony formation in additive-free collagen. Jag1 and Notch1/2 receptors 
were widely expressed in HMCL but did not correlate with colony formation. The 
addition of Notch1/2-Fc to previously clonogenic HMCL (KMM1 & JJN3) inhibited 
colony formation by 90%, as did stable silencing of Jag2 expression using shRNA. 
In 2005 Zweidler-McKay et al. 105 explored the issue of whether Notch activation 
caused proliferation or cell cycle arrest in a number of haematological malignancies 
by transducing various malignant B- (including RPMI-8226, NCI-H929 and U266) 
and T-cell lines with constitutively active Notch1-4 receptors. All four activated 
receptor subtypes were capable of inducing cell cycle arrest in B-cell malignancies 
but had the opposite effect on T-cell malignancies. This effect was also achieved by 
transducing the cells with HES1, suggesting that it was a key regulator of this 
phenomenon. 
Nefedova et al. 106 reported on the effects of Notch signaling on the sensitivity of 
MM cells to anti-myeloma drugs in 2008. They inhibited Notch signaling 
pharmacologically using a GSI (GSI-XII, Z-IL-CHO, Calbiochem) and demonstrated 
a reduction in MM cell Notch activity using both a luciferase reporter assay and RT-
PCR to confirm HES1 downregulation. MTT assays confirmed that GSI treatment 
led to a reduction in the viability of HMCL and primary MM cells but not of normal 
BM stromal cells. AV/PI staining confirmed that this was secondary to apoptosis, 
and time course measurements of HES1 expression and apoptosis confirmed that 
HES1 downregulation preceded any evidence of apoptosis in MM cells. When HES1 
was overexpressed in HMCL, the apoptotic effects of the GSI were reduced. When 
HMCL were co-cultured on a BMS monolayer, the stroma-associated protection seen 
against doxorubicin-mediated or mitoxantrone-mediated killing was reduced in the 
presence of GSI. In vivo, in a SCID/NOD xenograft MM tumour model, tumour 
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growth was significantly reduced when mice were co-treated with GSI and 
doxorubicin, while modest results were seen after the same doses of single agents. 
The same result was seen when the SCID/hu model was employed and serum human 
immunoglobulin levels were assayed. They concluded that pharmacological 
inhibition of Notch signaling in MM cells abrogates BM-mediated drug resistance 
and sensitises MM cells to chemotherapy, implying that a major route of BM-
mediated protection is the activation of Notch signaling in MM cells by Notch 
ligands present on stroma cells. 
This group subsequently evaluated the effect of combination treatment with GSI-XII 
and the proteosome inhibitor bortezomib (BZM) 107. HMCL (NCI-H929, RPMI-8226, 
U266) and primary CD138+ MM cells were treated with low doses of GSI-XII (3-
5µM, Calbiochem, as before) and BZM (2-3 nM) singly and together. This 
confirmed potent synergistic cytotoxicity from the combination. Interestingly, when 
active Notch1 ICD was overexpressed in HMCL, GSI-XII+BZM-associated 
apoptosis was reduced but not completely prevented. This suggested that other 
Notch-independent mechanisms might be involved. For comparison, an alternative 
GSI - DAPT (GSI-IX, Calbiochem) - was combined with BZM. This combination 
did not result in synergistic cytotoxicity, and Notch inhibition was confirmed by a 
dose-dependent reduction in HES1 expression in HMCL treated with DAPT alone. 
Thus it appeared that GSI-XII specifically synergised with BZM via a Notch-
independent route. Further investigations revealed that GSI-XII had an additional 
ability to inhibit trypsin-like activity within the proteosome. This study highlights the 
dangers of attributing all GSI-associated effects to Notch pathway inhibition.  
An independent study reported by Xu et al. 108 also examined potential interactions 
between the Notch pathway and BZM effects in MM. This group had previously 
reported that a modified MS5 stromal line expressing the Notch ligand DL1 was able 
to activate Notch signaling in murine (5T33MMvt) and human MM cells in co-
cultures 109, with upregulation of a number of downstream Notch targets including 
HES1. This activation could be blocked with the GSI DAPT. Interestingly the group 
also demonstrated that Notch activation was associated with enhanced colony-
forming capabilities, which was similarly inhibited by DAPT. This enhanced 
clonogenicity had in vivo implications as murine 5T33MMvt cells with prior Notch 
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activation engrafted more rapidly into naive animals with more rapid disease 
development. Cell cycle analysis of the murine MM cells revealed an association 
between Notch activation and a higher percentage of cells in S phase.  
Their subsequent work with BZM 108 used the same method of Notch activation 
(MS5.Dll1 stromal cells). In MM cells, Notch2 appeared to mediate Notch signaling 
- after co-culture, Notch2 was decreased and NICD2 was upregulated. Both murine 
and human MM cell lines were less sensitive to BZM after prior Notch stimulation 
but became more sensitive after co-treatment with DAPT. A drug resistance and 
metabolism gene array was used to investigate molecular mechanisms for this effect, 
and the cytochrome P450 enzyme CYP1A1 and its transcription factor AhR were 
identified as potential players. DL1 stimulation led to downregulation of AhR 
expression but upregulation of CYP1A1, implying that the latter's upregulation after 
DL1/Notch interaction was independent of its usual transcription factor. When 
CYP1A1 activity was inhibited either pharmacologically or using siRNA, BZM 
sensitivity was restored in DL1-stimulated MM cells. In vivo, in the 5T33MMvv 
model, co-treatment of mice with BZM and DAPT enhanced their survival compared 
to those treated with BZM or DAPT alone, and DAPT treatment was associated with 
downregulation of Notch targets. It is interesting that the synergistic killing of MM 
cells by DAPT and BZM seen in this model is in contrast to the absence of 
synergism seen by Nefedova's group when a different panel of HMCL and primary 
CD138+ MM cells were evaluated (see above 107). 
The effects of a novel Notch pathway inhibitor, arsenic trioxide (ATO), were 
reported by Hu et al 110. ATO treatment caused dose-dependent growth inhibition of 
RPMI-8226 cells (MTT assay), associated with both cell cycle arrest in G0/G1 and 
apoptosis. There was a dose-dependent reduction in the expression of Notch1 and 
Jag2 in ATO-treated cells, coupled with a reduction in HES1 transcripts. The 
PI3P/AKT pathway inhibitor PTEN was upregulated after ATO treatment. This 
suggests potential cross-talk between the Notch signaling pathway and the pro-
survival PI3P/AKT pathway, and may be another mechanism by which Notch 
activation promotes MM cell survival. 
 52 
Schwarzer et al. 111 also examined the effect of GSI treatment on MM cells, but 
looked specifically at the impact on MM cell-osteoclast (OCL) interactions. They 
treated HMCL classed as Notch1+ (OPM-2, LP-1, NCI-H929) and Notch1− (U266) 
with GSI 15 (RH02015SC, Maybridge, Acros Organics). In OPM-2 cells, which had 
high baseline HES1 expression, a dose-dependent reduction in HES1 and a 
concomitant reduction in cell proliferation was seen. No effect on proliferation was 
seen in U266 cells, implying that the effect was specific to Notch1. The anti-
proliferative effect was secondary to apoptosis, as evidenced by AVPI staining and 
cleaved PARP levels. When OPM-2 cells were co-cultured with human OCL, 
upregulation of HES1 was seen in the OCL but not in OPM-2. When co-cultured 
OPM-2 and OCL were treated with GSI15, apoptosis was seen in both cell types, 
coupled with downregulation of HES1 and markers of OCL activity. Osteoblasts and 
mesenchymal stem cells co-cultured with OPM-2 did not appear sensitive to GSI15, 
with no sign of apoptosis or changes in proliferation in these cell types. Schwarzer's 
group proposed that Notch signaling is a critical part of the specific interaction 
between MM cells and osteoclasts, and may play a key role in the evolution of bone 
disease in MM. 
Stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 mediate MM cell 
localisation within the BM and some interactions with osteoblasts and osteoclasts. 
Elevated serum SDF-1 levels are associated with MM bone disease and CXCR4 
expression correlates with poorer clinical outcomes. Mirandola et al. 112 reported an 
interaction between Notch receptors and the SDF-1/CXCR4 axis. GSI (GSI-XII) 
treatment reduced the viability of KMS-12, OPM-2 and RPMI-8226 cells, although 
interestingly this was associated with an increase in the G2/M phase (and a 
comparable reduction in G0/G1 and S phases). This contrasts to the findings of Hu et 
al 103,110. Notch pathway inhibition by GSI-XII was confirmed by the observation of 
HES1 downregulation after treatment. This was coupled with a reduction in SDF-1 
and CXCR4 expression (seen both by RT-PCR and flow cytometry (for surface 
CXCR4) and ELISA (for secreted SDF-1 in conditioned culture medium)). These 
findings were also seen after treatment with a highly specific Notch pathway 
inhibitor - SAHM1 (an antagonist for the Notch co-activator MAML1). The 
functional consequence of Notch-blockade (by GSI-XII) was a reduction in CXCR4-
driven migration of MM cells along a SDF-1 gradient. Forced Notch1 activation (by 
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transfection with extracellular domain-deleted, constitutively active Notch1) led to 
upregulation of SDF-1 and CXCR4, and this was shown to result from an interaction 
between ICN1 and the CXCR4 promoter. Having confirmed CXCR4/SDF-1 axis 
activity in the studied HMCL, the group then demonstrated that hyper-stimulation of 
this pathway was able to overcome GSI-XII-associated decrease in viability and cell 
cycle arrest.  
• Cellular effects of Notch receptor-mediated signaling in MM cells 
Diverse mechanisms have been proposed to explain the protective effect of Notch 
activation in MM cells and it is highly likely that there are complex interactions with 
other more classic pro-survival pathways. The binding of APRIL to its receptors, 
TACI and BCMA, activates NF-κB and PI3K pathways 76,113,114 and thus Notch 
activation by BM-derived ligands, such as Jag1, may boost pathway activation 
triggered by APRIL. HES1 also acts to downregulate PTEN, a negative regulator of 
PI3K activity 115, hence activated Notch receptors may co-operate with APRIL to 
potentiate PI3K pathway activation. These interactions provide a rationale for 
investigating potential synergy between these two pathways in promoting tumour 
cell survival. They may also explain the proliferative effect associated with Notch 
activation that has been reported in some systems. 
1.2.4 The HS-5 stromal cell line 
The HS-5 cell line was derived from human BM stromal cells, by immortalisation 
using replication-defective recombinant retrovirus containing the human papilloma 
virus E6/E7 genes (LXSN-16 E6E7) 116. The HS-5 cells were described as 
fibroblastoid and shown to secrete significant levels of granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), macrophage-
CSF (M-CSF), Kit ligand (KL), macrophage-inhibitory protein-1 alpha, interleukin-6 
(IL-6), IL-8, and IL-11. Additionally, of all the derived human stromal lines, only 
HS-5 cells support the proliferation of hematopoietic progenitor cells when co-
cultured in serum-deprived media with no exogenous factors. Conditioned media 
from HS-5 promotes growth of myeloid colonies to significantly greater extent than a 
cocktail of recombinant factors containing 10ng/mL of IL-1, IL-3, IL-6, G-CSF, 
GM-CSF, and KL and 3 U of erythropoietin (Epo).  
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Unmodified HS5 cells have been used to evaluate the contribution of the BM 
microenvironment in enhancing MM cell drug resistance - Perez et al. demonstrated 
that haemopoietic stroma induced resistance to Apo2L/TRAIL apoptosis in HMCL 
117 and subsequently that this resistance could be partially reversed by BZM 118. Co-
culture of certain HMCL with HS5 induced or upregulated expression of tumour-
associated B7-H1 molecules and this was attributed to IL-6 production by HS-5 
cells.119 B7-H1+ HMCL were more proliferative and less chemosensitive than their 
BY-H1- counterparts. 
A direct comparison between primary long-term BM stromal cell cultures and HS5 
cells in evaluating cell-cell contact mediated signals in myeloma was carried out by 
Schmidmaier et al. 120; they concluded that HS5 cells were superior in this setting in 
terms of feasibility and reproducibility. 
1.3 Hypotheses 
This work aims to evaluate the following hypotheses: 
• CD138− tumour cells derived from myeloma patient bone marrow aspirates 
displayed stem cell-like features including drug resistance, quiescence and 
enhanced clonogenicity, when compared to their CD138+ counterparts. 
• APRIL offers protection to myeloma cells exposed to anti-myeloma agents and 
is therefore a potential effector of bone marrow microenvironmental drug 
resistance. The effects of APRIL vary between different genetic subtypes of MM. 
• Notch pathway activation in MM cells renders them less sensitive to anti-
myeloma agents. This mechanism contributes to the protection offered to MM 
cells by their BM microenvironment.
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 Human myeloma cell lines 
The following autonomously growing human myeloma cell lines (HMCL) were 
routinely cultured in RPMI-1640 supplemented with 10% foetal bovine serum (FBS) 
and 1% penicillin/streptomycin (hereafter referred to as RPMI/10%FBS). Cells were 
usually grown in tissue-culture (TC)-treated 75cm2 (TC75) flasks and passaged every 
48-72 hours. The IgH/TCs found within each of these HMCLs are detailed Table 
2-1 . HMCL were independently authenticated by LGC Standards. 
Table 2-1 Human myeloma cell lines and D-type cyclin and genetic lesions. 
Predominant D-type cyclin expressed and 
IgH/TC 
HMCL 
Cyclin D1 and t(11;14) U266, KMS-12PE, KMS-21BM 
Cyclin D2 and t(4;14) 
NCI-H929, JIM3, OPM2, KMS-11, 
JJN3, JIM1 
Cyclin D2 and t(14;16) MM1S, KMS-11 
Cyclin D2 and t(16;22) RPMI-8226 
Uncharacterised KMS-27, KMS-28PE 
2.1.2 Adherent cell lines 
The following adherent cell lines (Table 2-2) were grown in Dulbecco modified 
Eagle Medium (DMEM, with glucose 4.5g/l and L-glutamine) supplemented with 10% 
foetal bovine serum (FBS) and 1% penicillin/streptomycin (hereafter referred to as 
DMEM/10%FBS). The cells were grown in TC75 flasks (lying flat) and passaged 
every 48-72 hours. The old media was aspirated and discarded and the cells washed 
gently with warmed Hank's balanced salt solution, which was then discarded. 
Warmed trypsin (0.25%)/EDTA was then added to the cells (2ml for a TC75 flask) 
and the cells were incubated at 37°C until the cells were fully dissociated from the 
flask and in a single cell suspension (five minutes). The trypsin was then neutralised 
by the addition of warmed DMEM/10% (twice the volume of the trypsin) and the 
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cells pipetted well to mix and further dissociate. The cells were split according to the 
growing speed and confluence of the starting population (usually 1:2-4) and the 
media topped up to a final volume of 8-10ml/TC75 flask. 
Table 2-2 Characteristics of commonly used adherent cell lines. 
Cell line Abbreviation Comments 
Human Embryonic 
Kidney 293T cells 
(HEK) 293T cells 
Highly transfectable derivative of 
HEK-293T cells; used in transfection 
and transduction protocols. 
Human Stromal-5 cells HS5 cells 
Human bone marrow stromal line 
derived from long-term bone marrow 
cells, transformed with the 
amphotropic retrovirus vector 
LXSN16E6E7. One of 27 different 
clones generated.  
2.1.3 Reagents 
Table 2-3 Commonly used reagents. 
Reagent Abbreviation 
Product 
number 
Manufacturer 
Cell culture reagents 
Hank’s balanced salt 
solution 
HBSS 14175-053 Lonza 
Foetal bovine serum (heat 
inactivated) 
FBS 10500-064 Gibco 
Bovine serum albumin BSA A2058 Sigma Aldrich 
Phosphate buffered saline  PBS 17-516 Lonza 
RPMI1640 (with L-
glutamine) 
R or RPMI BE12-702F Lonza 
Dulbecco modified Eagle 
medium (with L-glutamine 
and 4.5g/l glucose) 
DMEM BE12-604F Lonza 
Trypsin (0.25%)/ EDTA  T4049-100ml Sigma Aldrich 
Ficoll-Paque PLUS  17-1440-02 GE Healthcare 
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Penicillin/Streptomycin P/S 15140-122 Gibco 
0.4% Trypan blue  T8154 Sigma Aldrich 
autoMACS running buffer ARB 130-091-221 
Miltenyi 
Biotech 
CD138 microbeads  130-051-301 
Miltenyi 
Biotech 
Matrigel basement 
membrane matrix  
Matrigel 356234  BD 
Human plasma fibronectin 
purified protein 
 FC010 Millipore 
Human collagen type I  234138 Millipore 
Recombinant growth factors 
A PRoliferation-Inducing 
Ligand (TNFSF13) 
APRIL 884-AP R&D Systems 
Insulin-like growth factor-I IGF-I 100-11 Peprotech 
Interleukin-6 IL-6 200-06 Peprotech 
Chemotherapeutic agents 
Dexamethasone (water 
soluble) 
Dex D2915 Sigma Aldrich 
Bortezomib BZM Clinical excess 
Janssen-Cilag 
Ltd 
Lenalidomide Len sc-218656 
Santa-Cruz 
Biotechnology 
Melphalan  M2011 Sigma Aldrich 
2.1.4 Plastic-ware and equipment 
• 5ml, 10ml and 25ml sterile pipettes 
• Tissue culture (TC)-treated 25 cm2, 75cm2 flasks and 175cm2 flasks 
• TC-treated 6-, 12-, 24-, 48- and 96-well plates 
• TC-treated 10cm plates 
• 10cm petri dishes 
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• 5ml polypropylene and polystyrene FACS tubes  
• 15ml, 25ml and 50ml universal containers 
• 0.5ml and 1.5ml sterile and RNase-free microtubes 
• 20-40µm cell strainers 
2.1.5 Trypan blue exclusion 
This allowed determination of the number of viable cells in a cell suspension. Cell 
suspensions were diluted with 0.4% Trypan Blue (1:10-1:40) and applied to a 
haemocytometer. The viable cells were counted in all four quadrants of the chamber 
by light microscopy. The total number was divided by four and adjusted for the 
dilution factor, giving a viable cell concentration (x104/ml). 
2.1.6 Preparation and handling of primary MM bone marrow 
mononuclear cells 
2.1.6.1 Isolation of primary mononuclear cells from bone marrow aspirates by 
density centrifugation 
Mononuclear cells (MNCs) and CD138-positive (CD138+) MM cells were isolated 
from fresh bone marrow (BM) aspirates from patients with MM (after informed 
consent and with full approval of local ethics committee). BM aspirate samples were 
collected into EDTA Vacutainer (BD) blood collection tubes at the bedside. The 
whole BM sample was then washed through a 40µm cell strainer with HBSS and 
made up to a total volume of 25ml with HBSS. This solution was layered carefully 
over 25ml of Ficoll-Paque media in a 50ml universal tube and centrifuged at 
1,900rpm for 30 minutes with no acceleration or breaking. The mononuclear layer 
was carefully aspirated and re-suspended in 20ml of HBSS/5%FBS to wash the cells. 
The cell suspension was then centrifuged at 1,700rpm for ten minutes, the 
supernatant discarded and the pellet resuspended in media or buffer depending on the 
final destination of cells. The number of viable MNCs was ascertained by manual 
counting with a haemocytometer and using Trypan Blue dye exclusion. 
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2.1.6.2 Selection of primary CD138+ MM cells   
Freshly isolated MNCs were resuspended in autoMACS running buffer (ARB) and 
CD138 Microbeads were added. The required volume of both was determined by cell 
number: 20µl of CD138 Microbeads and 80µl of ARB per 10x106 viable cells. After 
thorough mixing, the cells were incubated for 20 minutes at 4°C. The cells were then 
washed with 10mls ARB and after centrifugation (1,600rpm, ten minutes) the pellet 
was resuspended in 1-3ml ARB (depending on total cell number) before being 
passed through a primed LS column set in a magnetic holder. The first run-through 
fraction of CD138-negative cells were set aside for further use as necessary. Having 
removed the column from the magnetic field, the CD138+ cells were flushed out of 
the column with further ARB and counted by Trypan Blue dye exclusion. Plasma 
cell purity was assessed by MGG-stained cytospins and flow cytometry. 
2.1.6.3 Preparation of culture media for primary MM cell culture  
Primary MM BM MNCs or CD138+ cells were cultured in RPMI containing 20% 
plasma pooled from MM patients (hereafter termed culture media; CM). Previous 
work in our group 18 had demonstrated superior survival of primary MM cells in this 
CM over RPMI/10%FBS (R10). Plasma samples were collected from MM patients 
(who were not on any active anti-myeloma treatment) into lithium-heparinised 
Vacutainers. These were centrifuged at 3,000rpm for 15 minutes and the plasma 
aspirated and pooled before freezing at −80°C. When required, the pooled plasma 
was thawed at 37°C and added to RPMI-1640 at a concentration of 20%. Prior to use, 
CM was passed through a 20µm filter. All CM was freshly prepared for each culture 
set up. 
2.1.6.4 Cryopreservation of primary MM cells 
A small number of experiments were performed on thawed CD138+ cells. These 
were frozen immediately after purification. The cells were pelleted at 1,500rpm for 
ten minutes and then resuspended in 100%FBS at 106/ml and placed on ice. An equal 
volume of freezing medium (80%FBS/20%DMSO) was added drop-wise over five 
minutes to the cell suspension with continual gentle agitation on ice and then the cell 
suspension was aliquoted into pre-chilled cryovials and frozen at −80°C using a 
freezing chamber (Mr Frosty) to ensure 1°C/min cooling. 
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2.1.6.5 Preparation of cytospins for staining and for cytogenetic analysis  
Each slide required ~20,000 cells. The appropriate volume of cells in solution (at 
~106/ml) was pipetted into a 1,500µl Eppendorf tube. The final volume was topped 
up to 100µl/slide with PBS. A glass slide was assembled with a piece of filter paper 
and the cytofunnel in a metal cage and the complex was placed into the cytospin 
centrifuge (Cytospin 3, Thermo Shandon). 95µl of the prepared cell suspension was 
pipetted into the cytofunnel and spun at 400rpm for two minutes. The slides were 
then removed and allowed to air-dry overnight before staining or sending for FISH 
analysis. 
2.1.7 Culture of unselected BM MNCs 
A variety of different approaches were used to culture MM BM MNCs (unselected 
or CD138-depeleted) with the goal of optimising in vitro MNC and LC-restricted 
subset survival over time periods of one to three weeks. The three-dimensional 
culture methodology employed by Kirshner’s group 44 was trialled in various formats. 
Certain materials were used specifically in the culture of primary MM BM MNCs 
and CD138+ cells: 
• BD Matrigel basement membrane matrix (354234; BD) 
• Human plasma fibronectin purified protein (FC010; Millipore) 
• Human collagen type I (CC050; Millipore) 
Prior to plating cells, tissue culture (TC)-treated wells were coated with collagen and 
fibronectin, as per Kirshner et al, to recapitulate the BM endosteum. Cells were 
cultured in RPMI/20% pooled MM patient plasma (thereafter referred to as culture 
media, CM). Previous work in our group 18 had demonstrated superior survival of 
primary MM cells in this culture media over RPMI/10% FBS (R10). Additionally a 
number of MM BM MNCs were cultured suspended in a semi-solid culture media 
(Matrigel), sandwiched by the collagen/fibronectin well coating and a layer of CM 44.  
MNCs were harvested at various time points up to three weeks and evaluated by flow 
cytometry to elucidate survival of sub-populations of LC-restricted cells. The 
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addition of cytokines (IL-3, IL-6 and IGF-I) was evaluated in terms of effect on the 
viability and cell cycle characteristics of the LC-restricted subpopulations. 
Additionally these parameters were assessed after the addition of anti-MM agents to 
the culture system (dexamethasone (Dex) and bortezomib (BZM)). Unfortunately, 
owing to limited numbers of primary BM MNCs, a dose response was not possible 
for each drug and patient; dosages were therefore chosen based on literature and 
experience within the group.  
2.1.8 Clonogenic assays 
In order to evaluate the clonogenicity of BM MNCs, a colony assay was set up in 
which CD34-depleted MNCs were suspended in methyl-cellulose supplemented with 
cytokines to stimulate MM colony growth. A number of different supplements were 
compared, including lymphocyte-conditioned media; pooled patient plasma (as per 
CM); IL-3/IL-4/IL-6; IL-2/IL-6/IL-10/IL-15; and SCF/GM-CSF/GCSF/IL-3/Epo. 
The latter cocktail was chosen as it supported the most numerous and clearly 
demarcated colonies. Assays were set up with either freshly isolated MNCs or with 
cells harvested after a period of time in culture, from control and drug-treated 
cultures. Colonies were counted from two weeks, and thereby the clonogenicity of 
the starting cells was enumerated.  
2.1.9 Culture of CD138-selected BM MNCs 
CD138+ cells were cultured in suspension in CM. Cultures were set up in 96-well 
plates using 100,000 cells/well in 200µl CM. Cytokines were added at set up 
depending on the assay: APRIL (200ng/ml), IL-6 (100ng/ml) or IGF-I (500ng/ml).  
Anti-myeloma treatments were also added at set up. Based on previous work, Dex 
was used at a final concentration of 1µM, with additional conditions wells treated 
with 100nM if sufficient cells were available from a given primary sample. 
Bortezomib (BZM) was used at a final concentration of 20nM and Lenalidomide 
(Len) at 100µM for the same reasons. PI103 (1µM; sc-203193; Santa Cruz Biotech) 
was used to block PI3K/AKT signaling. 
 62 
Surviving cells were harvested after 48 to 72 hours in culture. A fixed volume from 
each well (e.g. 150µl) was aspirated and pipetted into a pre-labelled FACS tube. The 
contents were stained by the direct addition of 300µl of AV/PI master mix (see 
2.4.2.1) and the percentage and absolute number of viable cells was analysed by 
AV/PI staining and Fluorosphere bead counts. 
2.1.10 HMCL cell culture  
HMCL were cultured in suspension in RPMI/10%FBS (R10) or serum-free RPMI 
(R). For the purposes of evaluating the effect of cytokines or drug treatments, 
cultures were set up in 96-well plates using 30,000 CD138+ cells/well in 100µl 
media. Cytokines were added at set-up while drugs were added in 50µl fresh media 
24 hours later. Surviving cells were harvested after 48-72 hours after exposure to 
drug.  
2.1.11 Co-culture of MM cells with modified stromal cell lines 
HS5 cells were modified to express either APRIL or Notch ligands (see Chapters 4 
and 5 respectively). Co-cultures were usually set up in TC-treated 48-well plates in 
DMEM/10%FBS, using FACS-based analysis as the final readout. Where alternative 
readouts were being utilised, for example protein expression by Western blotting or 
gene expression using qPCR, the co-cultures were scaled up to a 24- or 12-well 
format. The relative proportions of seeded cell numbers and media volumes were 
carefully preserved. 
For 48-well plates, HS5 cells were seeded on day one at 15,000 cells/well in 300µl 
DMEM/10%FBS. Where cell number allowed, conditions were always set up in 
triplicate. Control wells of HS5 cells alone were routinely seeded. By day four, the 
HS5 cells had formed a confluent layer over the base of the well. MM cells were 
then seeded into the wells in additional DMEM/10%FBS. The original media was 
not removed to avoid depleting the co-cultures of important secreted soluble factors. 
HMCL were seeded at 75,000 cells/well in 200µl. At this time HMCL were also 
seeded into a fresh TC-treated 48-well plate at the same concentration and in the 
same volume so that viability of the MM cells alone could be compared to that of the 
MM cells cultured with stroma. Drug treatments were undertaken on day five, with 
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drugs added in 50µl/well with a final volume of 550µl in the co-culture wells and 
250µl in the HMCL-alone wells. Bortezomib (BZM) was used at 0, 4 and 8nM. 
These doses were selected after a BZM dose-response killing assay was performed 
on HMCL cultured alone (see 4.2.5.1).  
Cells were harvested 24-48 hours after drug treatment (days seven to eight). Cells in 
suspension were harvested separately to those adhering to the well. The former 
fraction contained predominantly MM cells while the latter fraction contained a 
mixture of adherent MM cells and HS5 cells. The media in each well was pipetted up 
and down gently and then aspirated fully and reserved for analysis (suspension 
fraction) in a 5ml FACS tube. The well was rinsed once with 600µl warmed HBSS, 
and this was pooled with the reserved suspension fraction. 100µl of warmed 
Trypsin/EDTA was added to each well and the plate then incubated at 37°C for five 
minutes. Once the adherent cells were fully dissociated, the trypsin was neutralised 
by the addition of 100µl warmed DMEM/10%FBS and the resultant mixture pipetted 
well to disperse any cell aggregates. The well was fully aspirated and the contents set 
aside for analysis (adherent fraction) in a second 5ml FACS tube. The well was 
washed once with an additional 600µl DMEM/10%FBS, which was then aspirated 
and pooled with the reserved adherent fraction. Both fractions were then pelleted at 
1,500rpm for five minutes and then stained with antibodies as per the planned FACS 
analysis. 
The above method was employed when harvesting cells for FACS-based analysis. If 
cell lysis to extract protein or RNA was required, then different sample collection 
tubes were used and the adherent fraction was washed with HBSS and then lysed in 
situ (using RIPA lysis buffer or Trizol Reagent as appropriate) without prior 
trypsinisation.  
2.2 Flow cytometric analysis 
2.2.1 Materials for flow cytometric analysis 
• FACS (fluorescence-activated cell sorting) buffer - PBS with 0.1% BSA 
• Cytofix/Cytoperm buffer (554714; BD) 
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• Permwash buffer (PW; 10x; 554723; BD) 
• Cytoperm Plus buffer (559619 (kit); BD) 
• DNase (559619 (kit); BD) 
• Bromodeoxyuridine (BrdU; 559619 (kit); BD) 
• 7-Aminoactinomycin (7-AAD; 559619 (kit); BD) 
• Antibodies used in FACS analysis - Table 2-4 
Table 2-4 Antibodies used for flow cytometry. 
Target antigen Fluorophore Product number Manufacturer 
CD138 APC 130-091-250 Miltenyi Biotech 
CD138 PE 120-000-431 Miltenyi Biotech 
CD19 PB MCA1940 AbD Serotec 
CD27 PE MHCD2704 Invitrogen 
CD38 PE-Cy5 555461 BD 
BrdU FITC 347583 BD 
IgG kappa light 
chain 
APC 130-093-043 Miltenyi Biotech 
IgG lambda light 
chain 
APC 130-093-038 Miltenyi Biotech 
Annexin V-
FLUOS 
FLUOS 11828681001 Roche 
Annexin V APC 550474 BD 
Human DLL4 PE 346505 Biolegend 
Human Jagged 2 PE 346904 Biolegend 
Human DLL1 PE 346403 Biolegend 
Abbreviations: APC Allophycocyanin, PE Phycoerythrin, PB Pacific Blue, FITC Fluorescein 
isothiocyanate.  
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2.2.2 Detection of surface and intracellular targets by flow cytometry 
Cells (0.5-5x105 per tube in 50µl FACS buffer) were placed in 5ml polyethylene 
FACS tubes. An appropriate volume (1-10µl) of conjugated antibody directed against 
surface antigens was added to the cell suspension and after mixing this was 
incubated on ice for 30 minutes. The cells were washed with 1ml of FACS buffer, 
and then centrifuged at 1,500rpm for five minutes and the supernatant discarded. 
Where an intracellular target was to be assessed, the cells were then permeabilised 
with 100µl Cytofix/Cytoperm solution for 15 minutes on ice, and then washed with 
PW (1x). After pelleting the cells again (1,500rpm, five minutes), conjugated 
antibody directed against intracellular targets was added and mixed thoroughly and 
the solution incubated for a further 30 minutes on ice. After a final wash in PW, the 
cells were resuspended in FACS buffer for flow cytometric analysis. Analysis was 
performed using the Beckman Coulter CyAn ADP Analyzer or the BD FACSVerse 
Flowcytometer. 
2.2.3 Flow cytometric analysis of cell cycle in primary MM cells 
In order to assess cell cycle status of freshly isolated MM cells, MNCs were 
incubated in RPMI/10%FBS with BrdU for three hours (10µl of 1mM stock per ml 
culture media - i.e. final concentration 10µM) at a cell density not greater than 
2x106/ml. The cells were then harvested, distributed between individual FACS tubes 
and washed once in FACS buffer. They were stained for extracellular antigens 
(CD138) in the usual fashion.  
After incubation with this first antibody, the cells underwent a three-phase 
permeabilisation. They were first incubated in 100µl BD Cytofix/Cytoperm Buffer 
(1x) for 15 minutes on ice. After washing in BD Perm/Wash Buffer (PW; 1x) and re-
pelleting, the cells were then incubated in 100µl BD Cytoperm Plus Buffer (1x) for 
ten minutes on ice. After washing in PW and re-pelleting, the cells were incubated 
again in 100µl BD Cytofix/Cytoperm Buffer (1x) for five minutes on ice. They were 
washed once again in PW and pelleted.  
In order to expose incorporated BrdU, the cells were then treated with DNase (30µl 
DNase (1mg/ml stock) and 70µl PBS per tube) for one hour at 37°C and washed with 
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PW. The cells were then stained for intracellular antigens, specifically BrdU (using 
FITC-conjugated anti-BrdU antibodies) and light chains kappa and lambda. Prior to 
analysis, the cells were washed once more and then resuspended in 500µl FACS 
buffer with 20µl 7-AAD added. 
Samples were analysed by flow cytometry to measure BrdU incorporation as a 
marker of cell cycle progression and 7-AAD staining as an indicator of total cellular 
DNA content. This allowed estimation of the proportion of cells in sub-G0/G1, 
G0/G1, S and G2+M, both within the MNCs and within the LC-restricted CD138+ 
and CD138− sub-populations (Figure 2-1).  
 
Figure 2-1 Representative FACs plot of BrdU uptake and 7AAD staining in primary 
MM cells. 
Freshly isolated whole BM MNCs were pulsed with BrdU for three hours and then processed 
as detailed above. Cell cycle characteristics of clonotypic subsets were assessed. A 
representative plot for LC+CD138+ cells is shown. 
The gating strategy to allow analysis of these sub-populations separately is detailed 
in Figure 2-2. 
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Figure 2-2 Flow cytometric analysis of BrdU uptake and 7AAD staining in primary 
MM cells. 
The gating strategy for a representative primary BM MNC sample is shown. Plot 1 shows all 
events by forward scatter (FS) area/side scatter (SS) log (x/y respectively and hereafter) with 
a gate around intact cells. These are gated on to Plot 2 (7AAD area/7AAD linear) to allow 
exclusion of cell doublets. A gate around single cells is gated onto Plot 3 (SS log/anti-kappa 
or -lambda-conjugated APC) where a gate delineates the LC-restricted (LC+) population. 
The LC+ population is then gated onto Plot 4 (SS log/anti-CD138-conjugated PE) to allow 
LC+ CD138+ and CD138− fractions to be discriminated. The subset is finally gated onto 
Plot 5 and Plot 6. Plot 5 (7AAD linear/anti-BrdU-conjugated FITC) is used to distinguish 
subG0/G1, G0/G1, S, G2/M cells, as shown in Figure 2-1. Plot 6 (7AAD histogram) allows a 
simpler quantification of cellular DNA content. 
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2.3 Additional methods used to characterise primary cells 
2.3.1 Fluorescent in situ hybridisation 
Fluorescent in situ hybridisation (FISH) was also used in patients with known 
translocations to track clonotypic MM cells through the whole BM MNC culture 
system. This analysis was kindly performed by Dr Fiona Ross, Wessex Regional 
Cytogenetics Laboratory, Salisbury District Hospital, on cytospins prepared from 
cells of interest (see section 2.1.6.5).  
2.3.2 Immunocytochemistry and immunohistochemistry  
Cells extracted from the colony assay were evaluated by immunocytochemistry 
(performed by Dr Naina Chavda, University College London Hospital) and 
immunohistochemistry (performed by Dr Teresa Marafioti, University College 
London Hospital). This was undertaken on cytospins prepared from harvested cells. 
2.3.3 May-Grünwald Geimsa (MGG) staining 
Cytospins were prepared for the cells of interest. After drying completely, the slides 
were first immersed in May-Grünwald stain (MG1L; Sigma Aldrich) for five 
minutes. They were then washed in distilled water. The slides were immersed in a 
1X solution of Geimsa stain (GS1L; Sigma Aldrich; diluted 1:20 in deionized water) 
for 20 minutes. They were washed once more in distilled water, air dried and then 
evaluated by light microscopy. 
2.4 Apoptosis and survival assays 
2.4.1 Materials 
• AnnexinV buffer (150mM NaCl, 10mM CaCl2, 10mM Hepes (pH 7.4) made 
up with ddH2O) 
• Propidium iodide (PI; 81845; Sigma Aldrich) 
• FlowCheck Fluorospheres (6605359; Beckman Coulter) 
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2.4.2 AnnexinV/Propidium Iodide staining  
This assay allows viable, apoptotic and necrotic cells within a suspension to be 
distinguished. Cells undergoing apoptosis undergo changes in the extracellular 
membrane, leading to externalisation of the membrane phospholipid, 
phosphatidylserine. AnnexinV (AV) is a calcium-dependent phospholipid binding-
protein which binds to cells with exposed phosphatidylserine. Propidium iodide (PI) 
is a DNA dye, taken up by non-viable cells which have lost their membrane integrity, 
while live cells exclude the dye. Using both agents together, the percentage of viable 
(AV−/PI−), apoptotic (AV+/PI−) and dead (AV+/PI+) cells can be evaluated. The 
addition of a fixed volume of FlowCheck Fluorospheres to the cell suspension allows 
absolute numbers of intact cells to be calculated.   
Two protocols were devised and used depending on the choice of AnnexinV 
antibody. FLUOS-conjugated AnnexinV (Roche) emits at 488nm and was used for 
viability assays on CD138-selected MM cells and HMCLs. When assessing HMCL 
cell viability in co-culture with modified HS5 cells, APC-conjugated AnnexinV was 
used as the transduced HS5 cells co-expressed GFP which also emits at 488nm. 
2.4.2.1 AnnexinV-FLUOS protocol used for cells cultured in suspension  
A fixed volume (e.g. 150µl) of cell suspension, from either flasks or plates, was 
harvested and placed into a 5ml FACS tube on ice. To this was added 0.2µl FLUOS-
conjugated AV, 1.4µl PI (2.5mg/ml), 17.6µl Fluorospheres (1x106/ml in 
PBS/1%BSA), 175.5µl AV buffer and 105.3µl PBS. This was added from a master 
mix made up for all the tubes to be analysed. The cells were vortexed briefly to mix 
and, after incubation for a maximum of five minutes on ice, analysed by flow 
cytometry. Samples were run until 1,000 Fluorosphere beads had been counted. This 
enabled the absolute number of intact cells to be calculated.  
A representative result is shown in Figure 2-3. 
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Figure 2-3 Representative Annexin V/PI flow cytometry plot. 
Untreated NCI-H929 cells were harvested from culture and stained with AV-FLUOS and PI 
according to the protocol above. The plot is gated on intact cells, with the bottom left 
quadrant representing AV−/PI− viable cells (70.9%), the bottom right quadrant 
representing AV+/PI− apoptotic cells (10.3%) and the top right quadrant representing 
AV+/PI+ dead cells (18.6%). 
2.4.2.2 AnnexinV-APC protocol used for cells co-cultured with GFP-
expressing cells 
This protocol was employed when analysing cells mixed with or expressing GFP. 
Cells growing in suspension were pipetted gently up and down and then fully 
aspirated from each well and reserved in a 5ml FACS tube on ice. The well was then 
washed with HBSS and this added to the reserved suspension fraction. Where 
adherent cells were also being evaluated these were harvested after trypsinisation and 
neutralisation and pipetted into a fresh 5ml FACS tube. Both fractions were then 
pelleted at 1,500rpm for five minutes and the supernatant discarded. To each tube 
was added 1µl APC-conjugated AV, 2µl PI (2.5mg/ml), 17µl Fluorospheres 
(1x106/ml in PBS/1%BSA), and 450µl AV buffer. This was added from a master mix 
made up for all the tubes to be analysed. The cells were vortexed briefly to mix and, 
after incubation in the dark for 15 minutes at room temperature (RT), analysed by 
flow cytometry. Samples were run until 1,000 Fluorosphere beads had been counted. 
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This enabled the absolute number of intact cells to be calculated. Each 500µl sample 
was run until 1,000 Fluorospheres had been counted. As each sample contained 17µl 
of Fluorospheres at a concentration of 1x106/ml, i.e. 17,000 Fluorospheres, the 
absolute number of viable cells was calculated as (number of AV−PI− events) x 17.  
A typical result looked identical to that seen with AV-FLUOS staining (shown in 
Figure 2-3). 
2.4.3 MTS assay 
This assay utilises a colorimetric method for determining the number of viable cells 
in a cell suspension. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium (MTS) is an insoluble tetrazolium compound, which 
is reduced by viable cells to a soluble formazan product. This reaction is dependent 
on dehydrogenase enzymes found in cells which are metabolically active. The 
quantity of formazan product may be measured by absorbance of the cell suspension 
at 490nm and is proportional to the number of viable cells. 
Cells were cultured in a 96-well tissue culture plate with conditions in triplicate. At 
the time point of interest, 20µl MTS solution was added to each well and incubated 
for one to four hours. Absorbance at 490nm was measured using a Varioskan 
platereader. 
2.5 APRIL Enzyme-linked immunosorbant assay (ELISA)  
Soluble APRIL was quantified in the culture supernatant of modified HS5 using 
commercially available APRIL ELISA kits from Invitrogen (KHC3051) and 
Biolegend (439307). 
Culture supernatant was harvested into 15ml Falcon tubes, centrifuged at 3,000rpm 
for ten minutes at room temperature and stored in 500µl aliquots at −80°C 
The samples were thawed on ice and thereafter the ELISA was performed as per the 
manufacturer’s instructions. 
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2.6 Western blotting analysis 
2.6.1 Materials, buffers and reagents 
• RIPA lysis buffer (10x; 20-188; Millipore) 
• Phosphatase inhibitor cocktails II and IV (539132 & 539136; Calbiochem) 
• Complete protease inhibitor cocktail (04693116001; Roche) 
• Pierce BCA Protein assay (PI-23227; Pierce) 
• Methylene Bis-acrylamide (Acrylamide; 146072 Sigma Aldrich) 
• Tris (Hydroxymethyl) methylamine (Tris) 
• Sodium dodecyl sulphate (SDS; L3771; Sigma Aldrich) 
• Ammonium persulphate (APS; A3678; Sigma Aldrich) 
• Double-distilled H2O (dd H2O) 
• N, N, N′, N′-Tetramethylethylenediamine (TEMED; T9281; Sigma Aldrich) 
• Bromophenol blue (114391; Sigma Aldrich) 
• NuPAGE® SDS-PAGE 4–12% Bis-Tris Gel (Life Tech) 
• NuPAGE® LDS Sample Buffer (4X; NP0007; Life Tech) 
• NuPAGE® Sample Reducing Agent (10X; NP0009; Life Tech) 
• NuPAGE® MOPS SDS Running Buffer (20X; NP0001-02; Life Tech)  
• NuPAGE® Antioxidant (NP0005; Life Tech) 
• Amersham Hybond-C-Extra nitrocellulose membrane (10339574; GE 
Healthcare) 
• Tween-20 (P9416; Sigma Aldrich) 
• Dried skimmed milk powder (Marvel) 
• Amersham ECL Prime Western blotting detection reagent (ECL Prime; 
RPN2232; GE Healthcare) 
• High performance chemiluminescence film (28-9068; GE Healthcare) 
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Buffers: 
• RIPA lysis buffer: 0.5M Tris-HCl (pH 7.4), 1.5M NaCl, 2.5% deoxycholic acid, 
10% NP-40, 10mM EDTA, 0.1%SDS. 
• Loading buffer (LB; 2x): 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, 0.125M Tris HCl. 
• Running buffer (RB): 0.025M Tris (pH 8.5), 0.192M Glycine, 0.1% SDS, 
made up with ddH2O. 
• NuPAGE® MOPS SDS Running Buffer (20x): 50mM MOPS, 50mM Tris 
Base, 0.1% SDS, 1mM EDTA, pH 7.7  
• Transfer buffer (TB): 0.025M Tris, 0.192M Glycine, 10% methanol, made up 
with ddH2O. 
• Tris-buffered saline with Tween: (TBS-Tw; 0.05M Tris (pH 7.5), 0.15M NaCl, 
made up with ddH2O, with 0.05% Tween-20) 
Gels: 
• Resolving gel: volumes dependent on % acrylamide gel required (Table 2-5); 
dd. H2O, acrylamide, IM Tris (pH 8.8), 10% SDS, 25% APS, TEMED 
Table 2-5 Volumes of reagents required to make resolving gels of different acrylamide 
percentages (10ml, volumes in ml). 
Acrylamide % 5% 7.5% 12.5% 
dd.H2O 4.1 3.66 2 
Acrylamide 2.1 2.54 4.2 
IM Tris (pH 8.8) 3.74 3.74 3.74 
10% SDS 0.1 0.1 0.1 
25% APS 0.075 0.075 0.075 
TEMED 0.009 0.009 0.009 
• Stacking gel: 3.5ml dd. H2O, 835µl acrylamide, 625µl IM Tris (pH 6.8), 50µl 
10% SDS, 12.5µl 25% APS, 10µl TEMED. 
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Resolving gels were prepared in gel casters (BioRad), covered in isopropanol and 
allowed to set for 30-40 minutes. Once set the isopropanol was removed and the 
stacking gel was layered over the resolving gel and a 10- or 15-well comb inserted.  
Alternatively NuPAGE pre-cast SDS-PAGE gradient (4–12%) gels were used.  
Antibodies 
Table 2-6 lists antibodies used for Western blotting.  
All primary antibodies were at a 1/1,000 dilution in 5%BSA/TBS-Tw unless 
indicated. Secondary antibodies were at 1/2,000 dilution in 5% milk for targets of 
interest and 1/10,000 for loading controls. 
Table 2-6 Antibodies used in Western blotting. 
Target protein 
Product 
number 
Manufacturer 
Special 
instructions 
Primary antibodies    
Notch1 (D6F11) XP® Rabbit 
mAb 
#4380 
Cell Signalling 
Technology 
1/1,000 in 3% 
milk for one 
hour at room 
temperature 
Notch2 (D76A6) XP® Rabbit 
mAb 
#5732 
Cell Signalling 
Technology 
 
Notch3 (D11B8) Rabbit mAb #5276 
Cell Signalling 
Technology 
 
Cleaved Notch1 (Val1744) 
(D3B8) Rabbit mAb 
#4147 
Cell Signalling 
Technology 
 
DLL1 Antibody #2588 
Cell Signalling 
Technology 
 
DLL4 Antibody #2589 
Cell Signalling 
Technology 
 
Jagged2 (C23D2) Rabbit mAb #2210 
Cell Signalling 
Technology 
 
Jagged 1 (C-20) sc-6011 Santa Cruz  
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Biotechonology 
Secondary antibodies  
Both from GE 
Healthcare 
 
Amersham ECL anti-rabbit 
IgG horseradish peroxidase-
linked antibody 
NA934   
Amersham ECL anti-mouse 
IgG horseradish peroxidase-
linked antibody 
NXA931   
2.6.2 Protein lysate preparation 
Protein lysates were prepared from freshly isolated or cultured cells. Cells were 
washed once in ice cold PBS and then resuspended in RIPA lysis buffer, 
supplemented with complete protease inhibitor and phosphatase inhibitor cocktails. 
They were incubated on ice for 15-30 minutes and then centrifuged for 15 minutes at 
14,000rpm at 4°C. The lysate was aspirated and aliquoted into pre-chilled 1.5ml 
Eppendorf tubes.  
The protein concentration in lysates was quantified using the Pierce Protein 
quantification assay. In a 96-well plate, a BSA standard was prepared using dd. H2O 
as a diluent, in duplicate. Blanks were also prepared containing dd. H2O alone. 
Samples were diluted 1:12.5 in dd. H2O. The quantification reagent was prepared by 
combining 4µl Reagent B with 196µl Reagent A per well and adding this to each 
well containing lysate, standards or blanks. The plate was incubated for 30 minutes 
at 37°C in the dark and then protein levels were quantified colorimetrically looking 
at absorption at 562nm on the Varioskan platereader.  
Lysates were then used immediately or stored at −80°C until required. 
2.6.3 Western blot method 
Gels were placed within the gel tank (BioRad or Invitrogen) and running or MOPPs 
buffer added (depending on gel used). 
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20-40µg protein was aliquoted into a 1.5ml Eppendorf tube on ice. To this was added 
sample loading buffer, sample reducing agent and dd. H2O if required to achieve 
necessary dilutions of the latter two reagents. The mixture was then boiled at 100°C 
for five to ten minutes, spun briefly at 5,000rpm and replaced on ice prior to loading 
into the gel wells. A molecular weight marker was loaded into one well. The gel was 
run at 50V until the proteins passed the interface between stacking and resolving gels, 
and then the voltage was increased in stages to a maximum of 150V until the 
proteins had separated. 
Proteins were transferred from the gel to the nitrocellulose membrane by ‘wet 
transfer’ over two to three hours at 30V using transfer buffer and the XCell II Blot 
Module in the XCell SureLock Tank (both Novex). Successful transfer of proteins 
was visualised using Ponceau S staining. 
The membrane was blocked for one hour with 5% dried skimmed milk/TBS-Tw at 
RT and, after washing three times for ten minutes in TBS-Tw, the membrane was 
incubated in the primary antibody under conditions optimized for each antibody. 
Most were incubated in a 1/1,000 solution in 5%BSA/TBS-Tw overnight at 4°C. 
Following incubation with the primary antibody, the membrane was washed three 
times as before and then incubated with the appropriate secondary antibody 
conjugated to horseradish peroxidase-linked antibody for two hours at RT. The 
membrane was then washed three times as before and then incubated with ECL 
Prime for one minute, before being washed very briefly in PBS and drained. The 
membrane was then exposed to X-ray film for between five seconds and five minutes 
depending on the signal strength. 
2.7 Cloning 
2.7.1 Materials 
• Tris EDTA buffer (TE; 10mM Tris 1mM EDTA, pH 8.0) 
• Chemically-competent E.coli bacteria (subcloning or high-efficiency; New 
England Biolabs) 
• SOC outgrowth media (B9020S; New England Biolabs) 
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• Lysogeny broth (LB) medium (capsules; 113002041; MP) 
• Agar powder (05040; Sigma Aldrich) 
• Glycerol (>99%; G5516; Sigma Aldrich) 
• NucleoBond Xtra Midi kit (740410.50; Macharey-Nagel) 
• Genejuice (70967; Merck Millipore) 
• Polybrene (10mg/ml; TR-1003; Merck Millipore) 
• DH5α Subcloning Efficiency Competent E.Coli (18265-017; Invitrogen) 
2.7.2 Equipment 
• Waterbath 
• Heated mixing block (Eppendorf Thermomixer Comfort) 
• Sterile bacterial cell spreaders 
• Sterile bacterial inoculation loops 
• Incubator with shaker 
2.7.3 Preparation of LB media & LB agar plates 
LB medium was prepared by adding 25 capsules of powdered LB medium per litre 
of purified water and autoclaving at 121°C for 15 minutes. Ampicillin or other 
antibiotics required for selection were added at the time of media usage to avoid 
deterioration of antibacterial activity. 
LB-Agar plates were prepared by adding 25 capsules of LB medium and 15g Agar 
per litre of purified water and autoclaving at 121°C for 15 minutes. Once the 
autoclaved LB/Agar had cooled to hand warmth (<60°C), ampicillin (or other 
selection antibiotic) was added for a final concentration of 50µg/ml. After flaming 
the neck of the flask/bottle of warm LB/Agar, it was poured into sterile 10cm Petri 
dishes immediately next to a lit Bunsen burner. The lid of each Petri dish was 
replaced immediately after pouring. Once the whole flask of LB/Agar had been 
poured, the top surface of the poured plates was briefly ‘flamed’ to pop any bubbles 
in the cooling solution and sterilise the surface. Plates were left to set overnight at 
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RT and, once set, the base of each plate was labelled with the antibiotic used for 
selection. 
2.7.4 Amplification of DNA by bacterial transformation  
DNA was amplified in chemically-competent E.coli bacteria by transformation. 
DNA was first quantified by spectrophotometer (Nanodrop) and then diluted to 
20ng/µl. For each transformation one vial (50µl) of competent E.coli was thawed on 
ice. 2µl of DNA solution (40ng) was added to each vial as soon as the bacteria were 
fully thawed and the vial flicked gently to mix the DNA into bacterial suspension. 
The DNA-bacterial mixture was incubated on ice for 15-30 minutes, depending on 
the type of competent bacteria used and the manufacturer's recommendations. The 
bacteria were then heat-shocked in a water bath at 42°C for 30 seconds (or as per 
manufacturer's recommendations) and then replaced on ice for five minutes. 250µl 
SOC outgrowth medium at RT was added to each vial of bacteria, which were then 
placed on a heated mixing block (250rpm) at 37°C for one hour. 
Agar plates containing the appropriate selection antibiotic for the bacteria used 
(normally ampicillin) were warmed to 37°C and then a range of volumes (e.g. 20µl 
and 200µl) of bacterial solution were pipetted onto each plate and spread evenly 
using a bacterial cell spreader. Plates were left agar-down for one to two minutes to 
allow the bacteria/SOC solution to be absorbed and then inverted and incubated 
overnight at 37°C. 
The following day starter cultures were prepared from colonies which had grown on 
the agar plate. Single colonies were plucked with a sterile inoculating loop and used 
to inoculate a starter culture of 2ml of LB media (with freshly added ampicillin; final 
concentration 50µg/ml; fresh LB/amp media).  Further steps depended on the final 
quantity of DNA required and in most instances a ‘maxi-prep’ was undertaken. 
• For ‘mini-preps’ (up to 20µg DNA from 1-5ml bacterial culture suspension) 
the starter culture was incubated overnight at 37°C on a shaker at 250rpm. 
• For ‘midi-preps’ (100-350µg DNA from 15-25ml bacterial culture suspension) 
the starter culture was incubated for ~eight hours at 37°C on a shaker at 250rpm 
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and then ~200µl was used to inoculate 10-25ml fresh LB/amp media. This was 
incubated overnight at 37°C on a shaker at 250rpm. 
• For ‘maxi-preps’ (500-850µg DNA from 100-200ml bacterial culture 
suspension) the starter culture was incubated for ~eight hours at 37°C on a shaker 
at 250rpm and then ~2ml was used to inoculate 100-200ml fresh LB/amp media. 
This was incubated overnight at 37°C on a shaker at 250rpm. 
In all cases amplified plasmid DNA was harvested the following morning. Bacterial 
cells were lysed under alkaline conditions, denaturing genomic DNA and protein 
while the more stable plasmid DNA remains intact. The NucleoBond Xtra Midi kit 
(Macharey-Nagel) was used for maxi-preps, according to the manufacturer's 
instructions. Following elution and washing plasmid DNA was resuspended in sterile 
RNase-free H20 and quantified by spectrophotometer (Nanodrop).  
A small volume of bacterial culture (850µl) was set aside prior to DNA harvesting. 
After mixing well with 150µl glycerol (>99%), this was stored at −80°C as a long-
term glycerol stock. 
2.7.5 Using viral vectors to modify protein expression 
Viral vectors were used to deliver genetic material into cell lines in order to produce 
lines with stable long-term expression of a particular protein. Both retroviral and 
lentiviral vectors were utilised, and their differing biology had implications for their 
downstream use. Lentiviruses are capable of infecting both dividing and non-
dividing cells. In contrast, retroviruses are only able to infect dividing cells, because 
the breakdown of the nuclear envelope which occurs during mitosis is required for 
the pre-integration complex (viral DNA, RNA and proteins) to gain access to the cell 
nucleus.  
2.7.5.1 Retroviruses 
2.7.5.1.1 Triple transfection of adherent cells to generate intact retrovirus 
Retroviral vector was produced by transiently transfecting 293T cells with 
expression plasmids supplying gagpol, env (RD114) and the gene of interest. 
Supernatant was then harvested and frozen on two subsequent occasions. 
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The day prior to transfection, 1x106 rapidly growing 293T cells were seeded into a 
100mm TC-treated plate in 10ml of DMEM/10%FBS. This was repeated for 
sufficient plates, allowing one per transfection. The following day, the degree of 
confluence was assessed and only if cells were 50-60% confluent did the transfection 
protocol continue. For each plate, 470µl of serum-free DMEM was pipetted into a 
sterile 1.5ml Eppendorf tube. 30µl of Genejuice was added to this and mixed by 
gentle pipetting. The mixture was incubated for five minutes in a tissue-culture (TC) 
hood. The three plasmids were then added: a total cargo of 12.5µg DNA/plate, 
comprising 3.13µg env (RD114), 4.69µg gagpol and 4.69µg construct gene of 
interest. This was mixed by gentle pipetting and then incubated once again for 15 
minutes in a TC hood. Following incubation, the Genejuice-DNA mixture was added 
drop-wise to each plate and swirled gently to distribute. 
Forty-eight hours following transfection (when the 293T cells were 80-90% 
confluent), the supernatant was harvested and stored at 4°C overnight. Each plate 
received 10ml of fresh DMEM/10% FBS. Twenty-four hours later, the second 
aliquot of supernatant was harvested and added to the first, which was then frozen at 
−80°C. 
2.7.5.1.2 Transduction of adherent cells with retrovirus containing gene of 
interest 
The relevant human adherent cell line, e.g. HS-5, was washed, trypsinised, 
neutralised, harvested and counted. The cells were resuspended at 1x105 cells/ml in 
DMEM/10% FBS and 2ml was plated into each well of a TC-treated 6-well plate. 
The following day the appropriate retroviral supernatant was thawed on ice (one 
vial/well). Once fully thawed, the old media from each well was aspirated and 
replaced with the entire vial of retroviral supernatant. 1µl of polybrene (10mg/ml) 
was added to each transduced well, and swirled gently to mix. 
Forty-eight hours after the first transduction, a second transduction was attempted 
with a freshly thawed vial of supernatant and another 1µl of polybrene, if the 
adherent cells were not confluent. The transduced cells were then harvested and the 
efficiency of the transduction assessed.  
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Where a pure population was required, transduced cells were sorted using the 
Beckmann Coulter MoFlo High Speed Cell Sorter, gating on cells expressing either 
the protein of interest of a co-transduced fluorescent marker (e.g. GFP). 
2.7.5.2 Lentiviruses 
2.7.5.2.1 Triple transfection of adherent cells to generate intact lentivirus 
293T cells were transfected with the plasmid encoding the gene of interest in 
combination with the p8.91 plasmid encoding gag, pol and rev genes and the 
VSV.G-expressing envelope plasmid. This so-called triple transfection allowed the 
production of lentiviral supernatant capable of transiently infecting a second 
population of mammalian cells. 
The day prior to the transfection 293T cells growing well were trypsinised, harvested, 
washed, resuspended and counted. The cells were seeded at 1x106 per 10cm TC-
treated plate in their usual media (DMEM/10%FBS). The following day the plates 
were inspected under low-power microscopy to ensure that they were at 40-60% 
confluence.  
The transfection mixture was then prepared. 30µl Genejuice was added to 470µl 
serum-free DMEM in a sterile 1.5ml Eppendorf, pipetting up and down to mix. After 
incubating at RT for five minutes the DNA was added - 4µg target gene, 3µg p8.91 
and 3µg VSV-G (total 10µg; 1µg per 3µl Genejuice) - and mixed by pipetting up and 
down. The resultant DMEM-Genejuice-DNA mixture was incubated at RT for 15 
minutes to allow the formation of liposomes.  
Meanwhile the 293T cells were washed twice gently with HBSS and then given fresh 
serum-free DMEM (7ml/10cm plate). All of the DMEM-Genejuice-DNA mixture 
was then added drop-wise to the plate, with gentle agitation to distribute the mixture 
as evenly as possible. The 293T cells were then returned to the incubator. 
The media was replaced after 24 hours with DMEM/10%FBS. Supernatant 
containing lentiviral particles was then harvested at 48 hours following transfection 
and the media replaced with fresh DMDM/10%FBS. The supernatant was kept at 
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4°C overnight and then pooled with a second batch of supernatant harvested at 72 
hours following transfection. The pooled lentiviral particles were then concentrated 
by ultracentrifugation (23,000rpm at 4°C for two hours) and, after discarding the 
supernatant, were resuspended in 500µl DMEM/10%FBS and then stored in 100µl 
aliquots at −80°C. 
2.7.5.2.2 Titration of lentivirus  
This was done to compare the transduction efficiency of different preparations and 
dilutions of lentiviral supernatant. 
Optimally growing 293T cells were trypsinised, harvested, washed, resuspended and 
counted. They were seeded at 0.05x106/well in 400µl DMEM/10%FBS in a TC-
treated 24-well plate. The following day the media was aspirated and replaced with 
fresh DMEM/10%FBS containing Polybrene (10µg/ml). Dilutions of freshly thawed 
concentrated lentiviral supernatant were prepared (e.g. 1x, 0.1x and 0.01x) and added 
in a total volume of 60µl/well. Dilutions were tested in triplicate.  
The cells were harvested 48 hours later and the transduction efficiency assessed 
either by qPCR of the target gene (undertaken on total cellular DNA) or by flow 
cytometry to quantify protein expression (e.g. GFP expression). The former allows 
more accurate assessment of the lentiviral copy number/cell, while the latter may be 
a more functionally relevant readout. 
2.7.5.2.3 Transduction of adherent cells with lentivirus containing gene of 
interest 
The adherent cells to be transduced were trypsinised, harvested, washed, 
resuspended in their usual media and counted. Cells were seeded in TC-treated 24-
well plates at 0.05x106/well. The following day their confluence was assessed under 
low-power microscopy. Transduction was attempted if their confluence was 40-60%. 
The media was aspirated from the wells and replaced with fresh media to which 
Polybrene had been added (10µg/ml). Lentiviral supernatant was then added to each 
well at a volume previously determined by titration, ensuring that the final volume of 
media/Polybrene/viral supernatant is identical in each well transduced. 
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Twenty-four hours after transduction the media was either replaced or the 
transduction repeated to increase transduction efficiency. The transduced cells were 
then harvested and the efficiency of the transduction assessed. As for retrovirally-
transduced cells, if a pure population was required, transduced cells were sorted. 
2.7.6 Specific methodology for the production of modified HS5 cell lines 
2.7.6.1 Producing APRIL+HS5 cells 
2.7.6.1.1 The APRIL construct  
The APRIL construct was kindly donated by Dr Martin Pule. It contained the 
unmodified sequence for APRIL, preceded by eGFP, cloned into the retroviral SFG 
vector (Figure 2-4).  
 
Figure 2-4 APRIL construct. 
The SFG vector 121 is based on the Moloney murine leukaemia virus, with the 
transgene start codon located at the start site of the deleted viral envelope gene. 
Bicistronic transgene expression was achieved by inclusion of the 
encephalomyocarditis internal ribosomal entry site (IRES) allowing expression of the 
downstream reporter gene enhanced green fluorescent protein (eGFP). The retroviral 
long terminal repeat (LTR) acted as the promoter driving expression of both 
transgenes, although expression following an IRES tends to be considerably reduced 
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compared to that of the primary transgene. The APRIL protein was double tagged 
containing an amino terminal v5 tag and a carboxy terminal HIS tag. The plasmid 
backbone also contained the pBR322 origin of replication for amplification in 
bacterial culture and an ampicillin resistance cassette for selection. 
2.7.6.1.2 Making APRIL retrovirus 
293T cells were transiently transfected with expression plasmids, supplying gagpol, 
env (RD114) and either the APRIL construct (SFG.APRIL_v5-HIS.12.eGFP) or the 
empty vector negative control (SFG.eGFP). Supernatant was then harvested and 
frozen on two subsequent occasions. 
The supernatant produced using the SFG.APRIL_v5-HIS.12.eGFP construct will 
hereafter be referred to as APRIL.eGFP retrovirus, and the supernatant produced 
using the SFG.eGFP construct will hereafter be referred to as eGFP negative control 
retrovirus 
2.7.6.1.3 Producing an APRIL-positive HS5 line and its negative control 
HS5 cells were transduced as detailed in section 2.7.5.1.2 with the APRIL.eGFP and 
the eGFP negative control retroviral supernatants. The APRIL.eGFP-transduced HS5 
(Ap+HS5) were 14% GFP-positive (GFP+) while the eGFP negative control-
transduced HS5 (NC(Ap)HS5) were 3% GFP+. The transduced cells were then 
FACS-sorted by eGFP expression to obtain a ≥95% pure population in both the 
Ap+HS5 and NC(Ap)HS5 (Figure 2-5).  
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Figure 2-5 Purity of modified HS5 cells as assessed by eGFP expression. 
Two representative FACS plots are shown for Ap+HS5 (left) and NC(Ap)HS5 (right); intact 
adherent cells are shown. Abbreviations: FSC, forward scatter. 
2.7.6.2 Producing a Delta ligand-1 (DL1)-expressing stromal cell line  
2.7.6.2.1 The DL1 construct 
The bicistronic lentiviral plasmid pTRIPΔU3-EF1α-DL1-IRES-GFP, together with 
the empty vector negative control (NC; pTRIPΔU3-EF1α-GFP) was kindly donated 
by Dr Francoise Pflumio (Université Paris Descartes, Paris).  Her group modified the 
mouse stromal cell line MS5 in order to investigate the role of Notch in human T-
ALL122, and Xu et al108,109 went on to use the DLl+ MS5 line in MM. Figure 2-6 
shows the plasmid map and structure of the vectors. Both plasmids contained GFP 
under the EF1α promoter so expression of GFP would be predicted to correlate with 
expression of DL1. 
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Figure 2-6 Plasmid maps and structures for pTRIPΔU3-EF1α-DL1-IRES-GFP 
lentiviral plasmid (A, B) and empty vector negative control (C, D). 
2.7.6.2.2 Reconstitution of DL1-expressing lentiviral plasmids 
Lentiviral plasmids were donated on filter paper (1µg). The annotated paper was 
trimmed and placed in a 1.5ml Eppendorf tube with 100µl TE buffer. After 
incubation at RT for four hours, to allow plasmid DNA to enter solution, the 
resultant DNA solution was stored at −20°C until required. 
2.7.6.2.3 Amplification of pTRIPΔU3-EF1α-DL1-IRES-GFP and pTRIPΔU3-
EF1α-GFP 
2.5µl of thawed plasmid DNA solution for each plasmid was used to transform a vial 
of DH5α (subcloning efficiency) competent E. coli (18265-017; New England 
Biolabs). Starter cultures were prepared from single colonies generated and 
subsequently a maxi-prep was used to amplify the plasmid for further work. Glycerol 
stocks were made for each plasmid at this point. 
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2.7.6.2.4 Production of pTRIPΔU3-EF1α-DL1-IRES-GFP and pTRIPΔU3-
EF1α-GFP lentivirus 
293T cells were triple transfected (using Genejuice) with (i) p8.91; (ii) VSV-G and 
(iii) the DL1-expressing pTRIP vector or the empty vector negative control. 
Lentiviral supernatant was harvested at 24 and 48 hours following transfection and 
concentrated by ultracentrifugation. The transfection efficiency was assessed at this 
time by evaluating GFP expression by the 293T cells; the EF1α-DL1-IRES-GFP-
transfected 293T cells were 66% GFP-positive (GFP+) and the EF1α-GFP-
transfected 293T cells were 96% GFP+. 
2.7.6.2.5 Titration of EF1α-DL1-IRES-GFP and EF1α-GFP lentiviral 
supernatants 
The titration was undertaken in 293T cells to determine the optimum volume of 
concentrated EF1α-DL1-IRES-GFP and EF1α-GFP (NC) lentiviral supernatant 
required to transduce sufficient target cells to allow sorting for a pure population.  
 
Figure 2-7 Titration of EF1α-DL1-IRES-GFP and EF1α-GFP lentiviral supernatants.  
293T cells were transduced with increasing volumes of lentiviral supernatant (in 500µl total 
volume) as indicated on the x-axis, and analysed for GFP expression by FACS. One 
representative experiment. 
Figure 2-7 shows percentage transduction of 293T cells using a range (0.1-10µl) of 
volumes of viral supernatant. As the transduction efficiency was relatively low even 
at the highest supernatant doses (10µl), a volume of 50µl was selected to transduce 
the target cell (HS5 cell). 
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2.7.6.2.6 Transduction of HS5 cells with EF1α-DL1-IRES-GFP and EF1α-GFP 
lentiviral supernatants 
Optimally growing HS5 cells were transduced with 50µl of lentiviral supernatant. 
The resultant EF1α-DL1-IRES-GFP and EF1α-GFP-transduced cells were 87% and 
96% GFP+ respectively. Hereafter they will be referred to as DL1+HS5 and 
NC(DL1)HS5. The transduced cells were then FACS-sorted by eGFP expression to 
obtain a >95% pure population in both the DL1+HS5 and NC(DL1)HS5.  
2.7.6.3 Production of Jagged-2 and Delta ligand-4 (DL4)-expressing stromal 
cell line 
Retroviral supernatants for bicistronic retroviral vectors encoding Jagged-2 (Jag2) or 
Delta-like ligand-4 (DL4) in combination with eGFP were kindly provided by Dr 
Tom Taghon (Ghent University, Belgium). The Jag2 construct was generated in-
house by Dr Taghon's group and cloned into a bicistronic LZRS-IRES-EGFP vector 
123. The DL4 construct was donated to this group by Professor Adrian Harris 124 and 
cloned into the same vector backbone. The negative control for both ligands was 
therefore the empty vector expressing eGFP alone. 
2.7.6.3.1 Transduction of HS5 cells with LZRS-Jag2-IRES-EGFP, LZRS-DL4-
IRES-EGFP and LZRS-EGFP 
Optimally growing HS5 cells were transduced on two consecutive days. The 
transduction efficiency was relatively poor, with only 13% GFP+ LZRS-Jag2-IRES-
EGFP-transduced HS5 cells, 46% GFP+ LZRS-DL4-IRES-EGFP-transduced HS5 
cells and 12% GFP+ LZRS-EGFP-transduced HS5 cells. These are hereafter referred 
to as Jag2+HS5, DL4+HS5 and NC(DL4)HS5 respectively.The transduced cells 
were then FACS-sorted by eGFP expression to obtain a >95% pure population in all 
three cell subtypes. 
2.8 Quantitative polymerase chain reaction 
This is a method of quantifying expression of a specific gene by amplifying and 
simultaneously quantifying the transcript numbers from a cDNA template derived 
from RNA from the cell of interest. 
 89 
2.8.1 Materials 
• TRIzol reagent (15596-026; Ambion, Life Tech) 
• Chloroform (288306; Sigma-Aldrich)  
• PureLink RNA Micro kit (12183016; Ambion, Life Tech) 
• Absolute ethanol (459844; Sigma-Aldrich) 
• RNase-free H2O (AM9914G; Life Tech) 
• Oligo(dT)18 primers (BIO-38029; Bioline) 
• dATP, dCTP, dGTP, dTTP (BIO-39036; BIO-39038; BIO-39037; BIO-39039; 
Bioline) 
• SuperScript III Reverse Transcriptase (200U/µl; kit - 18080-044; Invitrogen) 
• 5X First-Strand Buffer (kit - 18080-044; Invitrogen) 
• 0.1M DTT (kit - 18080-044; Invitrogen) 
• RNaseOUT Recombinant RNase Inhibitor (10777-019; Invitrogen) 
• QuantiFast SYBR Green PCR Master Mix (204054; Qiagen) 
• Hs_HES1_1_SG QuantiTect primer assay (QT00039648, Qiagen) 
• Hs_DTX1_1_SG QuantiTect primer assay (QT00058744, Qiagen) 
• Beta-2 microglobulin  (B2M) primers - forward: 5' TCT CTC TTT CTG GCC 
TGG AG 3'; reverse: 5' AAT GTC GGA TGG ATG AAA CC 3' (Integrated DNA 
Technologies) 
2.8.2 RNA extraction using Trizol  
RNA was extracted from HMCL co-cultured with NL-expressing HS5 using TRIzol 
reagent and the PureLink RNA Micro kit. Usual measures to minimise RNase 
contamination and RNA degradation were undertaken. The suspension fraction of 
the co-cultures was aspirated into an RNase-free container, pelleted at 1,500rpm for 
ten minutes and the media was discarded. The pellet was then re-suspended in 500µl 
TRIzol and vortexed to mix well and allow complete lysis of the cells. The solution 
was then frozen at −80°C until RNA extraction could be resumed (within one week). 
 90 
Following aspiration of the media and suspension cell fraction, the adherent cell 
fraction was lysed in situ: 400µl TRIzol was added directly to each well (12-well 
plate) and pipetted up and down to mix thoroughly and lyse all adherent cells. The 
solution was then frozen at −80°C as for the suspension fraction. 
RNA extraction was performed using the PureLink kit as per the manufacturer’s 
instruction for TRIzol Plus Total Transcriptome Isolation. The thawed cell lysate 
with TRIzol was incubated at RT for five minutes. Where necessary, lysates were 
transferred into RNase-free 1.5ml Eppendorf tubes. Chloroform was added (0.2ml 
per 1ml TRIzol) and the capped sample was shaken vigorously by hand for 15 
seconds and then incubated at RT for two minutes. The samples were then 
centrifuged at >12,000 x g for 15 minutes at 4°C. The colourless aqueous upper 
phase was aspirated and transferred into a clean RNase-free tube. An equal volume 
of 100% ethanol was added to each sample (to obtain a final concentration of 50% 
ethanol) and the sample was vortexed to mix well. After inverting the sample twice, 
it was transferred into a PureLink Micro Kit Column and centrifuged at >12,000 x g 
for one minute at RT in order to bind the RNA to the silica-based membrane of the 
column. The bound RNA was then washed twice with 500µl Wash Buffer II with 
ethanol. Finally the RNA was eluted into a fresh tube with RNase-free water. It was 
then quantified by spectrophotometer (Nanodrop ND-1000). RNA samples were 
stored at −80°C for up to one month prior to cDNA synthesis. 
2.8.3 First-Strand cDNA Synthesis 
RNA samples were diluted to 50ng/µl. The following components were mixed in an 
RNase-free microcentrifuge tube: 
• 1.25µl oligo(dT)18 primers 
• 1.25µl each of dATP, dCTP, dGTP, dTTP (10mM) 
• 5µl RNase-free water 
• 5µl RNA at 50ng/µl 
This mixture was heated to 65°C for five minutes and then incubated on ice for two 
minutes. The following components were then added and mixed by gentle pipetting: 
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• 5µl 5x First-Strand Buffer 
• 1.25µl  0.1M DTT 
• 1.25µl  RNaseOUT 
• 1.25µl  SuperScript III RT 
This generated a total volume of 25µl, sufficient for 12 qPCR reactions. Where more 
RNA template was required, the reaction was scaled up, up to a maximum volume of 
50µl per microcentrifuge tube. This mixture was then incubated in a PCR 
thermocycler at 25°C for five minutes, 50°C for 40 minutes, 55°C for ten minutes 
and finally 70°C for 15 minutes to inactivate the reaction. cDNA samples were 
stored at −80°C for up to one month prior to amplification in PCR. 
2.8.4 Quantitative reverse transcriptase PCR  
Quantitative reverse transcriptase PCR (qPCR) using the QuantiFast SYBR Green 
PCR system was used to quantify the transcript levels of genes of interest in parallel 
with the transcript levels of a reference gene such as B2M. 
Each 25µl amplification reaction contained: 
• 12.5µl QuantiFast SYBR Green PCR Master Mix (2x) 
• 2.5µl Primer (10x) 
• 2µl cDNA template 
• RNase-free water to make up volume 
All cDNA samples were amplified in triplicate for each target gene and the reference 
gene. RNase-free water samples were run for each primer master mix as a negative 
control to exclude DNA contamination of the primers or SYBR Green Master Mix. 
Reactions were undertaken in MicroAmp Optical 96-Well Reaction Plates (Applied 
Biosystems) with MicroAmp 12-cap strips. qPCR reactions were run on the 
Mastercycler ep realplex real-time PCR machine (Eppendorf). 
Gene expression was quantified by subtracting the mean threshold cycle (CT) for the 
reference gene, B2M, from that of the target gene, either HES1 or DTX1 and this 
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value was termed ΔCT. Where the CT deviation value was >0.5 for a triplicate group, 
outlying samples were excluded and a more representative mean CT was calculated. 
Data was then presented as 2- ΔCT values for each sample. 
2.8.4.1 Quantitative reverse transcriptase PCR for HES1 and DTX1 
This was undertaken to verify Notch activation in HMCL co-cultured with NL-
expressing HS5 cells. On day one modified HS5 cells were seeded in 12-well plates 
at 86,000 cells/well in 1,700µl DMEM/10%FBS. On day four, when the HS5 cells 
were confluent, HMCL or DND41 cells were added to the wells at 430,000 cells/well 
in 1,100µl DMEM/10%FBS. Additional wells were seeded for U266, MM1S and 
DND41 cells, cultured alone at this stage. All cultures were also treated at this stage 
with the GSI L685 (final concentration 1µM). Cells were harvested 48 hours later on 
day six in two fractions: suspension and adherent and RNA was extracted according 
to the method detailed in section 2.8.2. 
cDNA synthesis was carried out as detailed in section 2.8.3. qPCR using the 
QuantiFast SYBR Green PCR system was used to quantify the transcript levels of 
Notch downstream targets HES1 and DTX1 in parallel with the transcript levels of 
the reference gene beta-2-microglobulin (B2M). This was chosen as a reference gene 
as expression varies minimally with experimental conditions 125,126.  
The multiple conditions mandated the use of 11 PCR plates, and so to allow 
comparisons between PCR plates, two standard cDNA samples were amplified in 
triplicate for each target gene and B2M on every plate. The cDNA was derived from 
DND41 cells cultured alone and treated with vehicle or L685 1µM (termed positive 
control (PC) and negative control (NC) respectively). These were generated from a 
different experiment. The conditions included in each qPCR plate are detailed in 
Table 2-7. 
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Table 2-7 Details of conditions and cDNA evaluated in each qPCR plate. 
qPCR plate 
number 
cDNA evaluated 
1 
U266, MM1S & DND41 cultured alone +/- GSI 
DND41 cultured alone +/- GSI (PC & NC) 
2 
U266, MM1S & DND41 co-cultured with Jag2+HS5 +/- GSI  
SUSPENSION FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
3 
U266, MM1S & DND41 co-cultured with Jag2+HS5 +/- GSI  
ADHERENT FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
4 
U266, MM1S & DND41 co-cultured with DL4+HS5 +/- GSI  
SUSPENSION FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
5 
U266, MM1S & DND41 co-cultured with DL4+HS5 +/- GSI  
ADHERENT FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
6 
U266, MM1S & DND41 co-cultured with NC(DL4)HS5 +/- GSI  
SUSPENSION FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
7 
U266, MM1S & DND41 co-cultured with NC(DL4)HS5 +/- GSI  
ADHERENT FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
8 
U266, MM1S & DND41 co-cultured with DL1+HS5 +/- GSI  
SUSPENSION FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
9 
U266, MM1S & DND41 co-cultured with DL1+HS5 +/- GSI  
ADHERENT FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
10 
U266, MM1S & DND41 co-cultured with NC(DL1)HS5 +/- GSI  
SUSPENSION FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
11 
U266, MM1S & DND41 co-cultured with NC(DL1)HS5 +/- GSI  
ADHERENT FRACTION 
DND41 cultured alone +/- GSI (PC & NC) 
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The layout for Plates 1 and 3 are shown in Figure 2-8 below, as representative 
examples of the arrangement of samples and primers. 
 
Figure 2-8 Representative qPCR plate layouts. 
Abbreviations: S, suspension; Ad, adherent; H2O, water; x, empty well. 
2.8.5 Patient-specific VDJ PCR 
To allow tracking of clonotypic primary MM cells through the whole BM MNC 
culture system, a method of isolating and amplifying the patient-specific IgH heavy 
chain VDJ region was optimised.  
RNA was extracted from patient tumour samples (~ 5x106 freshly isolated CD138-
selected primary BM MNCs) using the RNeasy Mini Kit (Qiagen) as per the 
manufacturer's protocol. First strand cDNA synthesis was then performed using 
Superscript III Reverse Transcriptase (Invitrogen) according to the manufacturer's 
protocol (see section 2.8.3 for more detail), using 500ng RNA. 
RT-PCR was performed using 12 primer pairs. All sets used a common reverse 
primer taken from the constant region of the IgH heavy chain locus (selected 
according to patient monoclonal protein isotype), with 12 different forward primers.  
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Figure 2-9 PCR amplification of patient-specific VDJ region using cDNA from freshly 
purified bone marrow CD138+ cells. 
RT-PCR performed on cDNA extracted from MM patient purified BM CD138+ cells using 
12 primer pairs. The patient-unique VDJ product was successfully amplified using the 
primers complementary to VH3 family (lanes 3 and 9). Abbreviations: L, ladder. 
Primers 1 to 6 were from the VH framework (VH-Fr) region and primers 7 to 12 were 
from the VH leader (VH-L) region. Primers Fr1 and L1 were from VH family 1, Fr2 
and L2 from family 2, and so on for six VH families (Figure 2-9). 
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CHAPTER 3. EVALUATING THE CD138-NEGATIVE 
POPULATION IN MULTIPLE MYELOMA 
3.1 Introduction 
3.1.1 Background 
The stem cell progenitor compartment in myeloma was championed for many years 
after it was initially proposed by Hamburger and Salmon in 1977 27. However, it was 
only in 2004 that a specific phenotype was proposed by Matsui et al 28. Building on 
the finding of clonotypic circulating B cells in the peripheral blood of myeloma 
patients 37-39, Matsui’s group suggested that as CD138 expression signalled terminal 
differentiation of both normal and malignant plasma cells, the pre-CD138 state might 
represent a myeloma progenitor. They demonstrated that within two CD138+ human 
myeloma cell lines (HMCL), there was small subset of CD138-negative (CD138−) 
cells. It was reported that this subset were more ‘clonogenic’, as evidenced by the 
formation of greater numbers of colonies in a methylcellulose-based colony 
formation assay (an in vitro technique designed to quantify clonogenicity and 
thereby ‘stemness’). This subset also expressed B cell markers (CD19 and CD20) as 
well as higher levels of the proliferation marker Ki67. When primary myeloma cells 
from both bone marrow aspirates and peripheral blood were evaluated, a similar 
pattern was found. Colony formation by CD138+CD34− MNCs was less than that of 
CD138−CD34− MNCs, although only with serial re-plating. CD138−CD34− BM 
MNCs successfully engrafted into NOD/SCID mice, with subsequent infiltration of 
the murine BM by human CD138+ cells and detectable human immunoglobulin. In 
contrast, primary CD138+CD34− BM MNCs did not engraft or recapitulate disease. 
The importance of B-cell markers on this CD138− fraction was also reiterated by the 
observation that pre-treatment of the subset with the monoclonal anti-CD20 antibody 
Rituximab reduced colony formation. 
The Matsui group’s second paper supporting the CD138− phenotype of myeloma 
stem cells was published in 2008 40, and it was this that triggered the experiments 
that form the bulk of this results chapter. They reported a number of additional stem 
cell-like features found within the CD138− subset of both HMCL and primary 
tumour cells. Firstly, they appeared to be relatively resistant to the cytotoxic effects 
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of commonly used anti-myeloma agents (dexamethasone, cyclophosphamide, 
bortezomib and lenalidomide), with preserved colony formation after treatment. 
Secondly, they segregated to the so-called ‘side population’ when stained with the 
DNA dye Hoescht 33342 (a feature reported for many different physiological and 
malignant stem cells). Thirdly, they had enhanced aldehyde dehydrogenase activity 
and finally, they displayed quiescence (in apparent contradiction to their previous 
finding of higher Ki67 staining).  
At around the same time, Julia Kirshner’s group published details of their novel 
culture system model for BM MNCs 44, which recapitulated elements of the normal 
BM architecture by culturing unselected cells within a layer of semisolid media 
(Matrigel). They used their system to culture myeloma patient BM MNCs and 
demonstrated prolonged survival of the tumour cells and specifically of apparent 
MM stem cells, which were CD20+ and localised in a quiescent state to the model’s 
‘endosteum’. 
Reviewing the literature (see Chapter 1. Introduction - section 1.2.1), it is apparent 
that Matsui’s proposed CD138− MM stem cell phenotype has by no means been 
widely accepted and the phenotype of the MM stem cell remains unknown. At the 
time that the work in this chapter was initiated many of the more recent reports 
examining the CD138+ and CD138− sub-populations had not yet been published and 
the phenotype hypothesised by the Matsui group was the most up-to-date and 
apparently robust. It was therefore taken as a starting point for the work presented 
here.  
3.1.2 Hypothesis and aims 
Hypothesis: CD138− tumour cells derived from myeloma patient bone marrow 
aspirates displayed stem cell-like features including drug resistance, quiescence and 
enhanced clonogenicity, when compared to their CD138+ counterparts. 
Aim 1: to phenotype primary myeloma tumour cells in terms of their expression of 
CD138, CD19, CD20 and CD27 in order to explore the proposal of Matsui et al that 
the CD138− compartment expressed B cell markers. 
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Aim 2: to set up and optimise an in vitro culture system that supported CD138− 
tumour cells from MM patient BM samples.  
Aim 3: to use the culture system to characterise this population in terms of drug 
resistance, cell cycle profile and colony-forming potential. 
3.2 Results 
3.2.1 Phenotyping fresh MM BM MNCs 
In order to achieve the first aim, the phenotype of freshly extracted BM MNCs was 
evaluated by flow cytometric analysis (method detailed in Chapter 2 – section 2.2) 
using antibodies for extracellular antigens including CD138, CD20, CD19, CD27 
and CD38. Additionally, cells were permeabilised in order to detect expression of 
intracellular antigens such as kappa and lambda light chains (LC). This allowed an 
assessment of the tumour burden within the sample as well as co-expression of other 
antigens by LC-restricted CD138+ (‘mature’) and CD138− (‘immature’) cells. 
Matsui proposed that in addition to lacking CD138, the progenitor compartment in 
MM expresses B-cell markers, such as CD19, CD20 and CD27 (specifically found 
on memory B-cells) 28,40.   
Two panels of antibodies were used to evaluate these cell populations. The first 
group of freshly isolated primary MM BM MNCs were phenotyped to quantify the 
proportions of the malignant clone (LC-restricted, LC+) expressing B-cell (CD20) 
and memory B-cell (CD27) markers, in combination with CD138. Analysis was 
confined to those with a LC+ clone greater than 10% and the percentages of the three 
subpopulations were expressed as a percentage of the malignant clone to allow 
comparison between patient samples. In all figures the samples were ranked by the 
percentage of CD138+ cells. Figure 3-1A shows the percentages of LC+ CD138+ vs. 
LC+ CD138−CD20+ vs. LC+ CD138−CD20− cells in 16 primary samples, while 
Figure 3-1B shows the percentages of LC+ CD138+ vs. LC+ CD138−CD27+ vs. 
LC+ CD138−CD27− cells in nine primary samples. In the second group of samples, 
using a second panel of markers, combined CD38 and LC positivity were used as an 
alternative, more stringent, method of quantifying the malignant clone, with CD19 
used as a B cell marker, alongside CD138 as before. Figure 3-1C shows the 
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percentages of LC+CD38+ CD138+ vs. LC+CD38+ CD138−CD19+ vs. 
LC+CD38+ CD138−CD19− cells in 18 primary samples. 
A 
 
B 
 
C 
 
Figure 3-1 Phenotyping primary MM BM MNCs. 
A. The proportions of LC+ CD138+ (grey), LC+ CD138−CD20+ (black) and LC+ 
CD138−CD20− (hatched) cells are shown, as a % of the LC+ cells (n=16; three new 
diagnoses, 13 relapses). B. The proportions of LC+ CD138+ (grey), LC+ CD138−CD27+ 
(black) and LC+ CD138−CD27− (hatched) cells are shown, as a % of the LC+ cells (n=9; 
three new diagnoses, six relapses). C. The proportions of LC+CD38+ CD138+ (grey), 
LC+CD38+ CD138−CD19+ (black) and LC+CD38+ CD138−CD19− (hatched) are shown, 
as a % of the LC+CD38+ clonal cells (n=18; seven new diagnoses, 11 relapses). All 
primary samples have LC+ cells populations >10% and are ranked in order of % of 
LC+CD38+ cells. 
Subgroup analysis looking at disease state or cytogenetic abnormalities did not 
reveal any association between B-cell marker expression and CD138 expression. It is 
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therefore apparent that the LC+CD138− sub-population is heterogeneous and does 
not reliably express B-cell markers. 
3.2.2 The whole BM culture system maintains LC-restricted MM cells in 
vitro for up to three weeks 
Previous work by John Quinn in the group had established the superiority of pooled 
MM patient plasma when compared with foetal bovine serum (FBS) for in vitro 
culture of primary MM cells. In addition, Kirshner et al 44 described how Matrigel-
based whole BM culture was able to maintain the MM clone in culture for several 
weeks. Thus initial experiments were set up to compare suspension and Matrigel-
based culture systems (see Chapter 2 – section 2.1.7 for methodology). Both the 
suspension and Matrigel-based systems were able to maintain viable LC+ tumour 
cells for up to three weeks. Figure 3-2 shows LC+ cells at baseline (D0) and after 
one week (D7) in culture.  
A 
 
B 
 
 
Figure 3-2 Survival of LC-restricted MM cells in vitro. 
Freshly isolated unselected MNCs from MM patient BM aspirates were cultured for up to 
three weeks in a system utilising CM (14 suspension culture, seven Matrigel culture). FACs 
analysis was used to quantify the LC+ population at baseline, day 0 (D0), and when 
harvested at D9 (n=21; two new diagnoses, 19 relapses). A. Survival of LC+ cells as a % of 
whole MNC population on D0 vs. D7. B. Absolute numbers of LC+ cells on D0 vs. D7. 
Significance values refer to the results of paired t-tests. 
Absolute numbers of total MNCs declined over the duration of the culture period to 
43.65±5.91% of starting values. However, the MM clone, identified by those cells 
 101 
which were LC+, was well maintained as a proportion of the whole and even 
increased in some cultures; at D7 absolute numbers of LC+ cells were 49.24±9.11% 
of starting values (Figure 3-2B; p=0.0005). 
For some patient samples, the presence of a known translocation in the starting 
tumour cell population made FISH analysis a useful method of confirming clonality 
of the harvested D9 cells. The example in Figure 3-3 below shows a CD138+ cell 
harvested after nine days in culture, stained with May-Grunwald Geimsa (MGG; see 
Chapter 2 – section 2.3.3 for methodology) to confirm plasma cell morphology and 
probed for translocations using FISH (see Chapter 2 – section 2.3.1 for methodology). 
It demonstrates a fusion signal consistent with t(11;14), which was known to be 
present in the patient's MM cells. 
 
Figure 3-3 Paired MGG staining and FISH analysis of cells harvested from whole BM 
culture on D9. 
MGG staining (left) of plasma cell harvested after nine days in culture, accompanied by 
FISH (right) showing fusion signal of t(11;14), arrowed.  
3.2.3 Comparison of suspension and Matrigel whole MNC culture 
systems 
Subsequently the survival of the CD138+ and CD138− subpopulations was 
compared between suspension and Matrigel-based cultures. Both systems included 
fibronectin and collagen and some cultures incorporated pro-survival cytokines (e.g. 
IL-6, IGF-I). The Matrigel system proved to be superior in terms of preservation of 
CD138− cells harvested following culture (Figure 3-4). 
By D7 there had been a reduction in LC+CD138− cells grown in suspension culture 
(49.4±18.97% compared to D0), whereas in Matrigel culture there had been an 
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increase (155.7±54.85%; Figure 3-4B). As this was the main sub-population of 
interest, the Matrigel method was selected for further work. 
A 
 
B 
 
Figure 3-4 A. Survival of primary BM MNCs in suspension vs. Matrigel cultures.  B. 
Survival of primary LC-restricted CD138− cells in suspension vs. Matrigel cultures. 
Primary whole BM MNCs were cultured in parallel for seven days in two different culture 
systems using CM: suspension- and Matrigel-based (n=9; all relapses). Viable cells were 
quantified by trypan blue exclusion. A. FACs analysis quantified LC+ (light grey) vs. LC− 
(white) MNCs, and, within the LC+ population, CD138+ (dark grey) and CD138− (black) 
cells. Absolute numbers of cells within each subpopulation on D0 and D7 are shown (mean 
& SEM). B. Viable LC+CD138− cells on D7 (as a % of baseline) are shown for both 
suspension (S) and Matrigel (M) culture systems (mean ±SEM; paired t-test NS). 
The system preserved MNCs, CD138+ and CD138− cells for up to three weeks, 
allowing assessment of the effect of cytokines and anti-myeloma drugs on the 
different sub-populations. The addition of pro-survival CKs had no impact on sub-
population survival in either system.  
Importantly, cultures set up from CD138-depleted MNCs were not able to repopulate 
a CD138+ clone, despite the hypothesised CD138− precursor phenotype (Figure 3-5). 
At seven and 14 days from set-up there were extremely low numbers of CD138+ 
cells present in the CD138-depleted condition, with no evidence of expansion of this 
compartment. 
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Figure 3-5 Enumeration of LC-restricted CD138+ cells cultured from whole BM MNCs 
compared to CD138-depleted BM MNCs. 
Primary BM MNCs were cultured in two parallel systems for seven days, either whole or 
following CD138-depletion at set up (to <1.5%; n=3; all relapses). Viable cells were 
quantified by trypan blue exclusion and FACs analysis was used to quantify LC+CD138+ 
cells. Absolute numbers of CD138+ cells present are shown (mean ±SEM). 
3.2.4 Effect of anti-MM agents in the whole BM culture system 
Using the Matrigel culture system, whole BM MNCs were grown in vitro for seven 
days and then treated with dexamethasone (Dex) or with the proteosome inhibitor 
bortezomib (BZM) for 48 hours prior to harvest on day nine. 
In this system Dex did not reliably cause a reduction of either LC+ or LC− cells 
(Figure 3-6A & B). Absolute numbers of CD138+ cells at D9 were 23.5±7.5% of 
baseline in the control condition compared to 22.0±9.7% in Dex-treated condition 
(paired t-test NS). In the LC+CD138− compartment, there was an increase in 
absolute terms at D9, to 132.1±46.5% in the control condition and 107.4±29.0% in 
the Dex-treated arm (paired t-test NS).   
In contrast, BZM treatment (Figure 3-6C & D) was associated with a reduction in 
CD138+ cells at D9: 23.1±6.4% in the control arm compared to 7.7±4.8% in the 
BZM-treated arm (paired t-test p=0.0239). At D9 there was enrichment of 
LC+CD138− cells, 138.9±43.58% in the control arm and 201.6±64.9% after BZM 
treatment (paired t-test NS).  
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Figure 3-6 Drug treatment of primary BM MNCs in Matrigel culture: A. 
dexamethasone and B. bortezomib. 
Primary whole BM MNCs were cultured in Matrigel & CM for seven days and then treated 
with Dex 1µM (A & B; n=3; all relapsed MM) or BZM 20nM (C & D; n=11; one new 
diagnosis, ten relapsed MM) for a further two days prior to harvest (D9). A & C. FACs 
analysis as per Figure 3-4, with pooled data for all sub-populations shown at baseline (D0) 
and D9 (A: Dex, C: BZM; mean ±SEM). B & D. Viable LC+CD138− cells on D9 as a % of 
baseline as shown for control (light grey) and treatment (hatched) arms (B: Dex, D: BZM; 
mean ±SEM). 
3.2.5 Cell cycle properties of CD138+ and CD138− cells 
The cell cycle characteristics of the LC+ sub-populations after a week in culture 
were assessed using a BrdU uptake-based flow cytometric analysis (see Chapter 2 – 
section 2.2.3 for methodology). This assay allowed evaluation of the cell cycle 
characteristics of the whole BM MNC population and comparison between them and 
those of LC+CD138+ and LC+CD138− cells (Figure 3-7A).   
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Figure 3-7 A&B. Cell cycle status of whole MNCs, CD138+ and CD138− cells, based on 
BrdU uptake and 7AAD staining. C. Representative cell cycle plots of CD138+ vs. 
CD138− cells, highlighting sub-G0/G1. 
A. Whole BM MNCs were cultured in Matrigel-CM. At nine days, cultures were pulsed with 
BrdU for three hours prior to harvest. Cell cycle characteristics at day nine were assessed 
using BrdU uptake and 7AAD staining. LC+CD138+, LC+CD138− and whole MNCs were 
analysed separately and the proportion of cells in sub-G0/G1 (black), G0/G1 (light grey) 
and S/G2M (hashed) are shown (n=9; one new diagnosis, eight relapsed MM; mean & 
SEM). B. Sub-G0/G1% for each subpopulation shown. *p<0.001. C. Representative FACs 
plots of CD138+ and CD138− cells (D9) from three primary samples are shown, 
highlighting proportion in sub-G0/G1.   
When the whole population of BM MNCs was examined, 2.19±0.3% was in S/G2M, 
while within LC+CD138+ cells the proportion was higher at 9.60±1.8% and in 
LC+CD138− cells the proportion was 1.00±0.2%. These differences were significant 
(MNCs vs. CD138+ p=0.001; MNCs vs. CD138− p=0.004; CD138+ vs. CD138− 
p=0.0003). 
The proportion of unselected MNCs in sub-G0/G1, indicative of dying cells, was 
45.95±5.7%, while in the LC+CD138+ subpopulation the proportion was much less 
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at 8.18±1.8%. LC+CD138− cells had the greatest proportion with 76.44±4.5% cells 
in sub-G0/G1. These differences were significant (p<0.001) in all combinations 
(Figure 3-7 B&C). 
Thus while the culture system had seemed on FACs analysis to demonstrate an 
enrichment of the LC+CD138− cell population, cell cycle analysis revealed that the 
majority (76%) of this sub-population were apoptotic (sub-G0/G1), although trypan 
blue-excluding, at day nine. 
3.2.6 Enumeration of clonogenic cells and evaluation of colony assays  
The colony assay was developed in order to quantify the colony-forming potential of 
primary MM cells in vitro, as a surrogate for self-renewal and proliferative capacity 
and a measure of ‘stemness’. The assay was modified from a methodology reported 
by Matsui et al 28. Here whole primary BM MNCs were depleted of normal CD34+ 
haematopoietic progenitors and plated at 1-5x105 in methylcellulose supplemented 
with 30% bovine serum albumin, 2-mercaptoethanol, glutamine and 10% 
lymphocyte conditioned media (LCM). Colonies were counted from 14 days post-set 
up. 
The method is detailed in Chapter 2 – section 2.1.8. Due to difficulties sourcing 
commercial LCM a number of supplementary cytokine combinations and lab-
produced LCM were tested in order to optimise the colony assay. Table 3-1 charts 
the different conditions trialled and resultant colony characteristics.  
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Table 3-1 Methylcellulose additives trialled and resultant colony features 
 Methylcellulose additives  Colony features 
1 
GMCSF 25ng/ml, Epo 2u/ml, IL-3 
30ng/ml, GCSF 25ng/ml, SCF 
10ng/ml 
Consistent colony formation although 
highly variable morphology and colony 
density. Occasional erythroid colonies 
(BFU). 
2 
GMCSF 25ng/ml, Epo 2u/ml, IL-3 
30ng/ml, GCSF 25ng/ml, SCF 
10ng/ml + 5% pooled MM patient 
plasma 
Some colony formation. Acellular 
precipitate throughout methylcellulose. 
3 
IL-3 30ng/ml, IL-4 10ng/ml, IL-6 
20ng/ml 
No colonies. 
4 LCM No colonies. 
5 
LCM (made without adherent 
monocytes) 
No colonies. 
6 No additives (methylcellulose alone) No colonies. 
7 10% pooled MM patient plasma 
No colonies. Extensive acellular 
precipitate. 
8 
IL-2 20u/ml, IL-6 50ng/ml, IL-10 
50ng/ml, IL-15 10ng/ml  
No colonies. 
9 
IL-2 20u/ml, IL-6 50ng/ml, IL-10 
50ng/ml, IL-15 10ng/ml + 10% 
pooled MM patient plasma 
No colonies. Extensive acellular 
precipitate. 
Following this comparison, it was decided that methylcellulose supplemented with 
GMCSF, Epo, IL-3, GCSF and SCF produced the greatest number and best 
demarcated colonies, allowing greater ease of counting. The addition of pooled MM 
patient plasma was associated with acellular precipitate, which made colony 
identification very difficult.  
A typical colony is shown in Figure 3-8. 
 108 
 
Figure 3-8 A representative colony grown from CD34-depleted MM BM MNCS. 
Photomicrograph of a single colony growing in methylcellulose, four weeks from set up, 
photographed in situ at 10X magnification. 
Additionally the concentration at which cells were seeded in methylcellulose was 
optimised. Colony assays were set up from freshly isolated MNCs (day 0) and after 
time in culture (Figure 3-9). Freshly isolated MNCs consistently generated higher 
numbers of colonies and therefore were seeded at 0.25x105cells/ml and 
0.12x105cells/ml, while colony assays set up on day seven to nine were seeded at 
1x105cells/ml and 0.25x105cells/ml. 
 
Figure 3-9 Colony formation at day zero versus day nine. 
Clonogenic assays were set up at baseline (day zero, D0) and D9 to enumerate precursor 
cells. Colonies were counted at 14 days. Data from individual samples, with medians 
indicated; n=8. 
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Colony formation by different subpopulations of BM MNCs was then compared. All 
colony assays were set-up using MNCs which had been depleted of CD34+ cells 
(using Miltenyi Biotec CD34-MicroBeads and leucodepletion columns), to prevent 
the outgrowth of normal haematopoietic progenitor cells. Clonogenic potential was 
then examined in CD34− MNCs, CD34−CD138− MNCs and CD34−CD138+ MNCs. 
Absolute numbers of colonies varied widely between primary samples, but there was 
not a significant difference in colony number between these three groups. 
Despite extensive efforts at optimisation, the colony assay had clear limitations. 
There was extremely variable colony formation between primary samples, even 
those taken at similar disease stages. Despite rigorous CD34+ cell depletion, 
erythroid burst-forming units (BFU) were sometimes seen, implying that there was 
CD34+ haematopoietic stem cell contamination or erythroid lineage cells were 
potentially arising from mesenchymal stem cells. Macroscopically, colonies grown 
were morphologically variable within a single assay and between D0 and D9. The 
cells within a single colony were also morphologically variable, as seen by MGG 
staining of cytospins from individual colonies (Figure 3-10). The majority of cells 
were plasmacytoid, while some had a monocytoid or macrophage-like appearance. 
 
Figure 3-10 Morphology of cells derived from colony assay. 
Single colonies were aspirated from methylcellulose and washed, and cytospins were made. 
Morphology was evaluated following MGG staining.  
A number of approaches were used to identify the cells making up the colonies. 
FACs analysis of single colonies was not possible owing to low cell number, 
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exacerbated by the necessity for multiple washes to remove sufficient 
methylcellulose to allow antibody binding. FACs analysis of pooled colonies from 
single primary samples did not show a CD138+ population (Figure 3-11A). It was 
postulated that syndecan-1 (CD138) might be disrupted or even removed by 
methylcellulose, but colonies generated from unselected HMCL were consistently 
CD138+ (Figure 3-11B).   
A 
 
B 
 
Figure 3-11 Flow cytometric analysis of cells from colony assays. 
A. Freshly isolated MM BM CD34−CD138− MNCs were seeded in methylcellulose. After 
four weeks colonies were plucked and pooled. After washing in warmed PBS, cells were 
stained for CD138-expression and examined by flow cytometry. Two examples are shown 
from two individual patients. B. KMS11 colonies were grown in methylcellulose. After 14 
days colonies were plucked and pooled. After washing in warmed PBS, they were stained for 
CD138 and kappa LC expression and examined by flow cytometry. 
Immunohistochemistry confirmed that cells within plucked colonies were CD138−, 
MUM1− but occasionally BLIMP-1+ (Figure 3-12).  
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Figure 3-12 BLIMP-1 staining of cells isolated from colony assay. 
Single colonies were aspirated from methylcellulose and washed, and cytospins were made. 
These were stained for CD138, MUM-1 and BLIMP-1. Representative cells positive for 
BLIMP-1 are shown; courtesy of Dr Teresa Marafioti. 
Immunocytochemistry using dual esterase staining (method detailed in Chapter 2 – 
section 2.3.2) demonstrated that in excess of 90% of cells from the plucked colonies 
were positive for alpha naphthyl butyrate (Figure 3-13), a stain for monocytes and 
macrophages.   
 
Figure 3-13 Dual esterase staining of cells isolated from colony assay. 
Single colonies were aspirated from methylcellulose and washed, and cytospins were made, 
as per Figure 3-10. These were stained for alpha naphthyl butyrate and chloroacetate. 
Representative cells positive for alpha naphthyl butyrate are shown. 
FISH analysis could not identify specific translocations in colony-cells grown from 
primary samples known to possess those translocations. It was not possible to 
analyse patient-specific VDJ sequences from colonies (see section 0 for method); 
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RNA extraction and RT-PCR of housekeeping genes was successfully performed 
from single colonies but the IgH VDJ sequence was not expressed at sufficiently 
high levels to be detectable by RT-PCR.  
3.3 Summary and discussion 
Phenotyping the MNCs in a large number (43) of MM patient BM aspirates 
demonstrated variable proportions of LC+CD138+ and LC+CD138− sub-
populations. LC+CD138− cells did not consistently express B cell antigens, in fact 
the majority had extremely low expression of CD19, CD20 and CD27. This 
contradicted the findings of Matsui et al. 
The modified three-dimensional culture system using fibronectin/collagen well-
coating, RPMI/20% pooled patient plasma and Matrigel was able to maintain LC+ 
MM cells over a period of up to two weeks and this allowed analysis of the 
LC+CD138+ and LC+CD138− sub-populations after a number of 
microenvironmental modifications and drug treatments.  
Over time and in the presence of anti-MM agents, there appeared to be an absolute 
increase in the number of LC+CD138− cells, although this was not accompanied by 
an increase in colony-forming potential, as might be anticipated. Cultures set up from 
CD138-depleted BM MNCs were not capable of generating mature CD138+ cells. 
When the cell cycle profiles of CD138− and CD138+ cells were examined separately 
using BrdU uptake and 7AAD staining, more than 70% of CD138− cells were found 
to be sub-G0/G1 (i.e. apoptotic), compared to <10% of CD138+ cells. This 
confirmed the findings of Jourdan et al. 56 and Christensen et al. 55. Hence a 
reinterpretation of the drug resistance assays was required: it appeared that the 
increasing number of CD138− cells in the culture system after anti-MM treatment 
reflected increased apoptosis and not enrichment for drug-resistant CD138− cells.  
It was also clear that our main assay for enumerating precursor cells (i.e. the colony 
assay), derived from the methodology reported by Matsui et al 28,40, was not 
reproducible and therefore not sufficiently robust to accurately and consistently 
quantify colony forming potential of tumour cell subsets.  
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In evaluating our hypothesis we accomplished our first and second aims, but our 
characterisation of the ‘stemness’ of the CD138− subpopulation (Aim 3) was limited 
by the colony assay. As this was not robust, despite extensive attempts at 
optimisation, clonogenicity of myeloma cell subpopulations could not be accurately 
evaluated. Nevertheless it was concluded that our hypothesis did not hold true, and 
CD138 negativity was not a reliable phenotypic marker for a stem-cell sub-
population in primary MM cells.  
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CHAPTER 4. APRIL-MEDIATED DRUG RESISTANCE 
IN MULTIPLE MYELOMA 
4.1 Introduction 
4.1.1 Background  
In the next phase of exploring the tumorigenic progenitor compartment within 
multiple myeloma, it seemed sensible to look from a functional angle and explore 
cellular mechanisms of drug resistance within primary myeloma cells and human 
myeloma cell lines. Drug resistance is a key feature of cancer stem cells, as it is for 
physiological stem cells, and appears to be mediated by a number of both intrinsic 
and microenvironmental mechanisms. 
It has been established that the bone marrow microenvironment is critical to MM cell 
drug sensitivity and that both soluble factors and direct cell-cell contacts are heavily 
implicated (see Chapter 1 - section 1.2.2). In this results chapter, the specific 
contribution of the cytokine APRIL will be explored. There is an increasing 
understanding of the importance of APRIL in the differentiation and long-term 
survival of memory B cells, plasma cells 68,70,71 and also to the survival of malignant 
plasma cells 75,76. APRIL is produced by a number of cell types within the bone 
marrow including all members of the myeloid lineage, osteoclasts and BM stromal 
cells71. It was recently demonstrated that levels of APRIL within the BM remain 
constant despite varying levels of MM cell infiltration at different points in the 
disease 127. When APRIL-producing cells within the marrow were characterised at 
different stages in the disease, it was apparent that as MM infiltration increased, the 
proportion of immature CD16− myeloid cells, which secrete the most APRIL, also 
increased. The same group have subsequently showed that MM cells were able to 
influence proportions of haematopoietic precursors. The majority are suppressed, 
with the exception of CD16− myeloid precursors 128 because this cell sub-group 
proliferate in response to IL-6 (in a RANKL-dependent fashion). It seems therefore 
that MM cells are able to modulate their environment to enhance APRIL secretion. 
The contribution of cytokines such as IL-6, VEGF and IGF-I to the survival of 
malignant plasma cells after treatment with anti-myeloma agents is relatively well-
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understood but it is only recently that APRIL has also been implicated as a potential 
effector of drug resistance 76. Moreaux et al demonstrated high levels of expression 
of APRIL receptors, BCMA and TACI, on both HMCL and primary MM cells and 
the secretion of APRIL into the culture media by MM cells. They also reported that 
APRIL was able to rescue IL-6 dependent HMCL from IL-6 deprivation and 
blockade of APRIL binding reduced the proliferation of cytokine-independent 
HMCL. The effects of dexamethasone on sensitive HMCL and primary MM cells 
were mitigated by the addition of excess APRIL. These findings were attributed to 
the actions of the NF-κB and PI3K/AKT pathways. 
Affymetrix microarrays were used to examine protein expression in purified MM 
cells from newly diagnosed patients77. Two groups were identified with higher 
versus lower TACI expression, and it was found that higher TACI expression 
correlated with better clinical outcomes. Analysis of the genes that were 
differentially expressed by the two groups showed that high TACI expression was 
associated with a mature plasma cell signature, implying dependence on the BM 
microenvironment, while low TACI expression was associated with a plasmablast 
gene signature, implying attenuated dependence on the BM, such as that seen in 
extramedullary MM cells. This hints towards the potential contribution of APRIL to 
BM microenvironmental support and protection of MM cells.  
Work published by our group showed that APRIL was able to trigger cell-cycle 
progression in primary MM cells 18, but only in those overexpressing cyclin D2 as a 
result of translocations involving the IgH gene locus (t(4;14) and t(14;16)). APRIL-
mediated drug resistance might similarly segregate to different genetic subtypes. 
Dependence on APRIL-mediated survival pathways may therefore render particular 
genetic sub-groups suitable for anti-APRIL strategies, as an alternative approach to 
those distinguished by TACI expression signature.  
4.1.2 Hypothesis and aims 
Hypothesis: APRIL offers protection to myeloma cells exposed to anti-myeloma 
agents and is therefore a potential effector of bone marrow microenvironmental drug 
resistance. The effects of APRIL vary between different genetic subtypes of MM. 
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Aim 1: to investigate the effect of soluble recombinant APRIL on the sensitivity of 
primary MM cells of different genetic subtypes to anti-myeloma agents. 
Aim 2: to identify cellular mechanisms underlying protection seen. 
Aim 3: to investigate the effect of APRIL-secreting HS5 cells on the sensitivity of 
co-cultured HMCL to anti-myeloma agents. 
4.2 Results 
4.2.1 Effect of soluble recombinant APRIL on drug resistance in 
primary MM cells 
4.2.1.1 APRIL does not influence survival of primary CD138+ cells 
Primary CD138+ MM cells were cultured in the presence of APRIL (see Chapter 2 – 
section 2.1.9 for detailed methodology). The addition of APRIL to CM at the time of 
culture set up had no consistent effect on the survival of CD138+ cells. Our group 
had previously reported that APRIL stimulated cell-cycle progression in CD138+ 
cells of specific genetic subtypes 18, and therefore the results were re-analysed by 
cyclin D-type expression into Cyclin D1 (CCND1) and Cyclin D2 (CCND2)-
expressing patients (see Figure 4-1) but no difference in survival was seen. 
 
Figure 4-1 Effect of APRIL on CD138+ cell survival.  
Primary CD138+ cells were cultured in CM +/- APRIL 200ng/ml. Cell viability was 
assessed after 48 hours by AV/PI staining. Viable AV−PI− cells in APRIL-treated condition 
are shown, as % of control (CM alone), sub-divided into CCND1 (D1; n=11) and CCND2 
(D2; n=7) MM cells. 
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4.2.1.2 APRIL attenuates dexamethasone-mediated apoptosis in primary 
CD138+ cells 
CD138+ MM cells were treated with dexamethasone (Dex) in the presence of APRIL 
as detailed in Chapter 2 – section 2.1.9.  
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Figure 4-2 Effect of APRIL, IL-6 and IGF-I on dexamethasone-induced apoptosis in 
CD138+ cells.   
Primary CD138+ cells were treated with Dex +/- APRIL, IL-6 or IGF-I for 48 hours. 
Apoptosis was quantified by AV/PI staining. Results are presented as apoptosis as a % of 
control. A. Pooled results from 43 experiments comparing treatment with Dex alone to Dex 
+ APRIL (individual results and median indicated). B. Results from 35 experiments are 
analysed by CCND-type expression (CCND2 n=17, CCND1 n=18; paired results shown). C. 
Representative FACs plots of CCND2 MM cells. The % of apoptotic cells is shown.  D. 
Primary CD138+ cells were treated with Dex (control) +/- APRIL +/- IL-6 (n=13) or IGF-I 
(n=5).  
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APRIL reduced Dex-induced apoptosis at 48 hours. This was seen in the majority of 
primary MM cells and was highly significant (paired t-test p=0.0002; Figure 4-2A).  
Segregation of primary samples into CCND1-expressing (CCND1+) and CCND2-
expressing (CCND2+) subtypes revealed more consistent and greater degrees of 
protection in CCND2+ CD138+ cells compared to CCND1+ CD138+ cells (paired t-
tests p=0.0094 and p=0.03 respectively; Figure 4-2B). The degree of Dex-induced 
apoptosis in the control condition varied between samples but a representative FACs 
plot from a CCND2+ sample is shown in Figure 4-2C.  
APRIL-mediated protection against Dex killing was compared to that associated with 
IL-6 or IGF-I in a small number of primary samples (Figure 4-2D). The numbers are 
limited and sub-group analysis by CCND expression was not possible. However, 
there is broad trend towards protection being greatest in cells treated with IL-6, then 
APRIL, with the least protection seen in samples treated with IGF-I. 
4.2.1.3 APRIL does not influence bortezomib- or lenalidomide-induced 
apoptosis 
CD138+ cells were treated with bortezomib (BZM) (Figure 4-3). BZM induced 
apoptosis in the majority of samples (median apoptosis 84.7% (range 1-95.2%), 
mean (±SD) apoptosis 67.9% ±28.6; n=13; see Figure 4-3A).  
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Figure 4-3 Effect of APRIL on bortezomib-induced apoptosis in CD138+ cells.   
Primary CD138+ cells were treated with BZM +/- APRIL for 48 hours. Apoptosis was 
quantified by AV/PI staining. Results are presented as apoptosis as a % of control (paired 
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results shown). A. All patients (n=13). B. CCND2+ and CCND1- patients (n=9). C. 
CCND1+ patients (n=3). 
However, there was no protection from apoptosis seen with the addition of APRIL 
(median 84.0% (range 0.1-96.2%), mean (±SD) apoptosis 67.9 ±29.1; paired t-test 
non-significant). This was true even when samples were analysed according to 
CCND-type (Figure 4-3B&C), although analysis was limited by the sample number 
of CCND1+ samples.  
MM cells were also treated with lenalidomide (Len) (Figure 4-4). Len induced 
apoptosis in all samples (median apoptosis 44.6% (range -10.5-89.6%), mean (±SD) 
46.9 ±33.6; n=18; see Figure 4-4A) but as with BZM there was no protection seen in 
cells co-treated with APRIL (median apoptosis 35.4%  (range 0.77-88.8%), mean 
(±SD) 42.5 ±30.12; paired t-test non-significant). Analysis of CCND1+ and 
CCND2+ samples separately did not reveal any protection (Figure 4-4B&C).  
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Figure 4-4 Effect of APRIL on lenalidomide-induced apoptosis in CD138+ cells.   
Primary CD138+ cells were treated with Len +/- APRIL for 48 hours. Apoptosis was 
quantified by AV/PI staining. Results are presented as apoptosis as a % of control (paired 
results shown). A. All patients (n=18). B. CCND2+ patients (n=7). C. CCND1+ patients 
(n=9). 
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4.2.1.4 The effect of PI3K/AKT pathway inhibition on APRIL-mediated 
protection from dexamethasone killing  
In order to explore whether the PI3K/AKT pathway was involved in APRIL-
mediated protection from Dex killing, the small molecule inhibitor PI103 was added 
to cells exposed to APRIL and/or Dex. This acts both on PI3K and the mTOR 
complex to cause complete blockade of the pathway. 
PI103 alone has a modest effect on MM cell viability (Figure 4-5A), which appears 
to be partially reduced in the presence of APRIL. In the five patient samples 
evaluated in this series of experiments, Dex killing was highly variable (as it was 
across the larger series in 4.2.1.2), hence the large error bars in Figure 4-5A. Thus 
drawing conclusions regarding the effects of both APRIL, PI103 and the 
combination is impossible in this series. Figure 4-5B highlights the differences in 
levels of apoptosis seen between patient samples and while there is a trend towards 
confirmation of APRIL-mediated protection against Dex killing, it is not statistically 
significant.  
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Figure 4-5 Effect of APRIL and PI103 on dexamethasone-induced apoptosis in CD138+ 
cells.   
Primary CD138+ cells were treated with Dex +/- APRIL and/or PI103 1µM for 48 hours. 
Apoptosis was quantified by AV/PI staining (n=5; all conditions set up in triplicate) A. 
Viable cells are shown as a % of control for all seven conditions (mean ±SEM). B. Apoptotic 
cells are shown as a % of control for each experiment.  
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This experiment highlighted the difficulty of working exclusively with primary MM 
cells, as the baseline viability and drug sensitivity was extremely variable between 
different samples. For this reason, it was decided to screen HMCL for sensitivity to 
Dex, in order to select suitable cell lines for further mechanistic work.   
4.2.2 HMCL cultured in the presence of soluble recombinant APRIL 
A panel of HMCL were screened to identify first those that were sensitive to Dex 
and secondly those who also had protection from Dex cytotoxicity in the presence of 
APRIL. 
4.2.2.1 HMCL sensitivity to dexamethasone 
The first stage of screening was undertaken using two Dex doses (1µM and 10µM) in 
RPMI/10%FBS (R10) and in serum-free RPMI (R) (for methodology see Chapter 2 – 
section 2.1.10). The following HMCL were screened: U266, KMS-12PE, KMS-
21BM, NCI-H929, JIM1, JJN3, KMS-11, OPM2, MM1S, RPMI-8226, KMS-27 and 
KMS-28PE. 
The effect on cell growth and viability is displayed below graphically in Figure 4-6. 
The results are tabulated in Table 4-1 (only figures for Dex 10µM are displayed).  
These experiments demonstrated that Dex-sensitivity was highly variable between 
the different lines, with no obvious pattern seen based on translocation group. The 
lines could be broadly grouped into moderately, minimally and in-sensitive based on 
ranking the effect of Dex on cell viability and cell growth (Table 4-2). KMS-11 and 
KMS-28PE were the most sensitive lines, both in terms of cytotoxicity and inhibition 
of growth.  
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Figure 4-6 Effect of dexamethasone treatment on HMCL cultured in R10 and R alone. 
HMCL were cultured in R10 or R alone and treated with Dex (hashed 1uM, block colour 
10uM; blue in-filled bars represent HMCL that were subsequently re-evaluated with APRIL) 
for 48 hours. Cells were harvested and viability and growth were assessed by AV/PI staining. 
All conditions were in triplicate and values above represent mean viable cell % or cell 
concentration of Dex-treated cells, as a % of untreated control cells. HMCL are arranged 
into groups by translocation type. 
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Table 4-1 Effect of dexamethasone treatment on HMCL cultured in R10 and R alone. 
Translocation  
Status 
HMCL 
Effect of dexamethasone treatment (10µM) 
Proliferation 
(Viable cells/ml as % of 
untreated control) 
Viability 
(% Viable cells as % 
of untreated control) 
Culture media  R10 R R10 R 
t(11;14) 
U266 127.84 103.84 104.04 99.02 
KMS-12PE 73.69 68.23 99.95 95.99 
KMS-
21BM 
72.62 1548.12 84.06 1408.56 
t(4;14) 
OPM2 60.62 88.37 87.32 85.95 
KMS-11* 31.23 57.68 50.12 72.04 
JJN3 92.00 139.83 99.06 138.13 
JIM1 94.39 148.82 101.59 152.03 
NCI-H929 102.35 275.74 99.60 254.07 
t(14;16) MM1S 53.75 83.48 90.81 83.95 
t(16;22) RPMI-8226 78.60 69.84 79.54 71.51 
Uncharacterised 
KMS-27 86.89 78.98 95.54 69.99 
KMS-28PE 44.53 56.04 78.91 48.55 
HMCL were cultured, Dex treated, harvested and analysed as per Figure 4-6. Values above 
represent mean viable cell % or cell concentration of Dex-treated cells, as a % of untreated 
control cells. *Also t(14;16) 
In all but MM1S cells, viability and growth were influenced in the same way by the 
presence or absence of serum (see Table 4-2, right-hand column); for example, 
KMS-11 cells were both less sensitive to Dex-associated cytotoxicity and Dex-
associated growth inhibition in the absence of serum. 
 
 124 
Table 4-2 HMCL sensitivity to dexamethasone. 
Sensitivity HMCL Effect of Dex in R alone cf. R10 
Moderate 
KMS-28PE 
KMS-11 
RPMI-8226 
MM1S 
Viability & growth decreased 
Viability & growth increased 
Viability & growth decreased 
Viability decreased but growth increased  
Low 
KMS-12PE 
KMS-27 
OPM2 
KMS-21BM 
Viability & growth decreased 
Viability & growth decreased 
Viability & growth increased 
Viability & growth increased 
No 
U266 
JJN3 
JIM1 
NCI-H929 
Not applicable 
Based on the findings of these experiments, five HMCL were taken forward for 
further testing of Dex sensitivity in the presence of APRIL: KMS-28PE, KMS-11, 
MM1S, KMS-12PE and KMS-27. Although RPMI-8226 were also Dex-sensitive, 
their growth in culture was erratic and their baseline viability was often poor. 
4.2.2.2 HMCL sensitivity to dexamethasone in the presence of APRIL 
HMCL were cultured in R10 and APRIL was added 24 hours before Dex treatment. 
Once again HMCL were treated with 0, 1 or 10µM Dex. Initial results were 
promising, with APRIL-associated protection seen in KMS-28PE and MM1S (Figure 
4-7). However, this protection was only seen in the form of mitigation of Dex-
associated growth inhibition.  
Similar levels of cytotoxicity were seen at both doses of Dex, compared to the 
previous screening experiments. No protection from Dex-associated cytotoxicity was 
seen in the presence of APRIL in any of the HMCL evaluated. 
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Figure 4-7 Moderately dexamethasone-sensitive HMCL exposed to APRIL. 
Three moderately sensitive HMCL were evaluated: KMS-28PE (A & B), KMS-11 (C & D) 
and MM1S (E & F). HMCL were cultured in R10 ± APRIL and treated with Dex for 48 
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hours (orange 1µM, red 10µM). Cells were harvested and viability and growth were 
assessed by AV/PI staining. All conditions were in triplicate and values above represent 
mean ±SD viable cell % or cell concentration of Dex-treated cells, as a % of untreated 
control cells. Hashed bars represent HMCL that were exposed to APRIL. The results of 
statistically significant analyses are shown (unpaired t-test; *p<0.05, **p<0.01). 
The relative resistance of many HMCL to Dex, and the variable sensitivity of the 
remaining cell lines, with no clear dose dependence of Dex-mediated killing, or of 
APRIL-mediated protection meant that this was not a suitable model to explore the 
drug resistance activity of APRIL.  
It is possible that the protective effect of APRIL is best explored in a stromal cell co-
culture system, utilising stromal cells modified to express APRIL. This was the next 
system that was evaluated.  
4.2.3 Modifying HS5 to express and secrete APRIL 
APRIL(Ap)+HS5 and their empty vector negative control NC(Ap)HS5 were 
produced as detailed in Chapter 2 – section 2.7.6.1. 
4.2.3.1 Confirmation of APRIL secretion by Ap+HS5 
ELISA was used to quantify APRIL protein in media in which Ap+HS5 or 
NC(Ap)HS5 had been cultured. The relationship between HS5 cell number and 
APRIL concentration is charted in Figure 4-8.  
Cells were harvested on days four, five and six. These time points were chosen as by 
day four the HS5 cells were usually >90% confluent and HMCL could be seeded 
onto them for co-culture experiments. Culture media was harvested at the same time 
points and APRIL was quantified by ELISA. Figure 4-8 shows that the growth of the 
two modified HS5 cell lines was not significantly different. It also shows that the 
modified HS5 cells exerted contact inhibition with minimal additional growth after 
reaching confluence.  
 127 
 
Figure 4-8 Growth of modified HS5 cells in culture and the secretion of APRIL. 
NC(Ap)HS5 (blue bars) and Ap+HS5 (red bars) were seeded on day 0 at 50,000 cells/well in 
a TC-treated 12-well plate. Viable cells (trypan blue-excluding) harvested on days 4, 5 and 6 
are charted. APRIL concentration in culture media harvested from Ap+HS5 cultures is 
shown as an orange line. 
APRIL was only detectable in the media harvested from Ap+HS5 cultures, 
confirming that HS5 cells had no inherent APRIL secretion and that the transduced 
APRIL construct was functional. Interestingly APRIL did not accumulate 
significantly over the time frame evaluated. This may reflect negative feedback to 
secretion or a short half-life to the secreted protein. 
4.2.4 HMCL co-culture with Ap+HS5 for growth and cytotoxicity assays 
4.2.4.1 Co-culture set-up and interpretation 
U266 and MM1S cells were cultured alone or in co-culture with either Ap+HS5 or 
their empty vector negative control - NC(Ap)HS5. Cultures were set up according to 
the protocol detailed in Chapter 2 – section 2.1.11.  
The purity of the modified HS5 cells was regularly assessed by flow cytometry for 
GFP expression. Both Ap+HS5 and NC(Ap)HS5 were consistently >90% GFP+. In 
samples containing both HMCL and modified HS5, GFP− cells were assumed to be 
HMCL and GFP+ cells were assumed to be modified HS5 cells. Figure 4-9 
illustrates the gating strategy with representative plots from both suspension and 
adherent fractions. 
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Figure 4-9 Gating strategy with representative FACS plots showing AV/PI staining on 
HMCL grown in co-culture with modified HS5. 
The gating strategy and representative plots from an assay in which untreated U266 cells 
were co-cultured with Ap+HS5 are shown. The % of cells in the various gates are shown. 
The left-hand top two plots (A & B) are derived from a suspension fraction sample and the 
right-hand two top plots (C & D) are derived from an adherent fraction sample. Dot-plots A 
& C show all events by forward scatter (FSC) area/ side scatter (SSC) log (x/y respectively 
and hereafter) with a gate around intact cells. These are gated on to B and D respectively 
(FSC area/GFP log) to allow determination of GFP+ and GFP− populations. The viability 
of GFP− cells is evaluated in dot-plot E (AV-APC log/PI log); in this example 89% of cells 
are viable (AV−PI−), 5% are apoptotic (AV+PI−) and 6% are dead (AV+PI+). The 
viability of GFP+ cells is evaluated in histogram F (AV-APC); in this example 94% of 
GFP+ cells are viable (AV−). 
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Intact cells were identified by their forward and side scatter characteristics (A and C) 
and then separated into two groups based on GFP expression. As Figure 4-9B and D 
show, GFP+ and GFP− populations were easily distinguished. The viability of GFP− 
cells was evaluated by AV and PI staining but PI staining in the GFP+ cells could 
not be interpreted as both PI and GFP emit at 488nm. For this reason viability of 
GFP+ cells was derived purely from AV staining (hence the use of the AV 
histogram).   
In order to compare sensitivity to anti-myeloma treatments under different conditions, 
the absolute number of viable MM (AV−PI−) cells was calculated. To correct for 
any contamination of the GFP− HMCL by GFP− (un-transduced) HS5, the 
proportion of viable GFP− HS5 cells was measured in the HS5-only wells 
(suspension and adherent fractions) and this value was subtracted from the number of 
viable MM cells. This method of correction made the assumption that HS5 cell 
growth was the same when cultured alone compared to cultured with HMCL, and 
that HS5 cell growth was not affected by treatment with anti-MM agents. 
In order to verify this assumption, the viability and growth of the adherent GFP+ 
fraction of the modified HS5 lines was analysed. NC(Ap)HS5 (Figure 4-10) and 
Ap+HS5 (Figure 4-11) were analysed separately but the same patterns emerged for 
both modified lines. 
There was no difference between the viability or growth of HS5 cultured alone 
compared to those co-cultured with either HMCL. BZM treatment was associated 
with a modest reduction in viability (Figure 4-10A and Figure 4-11A), which 
reached statistical significance in NC(Ap)HS5 when doses 0 and 8nM were 
compared (p=0.0331 for co-culture with MM1S, p=0.0422 for co-culture with 
U266). BZM treatment was associated with a more striking reduction in HS5 growth 
(Figure 4-10B and Figure 4-11B) in both modified lines, which reached statistical 
significance in NC(Ap)HS5 when 0 and 8nM, and 4 and 8nM were compared 
(p=0.0042 & p=0.0029 respectively for HS5 co-cultured with MM1S; p=0.0486 & 
p=0.0307 respectively for HS5 co-cultured with U266). 
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Figure 4-10 Viability and growth of NC(Ap)HS5 cultured alone compared to with 
HMCL and following treatment with bortezomib. 
NC(Ap)HS5 were cultured in D10 & once confluent either MM1S or U266 cells were added. 
BZM was added 24 hours later. Cells were harvested after 48 hours exposure to BZM and 
the viability (A) & growth (B) of adherent GFP+ HS5 cells was analysed after AV staining. 
Data from three experiments (conditions in triplicate) is shown; mean ±SEM. Bars signify 
statistically significant differences (unpaired t-test; * p<0.05; ** p<0.01).  
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Figure 4-11 Viability and growth of Ap+HS5 cultured alone compared to with HMCL 
and following treatment with bortezomib. 
Ap+HS5 were cultured, drug treated and harvested as per NC(Ap)HS5 (Figure 4-10). 
Viability (A) & growth (B) of adherent GFP+ HS5 cells was analysed after AV staining. 
Data from three experiments (conditions in triplicate) is shown; mean ±SEM. 
The implication of this analysis was that in order to accurately correct for potential 
contamination of the GFP− HMCL fraction within harvested cells by GFP− modified 
HS5 cells, an additional correction for the reduction in HS5 growth associated with 
BZM treatment at 4 and 8nM would need to be included. This was incorporated. All 
results displayed subsequently show absolute HMCL corrected in this way for GFP− 
HS5 contamination. 
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4.2.5 The effects of co-culture of HMCL with APRIL-expressing HS5 
cells: growth and bortezomib cytotoxicity 
For this series of experiments, HMCL were co-cultured with HS5 modified to 
express and secrete APRIL, and exposed to bortezomib (BZM) to investigate 
APRIL-mediated protection in the context of stroma. BZM was selected to explore 
whether a novel system might reveal protection which was not seen when 
recombinant soluble APRIL was used. 
4.2.5.1 Bortezomib dose response in HMCL cultured alone 
While baseline untreated viability of HMCL varied slightly between replicates, their 
sensitivity to BZM was very consistent (Figure 4-12A).  
 B 
 
 
Figure 4-12 HMCL viability twenty-four hours after treatment with bortezomib. 
A. Eight HMCL were cultured in R10 and treated with BZM 24 hours after set-up. Two 
replicates are shown for each HMCL, except KMS11 (solid line, 1st experiment; dotted line, 
2nd experiment). B. MM1S cells were cultured in R10 and four concentrations of APRIL 
before being treated with BZM. Cells were harvested 24 hours after drug treatment and % 
viability assessed by AV/PI staining and FACS. All conditions were set up in triplicate. Data 
is shown as mean ±SD.  
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JIM3 and OPM2 were relatively resistant to BZM; KMM1 and RPMI-8226 were 
moderately sensitive to BZM; and U266, MM1S and NCI-H929 were fully sensitive 
to BZM at the dose range examined. KMS11 had poor baseline viability and thus, as 
only one replicate was possible, sensitivity to BZM is hard to comment on. 
Based on these experiments, two HMCL were chosen for on-going experiments in 
co-culture with modified HS5 cells, U266 and MM1S. These two HMCL have 
different pathogenic (presumed) mechanisms, as a result of different IgH 
translocations, t(11;14) in the case of U266 and t(14;16) in MM1S. They are 
sensitive to BZM to a varying degree over doses between 2.5 and 10nM. 
In an exploratory assay, MM1S cells were cultured in R10 in the presence of 
escalating concentrations of recombinant soluble APRIL (0, 100, 200 and 400ng/ml) 
and treated with BZM 0, 2.5, 5 and 10nM. There was no difference in cytotoxicity 
seen at each BZM dose between the different concentrations of APRIL (Figure 
4-12B). 
4.2.5.2 The effect of co-culture with modified HS5 on growth of U266 and 
MM1S cells 
Co-culture of U266 cells with modified HS5 cells resulted in slightly higher numbers 
of MM cells compared to U266 cells cultured alone (Figure 4-13A), with the highest 
number of viable cells seen in co-culture with NC(Ap)HS5 (not significant on paired 
t-test). The same pattern was seen with MM1S cells but again, this did not reach 
statistical significance. This may be due to baseline variability in HMCL growth 
between the three experiments (hence the wide SEM). 
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Figure 4-13 Growth of U266 and MM1S cells alone compared to co-cultured with 
modified HS5. 
U266 (A) or MM1S (B) cells (GFP−) were seeded onto confluent Ap+HS5 or NC(Ap)HS5 
or cultured alone. Cells were harvested 48 hours later and stained with APC-conjugated AV 
and PI and analysed. Total viable (AV−PI−) GFP− cells are represented as the mean ±SEM 
of triplicates, corrected for viable GFP− HS5 cells (n=3).  
4.2.5.3 Bortezomib cytotoxicity in HMCL cultured alone compared to those 
co-cultured with modified HS5 (NC(Ap)HS5) 
HMCL were cultured in R10 alone, or co-cultured with modified NC(Ap)HS5, and 
BZM was added as detailed in section 4.2.4. Three experiments were undertaken for 
each line and the total number of viable cells as a percentage of the untreated control 
is shown in Figure 4-14.  
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Figure 4-14 Bortezomib cytotoxicity in HMCL cultured alone compared to those co-
cultured with NC(Ap)HS5. 
U266 and MM1S cells were cultured alone or seeded onto confluent NC(Ap)HS5. After 24 
hours, cells were treated with BZM and harvested 48 hours later. Viable (AV−PI−) GFP− 
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cells (corrected for viable GFP− HS5 cells) are shown as % of untreated control for each of 
three assays (cultured alone - empty bars, or co-cultured with NC(Ap)HS5 - hashed bars; 
mean ±SD of triplicates; paired t-tests: *p<0.05; **p<0.01) 
Co-culture on stroma reduced the sensitivity of both HMCL to BZM, but the effect 
was less pronounced in U266 cells (left-hand column, Figure 4-14), and only reached 
statistical significance in one experiment at the 8nM dose (p=0.0320). Protection 
was more striking in MM1S cells (right-hand column, Figure 4-14). Statistically 
significant increases in viable cell number were seen in all experiments at the 4nM 
dose, and in two out of the three at 8nM. It can therefore be surmised that the 
modified HS5 exert a protective effect on the HMCL, which is independent of any 
growth advantage as the results presented are standardised to the appropriate 
untreated control.  
Results from a representative experiment are displayed as absolute cell numbers in 
Figure 4-15 (A & B U266, C & D MM1S). When the distribution of viable cells 
between suspension and adherent fractions is considered it is apparent that U266 and 
MM1S cells display very different growth characteristics in this setting. Within U266 
cells a small proportion of the total number of viable cells was adherent, although it 
increases in the presence of stroma (Figure 4-15B). A much greater proportion of 
viable MM1S cells was adherent, both when cultured alone or with stroma, and this 
proportion does not change significantly with different culture conditions (Figure 
4-15D).  
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Figure 4-15 Bortezomib cytotoxicity in HMCL cultured alone compared to those co-
cultured with NC(Ap)HS5 - two representative experiments. 
Experimental set-up as per Figure 4-14. The results are presented in two different ways. In 
graphs A & B, representative plots from the same experiment (No. 2) using U266 cells are 
shown, while in graphs C & D, experiment No.2 using MM1S is presented. A & C show total 
absolute viable cells, treated with escalating doses of BZM. The dashed line represents the 
starting number of viable U266 cells seeded into the culture system. B & D show absolute 
numbers of suspension (red bars hatched with yellow) and adherent (red bars hatched with 
blue) viable cells, and the effect of BZM. 
Comparison of the three experiments for each HMCL reveals some variation in the 
sensitivity of the MM cells (Figure 4-14). For example, treatment of U266 cultured 
alone with 4nM BZM results in quite different numbers of viable cells: 6.09 ±0.71, 
28.72 ±1.28 and 21.96 ±3.22 (expressed as a percentage of the untreated control; 
mean ±SD). This probably reflects variation in the baseline growth of the HMCL at 
the time of each experimental set-up.  
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4.2.5.4 Effect of stromal cell-derived APRIL on bortezomib cytotoxicity in 
HMCL   
In the next series of experiments, HMCL were co-cultured with NC(Ap)HS5 or 
Ap+HS5, and effect of BZM on cell viability and total number of viable cells was 
assessed. Three experiments were performed for each HMCL. 
In U266 cells (Figure 4-16, left-hand panel), there was a clear trend for APRIL-
associated protection at the 4nM dose, across all three experiments. This only 
reached statistical significance with Experiment No.3 (p=0.0032). At 8nM there was 
no consistent pattern, with protection seen in Experiment No.3 but apparent 
sensitisation in the other two. 
With MM1S cells (Figure 4-16, right-hand panel), there was again a trend towards 
APRIL-associated protection at 4nM (p=0.0189 in Experiment No.2), but the trend 
was reversed in the third experiment and was similarly variable at 8nM. 
These results suggest that HS5 cells modified to express and secrete APRIL may 
confer additional specific protection against BZM killing and is worthy of further 
investigation. 
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Figure 4-16 Bortezomib cytotoxicity in HMCL co-cultured with NC(Ap)HS5 compared 
to those co-cultured with Ap+HS5. 
U266 and MM1S cells were seeded onto confluent NC(Ap)HS5 or Ap+HS5. After 24 hours, 
cells were treated with BZM and harvested 48 hours later. Viable (AV−PI−) GFP− cells 
(corrected for viable GFP− HS5 cells) are shown as % of untreated control for each of three 
experiments (co-cultured with NC(Ap)HS5 - hashed bars, co-cultured with Ap+HS5 - dotted 
bars; mean ±SD of triplicates; paired t-tests: *p<0.05; **p<0.01) 
4.3 Summary and discussion 
Initial experiments to explore Aim 1 were carried out using primary freshly selected 
CD138+ MM cells as this model was considered to more closely represent the in vivo 
disease, compared with immortalised cell lines. Challenges of this approach include 
the significant variability of primary MM samples in terms of viability in culture and 
sensitivity to drug treatment. The absolute numbers of CD138+ cells available for 
each experiment was often small, thus limiting the number of conditions that could 
be tested.   
Although APRIL alone had no effect on the survival of primary MM cells cultured in 
suspension, some attenuation of dexamethasone (Dex)-mediated killing was seen in 
the presence of APRIL, confirming the findings of Moreaux et al 76. This finding was 
statistically significant in the whole cohort of samples studied (p<0.001), with more 
consistent protection seen in samples derived from patients whose disease expressed 
CCND2. In a limited series of experiments, APRIL-mediated protection was more 
pronounced than that seen with IGF-I but less than that seen with IL-6. This is not 
surprising as IL-6 is a critical survival factor in MM, important both in the survival 
of primary MM cells and that of a number of HMCL.  
Soluble APRIL did not appear to reduce killing associated with MM cell treatment 
with bortezomib (BZM) or lenalidomide (Len). This indicates that soluble APRIL-
associated protection may act through specific pathways relevant to Dex-killing, 
which are not involved in the cytotoxicity associated with BZM or Len. This is 
consistent with the absence of a general pro-survival or pro-growth effect in MM 
cells treated with APRIL alone. 
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Exploration of the pathways involved in APRIL-mediated protection, which 
constituted Aim 2, was undertaken using a small molecule PI3K/AKT pathway 
inhibitor, PI103. However it proved extremely difficult in primary MM cells, owing 
to the subtlety of the protective effect and the variability of primary samples, 
discussed above. 
Screening an extended panel of HMCL to identify a Dex-sensitive line that might act 
as a model for APRIL protection was not fruitful. It is worth noting that the majority 
of HMCL are derived from primary extramedullary MM samples and have therefore 
evolved to proliferative autonomously without the network of cytokine and cell-cell 
interactions that are required for the survival of medullary MM cells. These cells are 
likely to be biologically quite different from primary CD138+ MM cells, which are 
critically dependent on the BM microenvironment, and hence more responsive to 
APRIL protection. 
In Aim 3, APRIL was examined within the context of other BM supportive signals, 
by modifying HS5 cells to express and secrete APRIL. U266 and MM1S cells were 
co-cultured on a confluent layer of Ap+HS5 or the empty vector negative control, 
and then treated with BZM. There appeared to be a modest growth advantage to 
HMCL co-cultured on HS5 cells, more noticeable with the negative control than 
those expressing APRIL, but this did not reach statistical significance in either 
HMCL used. Following drug treatment, a degree of protection from BZM killing was 
seen in HMCL co-cultured on stroma compared to those cultured in suspension. This 
reached statistical significance in MM1S cells.  
The results of drug treatment when HMCL were co-cultured with Ap+HS5 versus 
NC(Ap)HS5 were less consistent. At BZM 4nM, both U266 and MM1S cells 
appeared to be less sensitive in the presence of APRIL (seen in five out of six 
experiments), but this only reached statistical significance in one experiment. At 
BZM 8nM, the picture was more variable. Clearly this needs to be evaluated in a 
broader dose range in order to establish whether true protection is present.  
There is apparent contradiction in the effects of BZM between the experiments using 
soluble APRIL and that expressed and secreted in a co-culture system, whereby no 
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protection was seen in primary MM cells treated with BZM in the presence of 
recombinant soluble APRIL, while some protection was seen in HMCL treated with 
BZM in co-culture with Ap+ HS5. This may reflect biological differences between 
the MM cells evaluated (primary versus HMCL), but may also reflect the context and 
the effect of additional BM stromal signals. The same phenomenon was observed by 
Nefedova et al 62, when apparently opposing effects on cell cycle were observed in 
the same target cell population when cultured in direct contact with BMS compared 
to those cultured separated by a Transwell device. 
Ultimately, the results presented in this chapter support the hypothesis that APRIL 
contributes to drug resistance provided by the BM microenvironment in MM. 
However, that effect in the systems used here was modest, and that limited the 
exploration of underlying pathways involved. Modest differences were seen between 
the different genetic subtypes but these were not statistically significant.  
Further work in this area would usefully include extending the range of BZM doses 
evaluated, looking at alternative anti-myeloma treatments (including Dex and Len) 
and using the co-culture system with primary MM cells. It might be anticipated that 
culturing CD138+ MM cells on HS5 might enhance their baseline survival in vitro. 
This would potentially make the effects of drug treatments easier to evaluate.  
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CHAPTER 5. THE ROLE OF THE NOTCH PATHWAY 
IN DRUG RESISTANCE 
5.1 Introduction  
5.1.1 Background 
In additional to soluble factors, the resistance offered by BM stromal cells in MM 
also results from interactions requiring direct cell-cell contact 62. In this results 
chapter, an evaluation of the role played by the Notch pathway is reported. Notch 
pathway dysregulation has now been observed in a number of malignancies, both 
solid and haematological. The Notch pathway has also been implicated specifically 
in the context of cancer stem cells, with suggestions that it may play a role in the 
stem cell-like characteristics observed in these cell sub-populations 129. 
The structure and functioning of Notch receptors (Notch1, 2, 3 and 4) and their 
ligands (Jag1, Jag2, DL1, DL3 and DL4) is described in some detail in section 
1.2.3.5 of Chapter 1. Notch was first implicated in MM in 2004 when three 
independent groups demonstrated expression of Notch receptors and ligands on both 
myeloma cells and bone marrow stromal cells 96,98,99. Nefedova et al. reported that 
co-culture of HMCL with primary BM stromal cells led to activation of Notch1 96 (as 
evidenced by increased expression of intracellular Notch1 (ICN1) and the 
downstream Notch target, HES1). They were also able to activate Notch1 by co-
culture of HMCL with Jag1-expressing (Jag1+) fibroblasts and by adding 
recombinant soluble Jag1 to the culture media. The result of this activation was cell 
cycle arrest and activation was associated with a reduction in melphalan- and 
mitoxantrone-associated apoptosis. The HMCL U266 did not express Notch1 and 
showed no reduction of apoptosis after co-culture with Jag1+ fibroblasts. However, 
overexpression of the Notch1 receptor in U266 cells was able to reverse this finding, 
leading the authors to suggest that Notch1 activation of MM cells by Jag1 presented 
by adjacent BM stromal cells might be a mechanism of BM microenvironment-
associated drug resistance.  
Jundt et al. 98 found constitutive activation of Notch in a number of HMCL, as 
evidenced by HES1 expression. They were able to increase HES1 expression by co-
 144 
culture of selected HMCL with Jag1+ adherent cells, but interestingly this triggered 
proliferation of HMCL rather than the cell cycle arrest observed by Nefedova et al.. 
Notch-induced proliferation was inhibited by the addition of gamma secretase 
inhibitors (GSI) and other groups have subsequently reported that treatment of 
HMCL with GSI reduced their proliferation 103, implying that Notch pathway 
activation leads to cell cycle progression and growth. This controversy was 
addressed directly by Zweidler-McKay et al. 105. This group transduced various B 
and T cell malignant cell lines with constitutively active Notch receptors and showed 
that this had a proliferative effect on T cell lines but induced cell cycle arrest in all B 
cell lines. 
The role of Notch activation in drug resistance was examined further by Nefedova’s 
group in 2008 106. They showed that GSI was directly cytotoxic to HMCL and 
primary MM cells in HES1-dependent manner. MM cells grown on a BM stromal 
monolayer were protected from anti-myeloma drugs (mitoxantrone, doxorubicin) but 
this protection was reduced by the addition of GSI. In a SCID/NOD mouse model, 
myeloma tumour growth was inhibited by treatment of the mice with doxorubicin 
and GSI, in a synergistic fashion. They proposed that pharmacological inhibition of 
Notch signaling in MM cells abrogates BM-mediated drug resistance and sensitises 
MM cells to chemotherapy, implying that a major route of BM-mediated protection 
is the activation of Notch signaling in MM cells by Notch ligands present on stroma 
cells.  
An independent group examined Notch activation in MM cells and bortezomib 
resistance 108, using DL1-expressing MS5 cells to activate Notch in murine 
5T33MMvt cells and in human MM cells. They had previously demonstrated that 
Notch activation enhanced both colony formation and in vivo engraftment by murine 
MM cells, an effect which could be inhibited by GSI treatment 109. In their work, 
Notch2 was the critical receptor with decreased surface Notch2 and upregulated 
ICN2 in MM cells after co-culture with DL1+MS5. The cytotoxic effect of 
bortezomib was significantly attenuated by Notch activation, but sensitivity could be 
restored by treatment with the GSI DAPT. 
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Notch activation has also been demonstrated in BM stromal cells so it is likely that 
there is bi-directional signalling. Houde et al. 99 reported high expression of the 
ligand Jag2 in a panel of HMCL and primary MM samples (not seen in non-MM cell 
lines or normal plasmablasts). HES1 induction was then demonstrated in fibroblasts 
co-cultured with Jag2++ HMCL and this was accompanied by an increase in IL-6, 
VEGF and IGF-I levels in the culture supernatant. Thus MM cell activation of the 
Notch pathway in adjacent stromal cells might enhance production of pro-MM 
cytokines by those stromal cells, contributing to the survival and proliferation of the 
tumour population. 
5.1.2 Hypothesis and aims 
Hypothesis: Notch pathway activation in MM cells renders them less sensitive to 
anti-myeloma agents. This mechanism contributes to the protection offered to MM 
cells by their BM microenvironment.  
Aim 1: to confirm and characterise Notch receptor expression by HMCL. 
Aim 2: to activate the Notch pathway in HMCL by co-culturing them with Notch 
ligand-expressing stromal cells. 
Aim 3: to demonstrate that Notch activation is associated with a reduction in 
bortezomib-associated MM cell apoptosis. 
Aim 4: to identify key Notch receptors and ligands involved in this process. 
5.2 Results 
5.2.1 Notch receptor and ligand expression in HMCL  
Expression of the four subtypes of the Notch receptor present on mammalian cells 
(Notch1, Notch2, Notch3 and Notch4) was evaluated by Western blotting in a 
number of HMCL expressing a range of IgH translocations. MM1S cells have 
t(14;16), RPMI-8226 have t(16;22), NCI-H929, LP-1 and OPM-2 have t(4;14) and 
U266 cells have t(11;14). 
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Figure 5-1 Baseline expression of Notch receptors (1, 2, 3 & 4), cleaved intracellular 
Notch1 (ICN1) and Notch ligands (Jag1, Jag2, DL1 & DL4) by HMCL. 
Whole cell lysates were prepared using RIPA lysate buffer from optimally growing but 
otherwise un-manipulated HMCL. Precast 4-12% gradient gels were used. T-ALL cell lines 
CEM, DND41, Jurkat and HPB-ALL whole cell lysates were used as positive controls for 
Notch1, Notch2 and cleaved intracellular Notch1 (ICN1; they all have constitutive Notch1 
activation). Housekeeping proteins tubulin and GAPDH were used as LCs. A. Expression of 
Notch1, Notch2, Notch3 and Notch4 was evaluated in a panel of HMCLs. 20µg of protein 
was loaded per lane. B. Expression of Notch1, Notch2, Notch3 and ICN1 was evaluated in 
MM1S, U266 & OPM2 lysates (40µg protein). C Upper panel. Expression of Jag2, DL1 and 
DL4 was evaluated in U266 and MM1S lysates (40µg protein), using HS5 cells transduced 
to express the ligands as positive controls. C Lower panel. Expression of Jag1 was 
evaluated in a panel of HMCL, using Jag1-transfected HeLa cell whole cell lysate as a 
positive control. Abbreviations: TM, transmembrane; LC, loading control. 
Notch1 expression was only seen in MM1S and RPMI-8226 cells (Figure 5-1A&B); 
notably there was no expression of Notch1 by U266 cells, in confirmation of the 
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findings of Nefedova et al 96 and Houde et al 99. Unexpectedly Notch1 expression 
was not demonstrated on NCI-H929 cells, in contrast to what is reported 96. Notch2 
was expressed in all HMCL, although expression levels appeared to vary, with the 
highest expression seen in U266, RPMI-8226 and LP-1. Notch3 and Notch4 
(intracellular Notch4; ICN4) were expressed by all HMCL evaluated, with some 
variation in levels. ICN1 was not seen in either U266 or MM1S cells (Figure 5-1B), 
suggesting that neither cell line had constitutive Notch1 pathway activation. There 
are no reports of baseline ICN1 expression by HMCL. 
Notch ligand (NL) expression was also evaluated in HMCL by Western blotting 
(Figure 5-1C). Jag2 was present in U266 cells and to a lesser degree in MM1S cells. 
DL4 was seen only in U266 cells. Jag1 was expressed in all six of the HMCL 
examined: levels appeared highest in MM1S, and lowest in NCI-H929 and U266 
cells. 
5.2.2 Activating the Notch pathway in MM cells using Notch ligand-
expressing stromal cell lines 
In order to evaluate the contribution of Notch pathway activation to drug resistance 
in MM cells in a physiological way, the HS-5 stromal cell line was modified to 
express a panel of Notch ligands (NL) individually (methods are detailed in Chapter 
2 – section 2.7.6.2 and 2.7.6.3). Stromal cell-based activation of the Notch pathway 
within a co-culture system would recapitulate some aspects of the BM 
microenvironment. HS5 cells were selected for modification as they are known to 
resemble BM stroma and have been used as a feeder layer for primary 
haematopoietic progenitor cells. Mouse stromal cells (MS5) modified to express the 
NL DL1 were an effective means of Notch pathway activation employed by Xu et al 
109.  
5.2.2.1 Confirming the functional capabilities of DL1+, DL4+ and Jag2+HS5 
5.2.2.1.1 Expression of the transduced Notch ligands  
NL expression was first confirmed by flow cytometry by GFP expression and 
labelling with PE-conjugated anti-DL1/4 or Jag2 antibodies (detailed in Chapter 2 - 
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section 2.2.2). Results are shown in Figure 5-2. All modified HS5 cell subtypes 
expressed GFP in >99% of cells. 90.99% of DL1+HS5 cells (first row) expressed 
DL1 and GFP, but not DL4 (<1%). 96.5% of DL4+HS5 cells (third) row expressed 
DL4 and GFP, but not DL1 (<1%). Only 27% of Jag2+HS5 (fourth) row expressed 
Jag2 and GFP, although 94% expressed GFP alone. With the exception of low level 
Jag2 (~2-4%), the NC subtypes transduced with the empty vector alone did not 
express significant levels of any of the NLs. !
 
Figure 5-2 Expression of Notch ligands and GFP in modified HS5 cells. 
Optimally growing, sorted, modified HS5 cells were trypsinised, harvested, washed and 
stained with PE-conjugated anti-DL1, anti-DL4 and anti-Jag2 antibodies, as indicated. 
Intact cells were gated onto dot plots for FITC (GFP) on the y-axis and PE on the x-axis, 
shown above. Unstained cells are shown in the far left-hand column. 
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In order to confirm expression of DL1 and DL4 by the DL1+ and DL4+HS5 cells 
and clarify expression of Jag2 by all sets of HS5 cells, protein expression was then 
evaluated by Western blotting (Figure 5-3).  
A 
 
C 
 
B 
 
Figure 5-3 Expression of Notch ligands and Notch receptors by modified HS5 and the 
effect of EDTA on ICN1 expression. 
Whole cell lysates were prepared from 5x106 optimally growing modified HS5 cells using 
RIPA lysis buffer. Precast 4-12% gradient gels were used. 40µg protein was loaded per lane. 
A. The membrane was probed for NLs Jag2, DL4 and DL1. B. Modified HS5 cells were 
washed with warm HBSS and then dissociated from their wells in the usual fashion with 
trypsin/EDTA. The cells were then harvested, washed in ice-cold PBS, pelleted and then 
lysed with RIPA lysis buffer for 30 minutes on ice (designated +). Alternatively the HS5 cells 
were washed in their wells with ice-cold PBS and then RIPA lysis buffer was added to the 
cells in their wells and after incubating on ice for 30 minutes, the lysate was aspirated from 
the wells (designated −). The resultant membrane was probed for ICN1. DND41 whole cell 
lysate was used as a positive control for ICN1. C. Whole cell lysates were prepared from 
modified HS5 cells without exposure to EDTA and probed for Notch1 and Notch2. HPB-ALL 
whole cell lysate was used as a positive control for Notch1 and Notch2. The housekeeping 
genes GAPDH and tubulin were used as loading controls. 
 150 
There is clear overexpression of Jag2 by Jag2+HS5, DL4 by DL4+HS5 and DL1 by 
DL1+HS5 (Figure 5-3A). A weak band is seen for DL1 in the DL4+HS5 lysates but 
this is a remnant on the membrane, which had been probed first for DL4. Jag2 
protein is not seen in the lysates prepared from any cell subtype other than Jag2+HS5. 
Importantly there is no evidence of NL expression of any type probed in the 
NC(DL1/DL4)HS5 subtypes. 
5.2.2.1.2 Notch pathway activation in modified HS5 cells 
It has been reported that the calcium-chelator EDTA may be used to activate Notch 
signaling 130 as it disrupts the non-covalent bond between the external ligand-binding 
domain of the Notch receptor and the transmembrane domain. Dissociation of these 
two domains is then associated with cleavage of the transmembrane domain by 
gamma secretase and the intracellular portion of the transmembrane domain (ICN) is 
then able to shuttle into the nucleus and act on its downstream targets. As trypsin 
0.25%/EDTA was routinely used to dissociate all the adherent cells when harvesting, 
it was important to evaluate whether the five minute exposure to EDTA was 
sufficient to cause increased levels of ICN in the cells and potentially activate Notch 
signaling in the HS5 cells. Figure 5-3B shows that in all modified HS5 cells ICN1 is 
present when the cells are harvested using trypsin/EDTA. In contrast, when EDTA 
was not used, ICN1 was only seen in NL-expressing HS5 (Jag2+, DL4+ and 
DL1+HS5) and was not present in the NC(DL4/DL1)HS5. These observations 
suggested that firstly, exposure to trypsin/EDTA was associated with Notch pathway 
activation in all (modified) HS5 cells examined. Secondly, Notch pathway activation 
occurred in an EDTA-independent manner in NL-expressing HS5, supporting the 
fact that the NL expressed by these cells were functionally competent.  
Finally Notch1 and Notch2 expression by modified HS5 cells was evaluated (Figure 
5-3C). All five modified lines expressed both Notch1 and Notch2. The highest levels 
of both were seen in the NC(DL4/DL1)HS5 cells; it is possible that Notch1 and 
Notch2 is downregulated to some degree in NL-expressing cells, perhaps as part of a 
negative feedback loop following autocrine activation of the Notch pathway. 
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5.2.2.1.3 Notch activation of heterologous cells by NL-expressing HS5 
U266 and MM1S cells were cultured alone or in co-culture with modified HS5 cells. 
Co-cultures were set up as detailed in Chapter 2 - section 2.1.11. Preliminary 
experiments included additional wells of HS5 cells which were treated with 
bortezomib (BZM) at the same doses. Minimal changes in viability or cell growth 
were seen in BZM-treated HS5 cells (Figure 5-4) so these control wells were not set 
up for subsequent assays. 
The purity of the modified HS5 cells was regularly assessed by flow cytometry for 
GFP expression. Both DL1+HS5 and NC(DL1)HS5 were consistently >90% GFP 
positive (GFP+). The gating strategy used was identical to that used for HMCL co-
cultured with Ap+HS5 (Chapter 4 – section 4.2.4.1).   
In order to correct for any contamination of the GFP-negative (GFP−) HMCL by 
GFP− (untransduced) HS5, the proportion of viable GFP− HS5 cells was measured 
in the HS5-only wells (suspension and adherent fractions) and this value was 
subtracted from the number of viable MM cells. This method of correction made the 
assumption that HS5 cell growth was the same when cultured alone compared to 
cultured with HMCL, and that HS5 cell growth was not affected by treatment with 
anti-MM agents. In order to verify this assumption the growth of the modified HS5 
cells were analysed under different conditions (Figure 5-4).  
Co-culture with HMCL appeared to increase the growth of both types of modified 
HS5 cells (Figure 5-4A&B) although this was reduced with increasing doses of BZM. 
There is no evidence that BZM is directly cytotoxic to HS5 cells (Figure 5-4C). 
These findings suggest that HS5 cell growth is enhanced in the presence of MM cells, 
and that increasing BZM doses are associated with reduced numbers of HS5 cells 
secondary to the killing of MM cells. It is therefore likely that absolute MM cell 
number is slightly over-corrected for the presence of GFP− HS5 cells at higher BZM 
doses in the following series of experiments. 
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Figure 5-4 Growth of modified HS5 cultured alone or with MM cells and the effect of 
bortezomib. 
Viable modified HS5 cells are shown - harvested cells were stained with AV-APC as per 
protocol section 2.4.2.2. Absolute concentrations of adherent GFP+ AV− cells are charted. 
A-C DL1+HS5 or NC(DL1)HS5 cells were co-cultured with U266 or cultured alone. 
Modified HS5 cells were seeded on day one and U266 cells were seeded on days four to five; 
co-cultures were treated with BZM 24 hours later and harvested after 48 hours of treatment. 
Data are presented as absolute viable cell number (A & B) and % viable cells (C), mean 
±SEM of three experiments. 
In order to demonstrate that the NL-expressing HS5s were competent to activate 
Notch signaling in a paracrine manner, quantitative RT-PCR (qPCR) was undertaken 
on HMCL co-cultured with the modified HS5 cells (detailed methodology in Chapter 
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2 – section 2.8.4.1). The downstream Notch targets HES1 and Deltex-1 (DTX1) were 
evaluated in HMCL following co-culture with modified HS5.  
DND41 T-ALL cells were also used in co-culture with the NL-expressing HS5, as 
these cells have constitutively active Notch signaling and therefore would be 
expected to have high baseline levels of Notch downstream targets, including HES1 
and DTX1. DND41 cells would therefore act as positive controls for HES1 and 
DTX1 qPCR, and the ability of NL+ HS5s to enhance constitutive Notch activation 
in these cells could be evaluated.  
U266, MM1S and DND41 cells were all cultured alone so that their baseline Notch 
activation could be compared to levels seen in co-culture. Additionally all cells 
cultured were also treated with a gamma-secretase inhibitor (GSI; L685) at a dose 
known to suppress Notch activation (1µM; 131). This was to allow discrimination of 
Notch-dependent and Notch-independent target gene expression. The different 
experimental conditions are summarised in Table 5-1. 
Table 5-1 Conditions for Notch activation assay v.1. 
 
HS5 cells 
alone 
U266 MM1S DND41 
GSI (L685 
1µM) 
- + - + - + - + 
Alone ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Co-cultured 
with: 
        
DL1+HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
NC(DL1)HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
DL4+HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Jag2+HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
NC(DL4)HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
One plate was used for each modified HS5 subtype such that six TC-treated 12-well 
plates were set up: (1) U266, MM1S and DND41 cells cultured alone; (2) U266, 
MM1S and DND41 cells co-cultured with Jag2+HS5; (3) U266, MM1S and DND41 
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cells co-cultured with DL4+HS5; (4) U266, MM1S and DND41 cells co-cultured 
with NC(DL4)HS5; (5) U266, MM1S and DND41 cells co-cultured with DL1+HS5; 
and (6) U266, MM1S and DND41 cells co-cultured with NC(DL1)HS5.  
Analysis of gene expression in modified HS5 cells grown alone revealed HES1 
transcript levels were present in these cells (Figure 5-5A), with moderate suppression 
of HES1 expression by GSI, except in the case of NC(DL4)HS5. Interestingly, HES1 
expression levels were higher in NL-expressing HS5 compared with NC(DL4)HS5. 
DTX1 was undetectably low in all modified HS5 subtypes (data not shown). When 
analysing the adherent fraction of the co-cultures it was not possible to discriminate 
whether the original RNA had been extracted from HS5 cells or the HMCL/DND41 
cells and therefore further analysis of this fraction was not pursued.  
Analysis of gene expression in DND41 cells confirmed the effectiveness of the GSI 
L685 (1µM) at inhibiting Notch activation and expression of both downstream 
targets (Figure 5-5B). Co-culture of DND41 cells with modified HS5 upregulated 
HES1 (Figure 5-5B, left-hand) compared to DND41 cells cultured alone, irrespective 
of ligand expression. 
Interestingly highest expression of HES1 was seen following co-culture with 
NC(DL4)HS5 cells, which was greater than co-culture with either Jag2 or DL4                                                                     
expressing HS5.  When the DL1+HS5 and NC(DL1)HS5 were compared, there was 
evidence that expression of DL1 was associated with a higher HES1 transcript level. 
Where HES1 was upregulated in co-cultured DND41 cells, L685 was able to inhibit 
HES1 expression but it did not appear to be as effective as it was in DND41 cells 
cultured alone.  
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Figure 5-5 Expression of HES1 by modified HS5 cells and effect of co-culture on 
expression of HES1 and DTX1 by DND41 cells. 
Expression of target genes HES1 and DTX1 are shown as 2- ΔCT values, normalised to 
expression of B2M. Hashed bars represent cells treated with GSI. A. shows expression of 
HES1 by modified HS5 cells cultured alone, -/+GSI. B. shows expression of HES1 (left-hand) 
and DTX1 (right-hand) by DND41 cells, -/+ GSI, cultured alone or with modified HS5 cells. 
Culture conditions are as indicated.  
When DTX1 expression in DND41 cells was analysed (Figure 5-5B, right-hand), an 
increase in expression over that seen in cells culture alone was only seen when 
DND41 cells were co-cultured with NC(DL4)HS5. L685 appeared to be more 
effective in suppressing DTX1 transcription than in suppressing HES1. 
DND41 
Modified HS5 cells 
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In order to evaluate the inter-plate variation within the assay, the expression of HES1 
and DTX1 by the PC and NC were measured and are displayed in Figure 5-6.  
 
Figure 5-6 HES1 and DTX1 expression by untreated DND41 cells (PC) and GSI-treated 
DND41 cells (NC). 
Expression of target genes HES1 and DTX1 are shown as 2- ΔCT values, normalised to 
expression of B2M. Six replicates are shown (and the mean), with standard cDNA for each 
condition being used on each qPCR plate with identical primers.    
This compares transcript levels detected after qPCR using the PC and NC standard 
cDNA templates in each of the six suspension qPCR plates (i.e. plates 1, 2, 4, 6, 8 & 
10;   
The multiple conditions mandated the use of 11 PCR plates, and so to allow 
comparisons between PCR plates, two standard cDNA samples were amplified in 
triplicate for each target gene and B2M on every plate. The cDNA was derived from 
DND41 cells cultured alone and treated with vehicle or L685 1µM (termed positive 
control (PC) and negative control (NC) respectively). These were generated from a 
different experiment. The conditions included in each qPCR plate are detailed in 
Table 2-7. 
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Table 2-7, page 92). As the same cDNA template, primers and qPCR conditions 
were used, the results reflect inherent variation within the assay. 
 
Figure 5-7 Expression of HES1 by U266 and MM1S cells co-cultured with modified 
HS5. 
Expression of target gene HES1 by HMCL is shown as 2- ΔCT values normalised to expression 
of B2M. Experimental set up is as described in section 5.2.2.1.3 and in Methods chapter 2. 
Culture conditions are as indicated. Hashed bars represent HMCL treated with GSI. Results 
from two separate experiments (Assay 1 and 2) are shown.  
Having validated the qPCR assay for HES1 and DTX1 in assessing Notch activation, 
the HMCL U266 and MM1S were evaluated for Notch activation under similar 
experimental conditions (Figure 5-7, left-hand graphs, Assay 1). Unlike the DND41 
cells, DTX1 was almost undetectable in both cell lines in all conditions. For this 
reason, only HES1 transcript levels were compared. When cultured alone, U266 cells 
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expressed negligible levels of HES1 (Figure 5-7, top left-hand graph). HES1 
transcript levels increased in co-culture with all subtypes of modified HS5. As seen 
in the DND41 cells, when the Jag2/DL4/NC group were compared, the greatest 
HES1 expression was seen in co-culture with NC(DL4)HS5 cells. However, within 
DL1/NC group, higher HES1 levels were seen after co-culture with DL1+HS5 
compared to NC(DL1)HS5 cells. In all conditions HES1 levels were lower in the 
GSI-treated cultures, although the GSI was not able to completely ablate Notch 
activation. 
In contrast to the U266 cells, MM1S cells cultured alone showed significant HES1 
expression (Figure 5-7, bottom left-hand graph). However, general upregulation of 
HES1 was not seen across co-culture conditions. As with DND41 and U266 cells, 
when the Jag2/DL4/NC group were compared, the greatest HES1 expression was 
seen following co-culture with NC(DL4)HS5 cells, but this was comparable to that 
seen in MM1S cells grown alone. Notably, HES1 expression in MM1S cells co-
cultured on DL1+HS5 was higher when compared with co-culture on NC(DL1)HS5. 
In the presence of GSI, HES1 expression was modestly reduced in all conditions, 
with the exception of MM1S cells cultured alone. 
Having compared all modified HS5 in their ability to upregulate expression of HES1 
in MM1S and U266 cells, it appeared that DL1+HS5 were the most effective 
activators of the Notch signaling pathway. The high levels of HES1 seen after co-
culture with the NC(DL4)HS5 made it difficult to assess any Notch activation 
associated with exposure to Jag2 or DL4 in co-culture. 
A second experiment was conducted, this time with U266, MM1S and DND41 cells 
cultured alone, and in co-culture with DL1+HS5 and NC(DL1)HS5 cells (see Table 
5-2 for plan). The results of this assay are shown in Figure 5-7 (right-hand graphs; 
Assay 2) and show that HES1 is once again upregulated in U266 cells co-cultured 
with HS5 cells, and levels following co-culture with DL1+HS5 cells are higher 
compared to co-culture with the control NC(DL1)HS5. GSI did not suppress HES1 
transcription in these cells. Similarly, HES1 levels were higher in MM1S cells co-
cultured with DL1+HS5 compared to those co-cultured with NC(DL1)HS5 but not 
when compared to MM1S cells cultured alone. 
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Table 5-2 Conditions for Notch activation assay v.2. 
 
HS5 cells 
alone 
U266 MM1S DND41 
L685 1µM - + - + - + - + 
Alone ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Co-cultured with:         
DL1+HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
NC(DL1)HS5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Notch activation was also assessed by Western blotting for ICN1. Whole cell lysates 
were prepared from the suspension fractions of all conditions from the second assay. 
Figure 5-8 shows cleaved intracellular Notch1 (ICN1) is completely absent from all 
conditions. Despite the high levels of HES1 detected in MM1S cells by qPCR, ICN1 
was not seen. As U266 cells do not express Notch 1, it is perhaps not surprising that 
ICN1 is not seen.  
 
Figure 5-8 ICN1 expression in U266 and MM1S cells after co-culture with modified 
HS5 cells. 
Whole cell lysates were prepared from U266 or MM1S cells harvested from culture alone or 
from co-culture with DL1+HS5 or NC(DL1)HS5 cells. 20µg protein was loaded per lane. 
The membrane was probed for ICN1. HPB-ALL whole cell lysate was used as a positive 
control for ICN1. The housekeeping gene GAPDH was used as a loading control. 
Although Western blotting of suspension cells failed to detect ICN1, this does not 
necessarily discount Notch activation, as cells displaying highest levels of Notch-
activation may be contained within the adherent fraction that was not assessed. 
Similarly, the qPCR results may under-estimate the degree of Notch activation in the 
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HMCL. Taken together, it was concluded that the DL1+HS5 displayed the greatest 
capability of activating Notch signaling, in comparison to the appropriate control 
HS5 [NC(DL1)HS5]. These cells were therefore selected for testing in cytotoxicity 
assays to investigate the contribution of Notch to (stromal-mediated) resistance to 
anti-MM treatments.  
5.2.3 The effects of co-culture of HMCL with Notch ligand-expressing 
HS5 cells: growth and bortezomib cytotoxicity 
5.2.3.1 The effect of co-culture with Notch ligand-expressing HS5 on growth of 
U266 and MM1S cells 
Co-culture of U266 cells with modified HS5 cells resulted in lower numbers of MM 
cells compared to U266 cells cultured alone (Figure 5-9A), with a further statistically 
significant reduction in MM cell growth in the presence of DL1+HS5 (p=0.042, 
paired t-test). Absolute numbers are charted in Table 5-3. 
A 
 
B 
 
Figure 5-9 Growth of U266 and MM1S cells alone compared to co-cultured with Notch 
ligand-expressing HS5. 
U266 (A) or MM1S (B) cells (GFP−) were seeded onto confluent DL1+HS5 or 
NC(DL1)HS5 or cultured alone. Cells were harvested 48 hours later and stained with APC-
conjugated AV and PI and analysed. Total viable (AV−PI−) GFP− cells are represented as 
the mean ± SEM of triplicates, corrected for viable GFP− HS5 cells (n=3).  
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The same pattern was seen in MM1S cells, although there was minimal difference 
between MM cells cultured with NC(DL1)HS5 compared to DL1+HS5, and none of 
the paired t-tests showed a statistically significant difference (Figure 5-9B and Table 
5-3). 
Table 5-3 Growth of U266 and MM1S cells alone compared to co-cultured with 
modified HS5. 
HMCL Total viable cells/ well (mean ±SEM, n =3) 
 Cultured alone 
Co-cultured with 
NC(DL1)HS5 
Co-cultured with 
DL1+HS5 
U266 202664 ±36669 155097 ±23286 105546 ±13571 
MM1S 217091 ±54893 101761 ±25486 89200 ±18904 
These findings are also demonstrated in the representative experiments shown in 
Figure 5-11, looking at the bars representing untreated U266 and MM1S cells 
cultured alone compared to those cultured with NC(DL1)HS5. As the percentage of 
viable cells was similar between the three groups, it is likely that the difference in the 
absolute number of viable cells is secondary to differences in the proliferation of 
HMCL. It appears that those in co-culture with HS5 cells grow more slowly, with an 
additional inhibition in growth for U266 cells co-cultured with a NL-expressing 
stromal cell (DL1+HS5). 
5.2.3.2 Bortezomib cytotoxicity in HMCL cultured alone compared to those 
co-cultured with modified HS5 (NC(DL1)HS5) 
Bortezomib (BZM) shows clear dose-dependent killing in both U266 and MM1S 
cells cultured alone or with NC(DL1)HS5 (Figure 5-10). It is apparent that both cell 
lines growing in co-culture are relatively protected against BZM killing with higher 
numbers of viable cells recovered from co-cultures at equivalent BZM doses in all 
six experiments. A 4-parameter log inhibitor dose response curve analysis confirmed 
that the difference between the BZM dose response curve in HMCL cultured alone 
and that for HMCL co-cultured with NC(DL1)HS5 was statistically significant 
(p<0.0001 for all three U266 experiments; p<0.007 for all three MM1S experiments). 
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Figure 5-10 Bortezomib cytotoxicity in HMCL cultured alone compared to those co-
cultured with NC(DL1)HS5. 
U266 and MM1S cells were cultured alone (black) or seeded onto confluent NC(DL1)HS5 
(purple). After 24 hours, cells were treated with BZM and harvested 48 hours later. Viable 
(AV−PI−) GFP− cells (corrected for viable GFP− HS5 cells) are shown as % of untreated 
control in the form of a dose-response plot for each of three assays (mean ±SD of triplicates). 
 163 
This is clear evidence of protection from BZM-killing in the presence of stroma. 
Results from a representative experiment are displayed in absolute cell numbers in 
Figure 5-11 (A & B U266, C & D MM1S). 
U266 - No.2 MM1S - No.1 
A 
 
C 
 
B 
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Figure 5-11 Bortezomib cytotoxicity in HMCL cultured alone compared to those co-
cultured with NC(DL1)HS5 - two representative experiments. 
Experimental set-up as per Figure 5-10. The results are presented in two different ways. In 
graphs A & B, representative plots from the same experiment (No. 2) using U266 cells are 
shown, while in graphs C & D, experiment No.1 using MM1S is presented. A & C show total 
viable cells, treated with escalating doses of BZM. The dashed line represents the starting 
number of viable HMCL seeded into the culture system. B & D show absolute numbers of 
suspension (red bars hatched with yellow) and adherent (red bars hatched with blue) viable 
cells, treated with escalating doses of BZM. 
When the distribution of viable cells between suspension and adherent fractions is 
considered, it is apparent that U266 and MM1S cells display very different growth 
habits in this setting. Within U266 cells a very small proportion of the total number 
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of viable cells is adherent (Figure 5-11B; 3% of U266 alone and 3.5% of U266 co-
cultured with NC(DL1)HS5). That proportion does not appear to change greatly after 
treatment with BZM.  
In contrast, a large proportion of viable MM1S cells were adherent. 56% of MM1S 
cultured alone and 56% of MM1S co-cultured with NC(DL1)HS5 were harvested 
from the adherent fraction (Figure 5-11D). There is no significant difference in the 
size of the adherent fraction in MM1S cultured alone compared to those co-cultured 
with HS5 which supports the supposition that this is consistent with a known growth 
characteristic of the MM1S cell line. As with U266 cells, the proportion of adherent 
cells does not change with BZM treatment in the two culture conditions. 
Comparison of the three experiments for each HMCL reveals some variation in the 
sensitivity of the MM cells (Figure 5-10). For example, treatment of U266 cultured 
alone with 2.5nM BZM results in quite different numbers of viable cells: 43.2 ±4.124, 
80.13 ±7.518 and 65.43 ±10.99  (expressed as a percentage of the untreated control; 
mean ±SD). This likely reflects variation in the baseline growth of the HMCL at the 
time of each experimental set-up. It makes pooling results from the three 
experiments for each HMCL inappropriate. 
5.2.3.3 Effect of DL1 on bortezomib cytotoxicity in HMCL   
Next, the ability of DL1 expressed on stromal cells to provide further protection from 
BZM-mediated cytotoxicity was investigated, in each of these HMCL.   
In all three experiments using U266 cells, there is a reduction in BZM cytotoxicity 
when U266 cells are co-cultured with DL1+HS5 compared to NC(DL1)HS5 (Figure 
5-12, left-hand panel). When the dose response curves were analysed as before, a 
statistically significant difference between the curves was found in experiments No.1 
and No. 2 (p=0.0013 and p=0.0002 respectively).  
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Figure 5-12 Bortezomib cytotoxicity in HMCL co-cultured with NC(DL1)HS5 
compared to those co-cultured with DL1+HS5. 
U266 and MM1S cells were seeded onto confluent NC(DL1)HS5 (purple) or DL1+HS5 (red). 
After 24 hours, cells were treated with BZM and harvested 48 hours later. Viable (AV−PI−) 
GFP− cells (corrected for viable GFP− HS5 cells) are shown as % of untreated control in 
the form of a dose-response plot for each of three assays (mean ±SD of triplicates). 
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The same pattern was not seen in BZM-treated MM1S cells (Figure 5-12, right-hand 
panel), with no difference seen in the effect of BZM in MM1S cells co-cultured with 
DL1+HS5 versus their negative control. 
Taken together this strongly suggests that while stroma-mediated protection against 
BZM-killing is seen, there is an additional protective effect seen which is associated 
with the presence of the NL and therefore is likely to be secondary to Notch 
activation in MM cells. 
5.3 Summary and discussion 
Notch receptors and ligands were characterised in a panel of HMCL analysed, 
satisfying the requirements of Aim 1. Notch1 was present at high levels in MM1S 
and RPMI-8226 cells but absent from U266 cells. In contrast, Notch2 was expressed 
strongly by U266, RPMI-8226 and LP-1 cells, but much more weakly by MM1S 
cells. Notch3 and Notch4 were present to varying degrees on all HMCL within the 
panel. These findings confirm those of a number of research groups 96,98,99 and 
support the importance of Notch signaling within MM cells. There was no evidence 
of constitutive ICN1 expression in any HMCL examined. It is interesting that this is 
the case given that constitutive Notch activation, as evidenced by HES1 expression, 
has been observed by Jundt et al 98. That said, the later findings of the Notch 
activation assay (section 5.2.2.1) do show that there can be a discrepancy between 
HES1 activity and the presence of ICN1. 
 The NLs Jag1, Jag2 and DL4 were also expressed by HMCL. Jag1 was strongly 
expressed by MM1S cells with much weaker expression by U266; in contrast, 
expression of Jag2 was higher on U266 cells compared to MM1S cells and DL4 was 
expressed exclusively by U266 cells. It was therefore possible for MM1S and U266 
cells to be used to evaluate different aspects of the Notch pathway, with Notch1-
dependent signaling examined using MM1S and Notch2-dependent signaling 
through U266 cells. 
In order to evaluate the role of the Notch signaling pathway in MM cells, NL-
expressing HS5 stromal cells were produced as a tool to activate Notch signaling in 
co-cultured MM cells (Aim 2). A number of similar approaches have been reported, 
 167 
using Jag1+ 3T3 fibroblasts 96, Jag1+ HtTA-jag10 cells 98, DL1+MS5 cells 108. The 
approach reported here was chosen as it would provide Notch activation in 
combination with some of the additional physiological signaling provided by a BM 
stromal line. Thus Notch activation could be examined in a system that might more 
accurately recapitulate the BM microenvironment. Recombinant soluble NLs were 
used by Nefedova et al 96 but their effects are more limited and inconsistent, and in 
the absence of direct cell-cell contact that is a hallmark of Notch signaling, their 
value as a tool is less clear. 
The functional capabilities of NL-expressing HS5 stromal cells were assessed using 
RT-PCR to quantify expression of HES1, a key downstream target of the Notch 
signaling pathway used by a large number of groups in the context of MM 
96,98,99,101,103,105,106,109,111. DTX1 expression was also evaluated in MM1S, U266 and 
DND41 cells but while expression was substantial and modifiable in DND41 cells, it 
was not expressed at measurable levels in the HMCL. This suggests that the 
downstream effects of Notch pathway activation may differ between different 
haemopoietic lineages.  
HMCL were cultured alone and HES1 expression was compared to those co-cultured 
on HS5 cells expressing Jag2, DL4 or DL1, or the appropriate empty vector negative 
control. MM1S cells expressed detectable HES1 at baseline, when cultured alone, 
but there was no evidence of upregulation of HES1 in co-culture with NL-expressing 
HS5 cells. In contrast, U266 cells had extremely low levels of HES1 expression at 
baseline, but showed upregulation in the presence of stromal cells, with additional 
upregulation in co-culture with NL-expressing HS5 cells. Unfortunately, striking 
upregulation of HES1 was seen in U266 cells co-cultured with the negative control 
HS5 cells for the Jag2 and DL4-expressing lines so this sub-group could not be used 
further. It is not known why this was the case but the concern is that the vector used 
for this group of lines might cause confounding Notch activation through an 
unknown route. Interestingly the same phenomenon was seen in DND41 cells co-
cultured with the panel of modified HS5 cells - the greatest upregulation of HES1 
and DTX1 was seen in DND41 co-cultured with NC(DL4)HS5 cells. 
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It was striking that the efficacy of GSI-L685 within the Notch activation assay varied 
widely between conditions. It appeared to inhibit HES1 expression most profoundly 
in DND41 cells cultured alone (>80% reduction; Figure 5-5B). In co-culture with all 
modified HS5, inhibition was reduced to ~60%. A similar, albeit less striking, effect 
was seen with DTX1 expression in DND41 cells. When the effect of GSI-L685 on 
U266 cell Notch activation was assessed, it was not possible to comment on its 
effects on U266 cells cultured alone as they had no detectable HES1 expression 
(Figure 5-7, upper plots). However, in co-cultured U266 cells, where HES1 
upregulation was seen, there was modest (<50%) and highly variable inhibition of 
this by GSI-L685, as could be seen when the two assay versions are compared. The 
reasons for this are unclear. There may be pharmocokinetic changes in co-culture 
such that the drug is metabolised more rapidly in the presence of HS5 cells, reducing 
its efficacy. It is also possible that GSI-L685 has less efficacy in HMCL which may 
express a different gamma secretase subtype to that seen in T-ALL lines. Finally it 
may be that HES1 was being upregulated through a Notch-independent route, 
although this seems unlikely as it is a well-validated and specific Notch target in MM, 
and no alternative routes have been reported in the literature. 
It is not clear what is responsible for the differences in Notch activation (as 
quantified by HES1 expression) seen in U266 and MM1S cells when co-cultured 
with DL1+HS5. There were a number of differences between the two HMCL used in 
this system. Firstly, MM1S cells cultured in TC-treated plastic-ware showed a much 
greater tendency to adhere to the base of the well, when compared to U266 cells. 
This was seen both when MM1S were cultured alone and when co-cultured with 
modified stroma. Up to 60% of viable MM1S cells were seen in the adherent fraction, 
compared to 10-20% of viable U266 cells. This may have led to a significant 
proportion of cells retained in the adherent fraction that were not analysed, thus 
leading to an under-estimation of the level of Notch pathway activation.  The 
Transwell system was not used in this activation assay; repeating the assay with 
additional conditions in which co-cultured cells were separated by a Transwell insert 
might clarify this issue. It is also known both from this work and the literature that 
MM1S cells are Notch1 positive and only weakly positive for Notch2, in contrast to 
U266 cells which express very low levels of Notch1 and are strongly Notch2 positive. 
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Selective blockade of the Notch1 and Notch2 receptors using antibodies might be 
used to clarify this issue. 
HES1 expression was consistently higher in both U266 and MM1S (and to a lesser 
extent, DND41) when co-cultured with DL1+HS5 cells, compared to the control 
NC(DL1)HS5, so this pair of modified HS5 cells was taken forward as a tool for 
further evaluation of the role of Notch in drug resistance of MM cells. Unfortunately 
the lack of success with transducing HS5 with other functionally competent Notch 
ligands made achieving Aim 4 impossible as it did not allow a formal comparison of 
the effects of different ligands.  
Western blotting for ICN1 in HMCL co-cultured with modified HS5 cells did not 
show any ICN1 in even the cells shown to have Notch activation on the basis of 
HES1 upregulation (i.e. U266 cells in the presence of DL1+HS5). This may reflect 
sampling of protein at a time point at which ICN1 was no longer present. A time 
course analysis, in which lysates of U266 cells were harvested at different time 
points after first incubation with DL1+HS5 cells might clarify this. Alternatively, the 
discrepancy may reflect the known low expression of Notch1 by U266 cells. 
Although some cross-reactivity may be expected of the ICN1 antibody to ICN2 
(given the structural homology of the two receptor subtypes), it has not been 
optimised for this target and therefore is likely to grossly underestimate levels of 
Notch2 in the cytoplasm. 
Having demonstrated that U266 cells co-cultured with DL1+HS5 cells showed 
evidence of Notch pathway activation, the impact of this on MM cell sensitivity to 
anti-myeloma treatment was then assessed. U266 cells cultured alone, with 
DL1+HS5 or with NC(DL1+)HS5 were treated with escalating doses of the 
proteosome inhibitor bortezomib (BZM). Dose-dependent killing was observed, and 
this was reduced in U266 cells co-cultured with HS5 cells, with an additional 
reduction in BZM-associated killing in U266 cells co-cultured with DL1+HS5. This 
strongly suggested that activation of the Notch pathway in U266 cells was associated 
with a reduction in sensitivity to BZM treatment.  
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The same pattern was not seen in MM1S cells. When co-cultured with HS5 cells 
there was a clear stroma-associated resistance to BZM killing, with minimal 
additional protection conferred by DL1+HS5. This was consistent with the lack of 
HES1 upregulation seen in MM1S cells co-cultured with DL1+HS5 cells. 
The differences in Notch activation seen between MM1S and U266 cells co-cultured 
with DL1+HS5 appear to predict for the level of NL-mediated protection from BZM 
killing. This does suggest that Notch activation contributes to BM stroma-mediated 
protection against BZM-killing, satisfying Aim 3. The DL1-Notch2 interaction 
maybe specifically implicated, but this is speculation in the absence of the additional 
mechanistic work outlined above. However, it is notable that Xu et al 108 used 
DL1+MS5 and identified Notch2 as the primary mediating receptor. They also 
observed that prior stimulation of murine 5T33MMvt MM cells by DL1+HS5 
rendered them less sensitive to BZM.  
The results presented in this chapter support the hypothesis that Notch activation 
attenuates BZM killing of MM cells. It was demonstrated that Notch receptors and 
their ligands are expressed in the majority of HMCL. Using a novel co-culture 
system utilising a NL-expressing BM stromal line, activation of the Notch pathway 
was seen in HMCL. This activation is associated with clear protective advantage 
against a key anti-myeloma agent. Further work is required to identify molecular 
mechanisms mediating this Notch-dependent protection; to explore whether 
protection is seen against other anti-myeloma agents; and also validate the system 
using alternative HMCL and primary CD138+ cells. 
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CHAPTER 6. DISCUSSION 
6.1 The role of the stem cell progenitor compartment in MM 
The MM stem cell was first proposed in the late 70s 27, but it was not until 2004 that 
a convincing phenotype was proposed by William Matsui’s group in Baltimore 28, 
seemingly further validated in 2008 40.  
The work reported in Chapter 3 is not compatible with Matsui’s model of the MM 
stem cell. When MM patient BM aspirate MNCs were phenotyped, the LC-restricted 
CD138− proportion was extremely small, although it appeared to increase in patients 
with lower BM tumour burdens. I believe this is an artefactual result of FACS 
analysis of very small populations of cells where the gated population (LC-restricted, 
LC+) is not clearly segregated from the whole. In patients with larger tumour 
burdens, and therefore clearer LC+ subpopulations, further analysis was more robust. 
It is also clear that the LC+CD138− cell fraction expressed B cell antigens very 
inconsistently.  
The modified three-dimensional culture system optimised for the longer-term culture 
of clonal BM MM cells did appear to show evidence of a LC+CD138− population 
that increased in both relative and absolute terms over time and after drug treatment. 
However, cell cycle analysis (using BrdU uptake and 7AAD staining) of these 
primary MM cells when freshly isolated and after time in culture clearly indicated 
that the majority (>70%) of LC+CD138− cells were sub-G0/G1 (in comparison, <10% 
of LC+CD138+ cells were in sub-G0/G1). This suggested the drug treatment induced 
apoptosis in clonal cells, associated with a loss of CD138 expression. 
These findings are entirely consistent with those of a number of groups 
32,46,48,49,51,55,56,132, some of which have reported since the landmark papers of Matsui, 
and since the initiation of the work presented in this chapter. 
The stem cell model in which the tumorigenic cell in MM is drug resistant and 
therefore responsible not only for disease initiation but also for relapse after 
apparently successful treatment is still very compelling. However, it seems unlikely 
that this cell has a fixed phenotype. Rather, given the bi-directional plasticity of stem 
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cell populations, as indicated by inducible pluripotent stem cell technology 133, it 
seems likely that drug resistance is a feature of a number of different clonal 
subpopulations over the natural history of the disease, expressing different cell 
surface markers. A recent report has proposed the presence of four hierarchically 
organised, clonally related, subpopulations in MM 134, with tumour-propagation 
capacity exclusively seen within a small population of so-called ‘pre-PC’ that are 
CD19−CD138−. Importantly this subpopulation appears to undergo reversible bi-
directional transition to a CD19−CD138+ phenotype, through epigenetic changes. 
This model has yet to be confirmed by another group but offers some significant 
refinements on Matsui’s model. 
Ultimately, addressing inevitable relapse in MM needs more understanding of the 
mechanisms of drug resistance, as it is likely that a number of factors contribute to 
the protection of the tumorigenic compartment. 
6.2 APRIL and drug resistance in MM 
The role of APRIL as a survival factor in MM is uncontroversial 70,71, but its specific 
contribution to drug resistance remains unclear.  
The first part of the work presented in Chapter 4 utilised primary freshly selected 
CD138+ MM cells cultured in culture media alone (RPMI with 20% pooled patient 
plasma), in the presence or absence of recombinant soluble APRIL. Dexamethasone 
(Dex) treatment of MM cells under these conditions revealed a consistent, albeit 
small calibre, protection from Dex killing in the presence of APRIL, which was not 
attributable to a proliferative or survival effect (APRIL alone had no effect on viable 
CD138+ MM cell number and all results were compared to an untreated APRIL-only 
control), confirming the findings of Moreaux et al. 76. In a small series, where the 
protection offered by APRIL, IL-6 and IGF-I were compared, APRIL offered greater 
protection than IGF-I, although less than IL-6. There was some suggestion that the 
protection offered by APRIL was more pronounced in Cyclin D2+ (compared with 
Cyclin D1+) MM samples, which would be compatible with the difference in 
APRIL-associated cell cycle effects observed in this group 18. In this experimental 
model, protection was not seen when MM cells were treated with bortezomib (BZM) 
or lenalidomide. 
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When APRIL secretion was incorporated into a novel co-culture model using 
modified HS-5 cells, the human myeloma cell lines - U266 and MM1S - were 
protected from BZM killing in the presence of stroma per se, but additional 
protection from secreted APRIL was not clearly demonstrated. This may have been 
related to insufficient levels of secreted APRIL, but merits further investigation.    
This work indicates that APRIL is a likely component of the drug resistance 
provided by the BM microenvironment in MM. APRIL is produced by a number of 
cells within the BM, including myeloid cells and osteoclasts 70,71,76, and this 
production may be up-regulated in the presence of MM cells, in similar fashion to 
IL-6 59,60. However, with the modest protective effect seen in the two models 
employed in this work, it was not possible to undertake an additional mechanistic 
evaluation of this protection. 
Further work in this area would usefully include extending the range of BZM doses 
evaluated to see if a greater protection might be evident at different doses, allowing 
more opportunities for evaluating the involved pathways. It would also be valuable 
to examine the effects of alternative anti-myeloma treatments (including Dex and 
lenalidomide) to see if protection varies with class of agent and mechanism of action. 
Finally, it would be interesting to use the co-culture system with primary MM cells, 
with and without drug treatments. This, however, may require further optimisation of 
the culture conditions for primary CD138-selected MM cells.   
6.3 Notch pathway activation and drug resistance in MM 
The Notch signaling pathway is an evolutionarily conserved pathway involved in cell 
fate, proliferation and survival in a number of tissues. It is dysregulated or 
abnormally activated in a number of malignancies 88, both solid tumours and 
haematological, e.g. T-ALL 89. Both MM cells (primary and HMCL) and BM 
stromal cells express Notch receptors 96,98,99 and Notch ligands are present on BM 
stromal cells 95,96. 
The reported effects of Notch signaling have not been consistent, with some groups 
demonstrating cell cycle arrest in Notch-activated MM cells 96,105, while others report 
that proliferation results from Notch activation 98,99,103,111, either directly or through 
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an intermediary such as IL-6, or the PI3K/AKT pathway. However, there appears to 
be a consensus that Notch activation is associated with enhanced MM cell survival 
and also clonogenicity 104. Increasingly there is also a sense that Notch signaling is 
directly involved in drug resistance, and different ligand-receptor pairs, e.g. Jag1-
Notch1 96,106,107, DL1-Notch2 108 have been implicated. These effects have been seen 
with different anti-MM agents, including mitoxantrone and bortezomib. 
Chapter 5 first reports observational data regarding the expression of Notch receptors 
and ligands on HMCL. Constitutive Notch activation was not observed, as assessed 
by expression of ICN1 (Western blotting) or HES1 (RT-PCR). These results 
provided the rationale for selecting the two HMCL, MM1S and U266, for subsequent 
work: MM1S expressed Notch1 and U266 Notch2 (in keeping with the reports of 
other groups). 
In order to evaluate the effect of Notch signaling in MM cells, a novel method of 
Notch activation was set up using HS5 cells modified to express different Notch 
ligands. The functional effect of these ligands was verified by RT-PCR to quantify 
the upregulation of the Notch down-stream target HES1. Based on this DL1+HS5 
were used for subsequent co-culture experiments to evaluate the influence of Notch 
signaling on bortezomib sensitivity. There was strong evidence of Notch-associated 
protection in U266 cells, with the same trend seen in MM1S cells, albeit at lower 
levels. This difference in effect may indicate that Notch2 is the critical receptor 
ligating DL1, but additional work is needed to support this claim. This could be 
explored through the use of selective Notch1 and Notch2 blocking antibodies. 
Additionally other HMCL expressing Notch1 or Notch2 predominantly might be 
evaluated to see if a similar pattern was observed.  
Within the limited time using this model it was not possible to look at the effect of 
co-treatment of MM cells with Notch pathway antagonists, such as GSIs or some of 
the newer, more specific agents e.g. SAHM1. Bortezomib treatment causes 
reversible inhibition of the proteasome within MM cells, and downstream effects on 
NF-κB signaling. It would be interesting to explore whether small molecule 
inhibitors of this pathway or of the PI3K/AKT pathway can attenuate DL1-
associated protection. Further mechanistic work would also be relevant if testing 
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different myeloma agents such as dexamethasone or a novel agent such as 
lenalidomide, which is known to have a range of effects on the BM 
microenvironment.  
Recombinant soluble Notch ligands have been used by some groups to activate 
Notch receptors and explore the effect of Notch signaling in MM cells. This would 
be an interesting approach to use, but a demonstration of its efficacy would be 
needed as these soluble agents differ so profoundly from the physiological molecule 
that they mimic. 
6.4 Future directions 
The work presented in this thesis represents an exploration of various models of drug 
resistance in MM cells, both primary and cell-line based. It seems that future work 
should reasonably focus on the Notch pathway, taking the co-culture model 
employed as a starting point and undertaking the work outlined above. 
It might reasonably be hypothesised that crosstalk between Notch signaling and 
pathways activated by APRIL exists, given the shared downstream targets feeding 
into the NF-κB and PI3K signaling pathways. This might be evaluated through 
combinations of modified HS5 cells or utilising DL1+HS5 in combination with 
soluble recombinant APRIL.  
The different genetic subtypes in MM will need to be evaluated separately, given the 
differences conferred by the various genetic lesions on the biology of MM cells and 
the diseases they generate 18,19,135. Ultimately the hunt for novel targets within the 
MM cell drug resistance armoury remains critical, even in this age of novel therapies, 
and it seems likely that individual patients will require therapeutic interventions 
tailored to targets known to act more strongly in their genetic subtype. 
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